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Abstract
Haemophilia B is an X-linked recessive bleeding diathesis caused by a deficiency of 
biologically active factor EX (FIX). Correction of this phenotype is possible by 
introducing a normal copy of the gene into cells capable of producing functional FIX. 
Engineered virus or synthetic molecules have been utilised as carriers to perform this 
task with varying levels of success. Lipidic peptide dendrimers (LPD) have an in vitro 
capacity for gene transfer, are able to transfect a number of cell lines and exhibit 
minimal cytotoxicity. This thesis reports the characteristics and performance of LPD as 
a means of delivering a FIX gene construct.
LPD/DNA complexes are capable of delivering a human FIX gene to cultured cells 
and produce a functional protein. The complexes showed improved gene transfer to 
cultured liver cells when a co-lipid displaying a ligand specific to the cell-type was 
incorporated into the complexes. In vivo experiments involved delivery of the 
complexes to mice by way of oral and intra-venous administration. Liquid scintillation 
counting and PCR studies indicated the presence of both dendrimer and plasmid DNA 
respectively in the liver of treated mice, but not in tissues of the reproductive or central 
nervous system. Factor EX protein was not detected in murine tissues by 
immunohistochemistry or in the plasma by ELISA. Gastro-intestinal tract tissue 
indicated activity of a reporter gene from glucose-modified complexes delivered 
orally.
Immune responses to the complexes were investigated by means of complement 
activation and cytokine gene expression assays. Cytokines IL-lp, TNFa and IL-6 
were investigated using RT-PCR to quantify localised and systemic inflammatory 
responses. These tests showed a general increase in the expression of inflammatory 
cytokines, particularly in the liver of animals to which the complexes were 
administered. All LPD/DNA complexes were found to activate complement to 
different degrees and relative to the charge density of the dendrimer used.
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Chapter 1 
Introduction
14
1.1 A historical perspective of haemophilia
Haemophilia (gr. Haima: blood; philein: to love). A bleeding diathesis caused by a 
deficiency of clotting factors VIII or EX.
Haemophilia is the name given to two diseases with the similar clinical manifestations 
of spontaneous and excessive bleeding. Haemophilia A (classic haemophilia) and 
haemophilia B (Christmas disease) are caused by a deficiency in clotting factors VIII 
(FVIII) and factor EX (FIX) respectively. The term haemophilia was first written in a 
dissertation by Hopf entitled Die Hamophiliet at Wurzburg in 1828 (Brinkhous 1975). 
However, it is Schonlein (of whom Hopf was a student) who is accredited with its first 
use.
It is entirely possible that genetically determined bleeding disorders have been in 
existence throughout human history, but reports by early Egyptian, Roman or Greek 
physicians have not been discovered. The earliest documented instance of a familial 
bleeding disorder is in the fourth-century Babylonian Talmud (Rosner 1969) and occur 
thereafter in Rabbinic writings and legal edicts. These were incorporated into the laws 
to prevent circumcising a child following the deaths of two siblings due to excessive 
bleeding from the operation. Subsequently, sporadic case reports appear in scientific 
literature, describing patients with excess bleeding from the umbilical stump, abnormal 
epistaxis and minor injuries causing life threatening bleeding.
It is likely that the first reported case of haemophilia in the USA was in 1791, where an 
obituary in a local paper described the death of a 19-year-old-man from exsanguination 
due to a slight cut on his foot as reported in the Salem (Massachusetts) Gazette, 1791. 
This obituary went on to describe the death also by exsanguination of the deceased’s 
five brothers following minor trauma. It is not known if this statement, suggesting a 
familial bleeding disorder, was examined further. However, twelve years later it was 
recorded that, within a particular affected family showing bleeding tendencies, only the 
males were subject to this affliction with the females exempt, although they were still 
capable of transmitting it to their male children (Otto 1803).
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The first European case reported was by the editor of Sampling Auserlesener 
Abhandlungen (1805) and was followed by a publication of detailed clinical and post­
mortem observations (Blagden 1817; Wilson 1819) although unfortunately the first 
actual report of a coagulation defect in haemophilic blood (Ward 1819) appeared to be 
largely ignored for 80 years.
During the early 19th century complete descriptions of the disease could be found 
(almost exclusively) within contemporary German textbooks of Schonen, Constatt, 
Neumann and Fuchs. These studies and the increasing trend towards a standardised 
procedure for post mortem examinations produced some significant observations of 
cellular pathology (Virchow 1854), but the aetiology of the disease was still elusive 
and often misinterpreted.
The connection between gender and transmission of the disease arose again when all 
cases of abnormal bleeding disorders, published up to that time, were collated. This 
study found of 484 cases, 452 (93%) were male and 32 (7%) female (Grandidier 
1855). The criteria for the study are reported to be quite broad and included all cases 
of hemorrhagic disease, haemorrhages following circumcision or from the umbilical 
cord and menorrhagia. A Tretise on Haemophilia compiled nearly twenty years later 
comprehensively described the genetic transmission of the disease and addressed the 
problems facing those affected (Legg 1872). In this text the causes of mortality 
psychiatric implications as well as the characteristic spontaneous bleeding episodes 
were examined, however, the mainstream medical community largely ignored this 
valuable information for some time.
In 1893 Wright determined that the clotting time of the patient’s blood was prolonged 
(Wright 1893), introducing a quantifiable property to characterise the condition. This 
would seem to be the first step in progressing from merely characterising the disorder 
to understanding its mechanisms and developing a strategy for its management. The 
momentum was maintained with the observation that the clotting defect could be 
corrected by the addition of normal blood (Addis 1911; Minot 1916), a position which 
concurred with an observation much earlier that a blood transfusion would be 
beneficial to sufferers (Lane 1840). This development was then reviewed and 
improved upon by the use of plasma infusion (Feissly 1923; Payne 1929) which was 
shown to be a superior treatment and became standard practice for several decades.
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Haemophilia was considered to be a single disorder until 1947 when it was observed 
that in one instance, blood from one haemophiliac patient could correct the clotting 
defect in the blood of another both in vitro and in vivo (Koller 1950; Schulman 1962). 
The development of the thromboplastin generation test and clinical data from the 
treatment of ‘haemophilic’ patients, whose clotting defect could be corrected with an 
infusion of plasma from another haemophiliac (Aggeler 1952; Biggs 1952) confirmed 
the existence of two groups of patients deficient in different clotting factors but 
displaying the same symptoms. This newly discovered disease was termed Christmas 
disease after the factor found lacking in a family of that name (Christmas factor -  CF 
or factor IX -FIX ).
The combined incidence for both forms of haemophilia is approximately 1:5000 live 
male births. The disease has now been described in every race (Prentice and Ratnoff, 
1967) but is said to be uncommon in the American Negro (Lewis et al 1963) and the 
Japanese (Yoshida 1961) ethnic groups.
1.2 Haemophilia B
Haemophilia B (Christmas disease) arises from the absence or low level of blood 
coagulation factor IX clotting activity and affects 1 in 30,000 males. Clinically the 
disorder is indistinguishable from haemophilia A (classic haemophilia; caused by 
factor VIII deficiency, affecting 3-4 per 100,000 males in the UK) and was identified 
as a new disease in 1952 (Aggeler 1952; Biggs 1952).
The severity of the disease or bleeding tendency is classified according to the amount 
of circulating FIX levels; with severe defined as <lU/dl, moderate as l-5U/dl, and 
mild as >5U/dl. This classification generally predicts bleeding risk and guides the 
optimal management strategy to predict outcome. Although most severe 
haemophiliacs require replacement therapy (i.e. infusion of deficient factor) on a 
regular basis, relatively few of the moderate and more mildly affected patients bleed 
spontaneously and as such only occasionally need treatment (UKHCDO 2002).
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1.2.1 Haemostasis and the role of FIX
Overview
Bleeding occurs in haemophilia due to failure of secondary haemostasis. Primary 
haemostasis (formation of the platelet plug), occurs normally but the subsequent 
stabilisation of the platelet plug by fibrin is defective because inadequate amounts of 
thrombin are generated.
All components of the haemostatic mechanism exist under resting conditions in an 
inactive form. Following injury there is immediate vasoconstriction and reflex 
constriction of adjacent small arteries slowing blood flow into the damaged area. The 
reduced blood flow allows contact activation of platelets by tissue injury (or other 
agonists), whereby they undergo a series of physical, biochemical and morphological 
changes. The platelets adhere to exposed connective tissue, mediated in part by von 
Willebrand factor, with the collagen exposure and local thrombin generation leading to 
secretion of platelet granule contents. These contents include ADP, serotonin, and 
fibrinogen, which further enhance platelets to be activated, form aggregates and 
interact with other platelets and leucocytes. This forms the initial platelet plug.
The vascular endothelium additionally undergoes a series of changes to move from its 
resting phase (with predominantly anticoagulant properties) to a more active 
procoagulant and repair phase. In concert with these cellular changes, inactive plasma 
coagulation factors are converted to their respective active species by cleavage on one 
or two internal peptide bonds. In sequence these active factors generate thrombin 
which leads to formation of fibrin from fibrinogen (to stabilize the platelet plug), cross 
linking of the fibrin formed (via activation factor XIII), further activation of platelets 
and also activation of fibrinolytic pathways (to enable plasmin to dissolve fibrin 
strands in the course of wound healing). Additionally thrombin interacts with other 
non-haemostatic systems to promote cellular chemotaxis, fibroblast growth and wound 
repair.
Figure 1.1 shows the process by which these coagulation factors are activated during 
secondary haemostasis. Although the classically described ’waterfall’ hypothesis of 
coagulation proposes two separate pathways, it is now clear that FVIII and FIX are 
central to the process of blood coagulation and for the adequate generation of 
thrombin. Following initial injury, activation of the tissue factor-factor Vila complex
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mediates generation of factor Xa. This must be amplified by FIX and FVIII to allow 
coagulation to progress to completion. Using this scheme it is clear that in the absence 
of FVIII or FIX a shortfall in consolidating the generation of factor Xa will produce 
conditions which are insufficient to sustain haemostasis and bleeding will ensue.
F igure  1.1 T he blood coagulation process
Key: Coagulation factors are shown by their abbreviated name with “a ” denoting
the activated factor. TF -  Tissue Factor, PI -  Platelet.
Coagulation is initiated by tissue damage exposing tissue factor. Factor VII binds 
tissue factor and the tissue factor-factor VII complex then directly activates factor X to 
factor Xa, and some factor IX to factor IXa. In the presence of factor Xa, tissue factor 
pathway inhibitor (TFPI) inhibits further generation of factor Xa and factor IXa. 
Following inhibition by TFPI the amount of factor Xa produced is insufficient to 
maintain coagulation. Further factor Xa, to allow haemostasis to progress to 
completion, can only be generated by the factor IX / factor VIII pathway. Enough 
thrombin has then been generated to activate factor VIII and together with factor IXa
Thrombin
activation
Xa va
Prothrombin Thrombin
Fibrinogen FIBRIN
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(generated by tissue factor-factor Vila) further activation of factor X can proceed. 
Augmentation of factor IX activation occurs via thrombin activation of the factor XI 
pathway. Without the amplification and consolidating action of factor VIII / factor IX, 
bleeding will ensue as generation of factor Xa is insufficient to sustain haemostasis.
Factor IX
FIX is a serine protease synthesised in the liver and is the largest of the family of 
vitamin K-dependent proteins. Vitamin K is needed to allow the terminal y- 
carboxylation of glutamic acid residues to form the Gla domains of the FIX protein, 
crucial to normal function and biological activity. FIX is present in the plasma within 
a normal range of 1.5-4.5 mg/dl, with the secreted protein having a biological half-life 
of approximately 24 hours (Smith and Thompson 1981).
FIX is a 415 amino-acid (AA) polypeptide, preceded by a leader peptide consisting of 
a pre- and a pro-domain. These domains are necessary for correct secretion and y- 
carboxylation of the amino-terminal glutamic acid residues respectively. Circulating 
FIX consists of several domains which, from the amino end are:
• a Gla domain containing 12 glutamic acid residues;
• a short hydrophobic domain;
• two epidermal growth factor-like domains;
• catalytic (serine protease) region.
Following synthesis the polypeptide undergoes cleavage of the pre- and pro-segment 
of the signal peptide prior to secretion as well post-translational modifications in the 
endoplasmic reticulum. These include y-carboxylation of the first 12 glutamic acid 
residues, O-linked glycosylation at Ser 53, Ser 61 , Thr 159, and Thr 169 (Agarwala, 
Kawabata, Takao et al. 1994), N-glycosylation at Asn 157 and Asn 167, and p- 
hydroxylation of Asp 164. The activation of FIX involves excision of the peptide 
containing residues 146-180.
Pathophysiology of FIX
FIX is activated through specific proteolytic cleavage by activated factor XI (FXIa) 
(Walsh, Bradford, Sinha et al. 1984) as part of what is classically described as the 
intrinsic coagulation pathway, or by the factor Vlla-tissue factor complex of the 
extrinsic pathway (Jesty and Morrison 1983). Activation of factor IX occurs via
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cleavage of two peptide bonds, Arg 145-Alai46 and Argl80-Vall81. Cleavage of the 
Argl45-Alal46 occurs rapidly whilst the Argl80-Vall81 cleavage is rate limiting. 
Cleavage into factor IXa generates a protein with a heavy and light chain bound 
together via a single disulphide bond. Activated factor IX (FIXa) then cleaves factor X 
at a specific site (a process requiring the presence of platelet phospholipid, calcium 
ions and FVIIIa), transforming it into an active serine protease. The conversion of 
prothrombin to thrombin by FXa follows, producing the enzyme ultimately responsible 
for the fibrin formation that reinforces and stabilises the platelet plug
Molecular genetics of FIX
The human FIX protein (hFIX) is encoded by a single functional gene located on the 
long arm of the X chromosome at Xq 27 (Eyster, Gill, Blatt et al. 1978; Chance, Dyer, 
Kurachi et a l 1983). The hFIX gene (F9) was described in detail in 1982 where a 
bovine FIX cDNA clone (isolated using synthetic oligonucleotides as probes) was used 
to screen a cloned human gene library. At the same time the partial characterization of 
a lambda recombinant phage containing F9 was reported (Choo, Gould, Rees et al 
1982; Anson, Choo, Rees et al 1984). F9 itself is composed of eight exons and seven 
introns. Each of the eight exons corresponds to a domain of the protein:
• exon 1 encodes the signal peptide;
• exon 2 the propeptide and the amino terminal glutamic rich domain, the Gla
domain;
• exon 3 an aromatic acid-rich stack;
• exons 4 and 5 two epidermal growth factor-like domains,
• exon 6 the activation peptide;
• exons 7 and 8 the catalytic domain.
Mutations in the factor IX gene
Progress in molecular biology and the use of polymerase chain reaction has yielded a 
significant expansion in the detailed analysis of haemophilia B mutations. With advent 
of PCR and rapid screening procedures based on PCR (e.g. single stranded 
conformation polymorphism and cycle sequencing) the pace of detection has increased 
dramatically. To utilise this data effectively, 2100 factor IX gene mutations are 
recorded on an international database and available on the internet 
(www.kcl.ac.uk/ip/petergreen/haemBdatabase.html).
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Mutations are described in all regions of the factor IX gene, the vast majority being 
point mutations, with approximately two thirds of these being missense. Some 20-30% 
of mild haemophilia B instances are due to a small number of founder-effect mutations 
(Sommer, Scaringe and Hill 2001). Of these, approximately 7% are short additions or 
deletions and 3% gross gene deletions or complex rearrangements. Substitutions in the 
promoter region of factor EX gene classically result in the unusual Factor EX Leiden 
phenotype which is described below.
In a recent study of the haemophilia B database it was found that while mutations 
responsible to account for all 2348 haemophilia B patients covered 20% of the FIX 
cDNA, only 1% of the cDNA involving mostly CpG dinucleotides accounted for 
mutation in 42.4% of the patient pool (Mukheijee, Mukhopadhyay, Chaudhuri et al. 
2003). This occurs because in eukaryotes, the cytosine in CpG doublets is usually 
methlylated, making it chemically unstable and susceptible to deamination. With 
deamination, the methylated cytosine is converted to thymine which is a normal 
nucleotide present in DNA. This damage is not recognised by DNA repair enzymes 
and as such is not repaired resulting in a stable mutation. An effect of this mutation is 
the creation of premature stop codons in the mRNA sequence (UAA, UAG or UGA) 
resulting in a truncated protein with no or greatly reduced activity. CpG doublets 
appear to be hotspots for mutations, which may explain the high number of sporadic 
mutations which cause haemophilia B.
Substitutions in the promoter region of FIX have classically resulted in the factor 
Leiden phenotype (Veltkamp, Meilof, Remmelts et al. 1970). Most patients with this 
phenotype have a severe haemorrhagic disorder and lack detectable FIX antigen and 
activity at birth. At puberty however there is gradual increase in levels (-4-5 % per 
year) in line with increasing testosterone levels. A proportion of the FIX promoter 
region resembles an androgen response element which explains this response to 
increasing testosterone levels (Crossley, Ludwig, Stowell et al. 1992). This continues 
until the patient reaches about age 20 when the increase in circulating factor IX 
alleviates the haemophilic condition.
1.2.2 Pathophysiology of haemophilia B
The severe condition is characterised by frequent spontaneous bleeds into soft tissues 
(haematomas) and joints (haemarthroses), the latter often resulting in chronic and
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debilitating arthropathy. More serious and potentially life threatening is the 
complication of bleeding into critical enclosed spaces such as the intra-cranial or the 
retro-peritoneal space. Moderate and mild haemophiliacs usually suffer bleeds 
following surgery or trauma, with moderate sufferers presenting occasional 
spontaneous bleeding, a rare occurrence in the mild form of the disease.
The regular occurrence of haematomas and haemarthroses (bleeding into the joints, 
accompanied by reduced mobility) are characteristic of the severe form of haemophilia 
A and B. Haemarthroses become frequent as the young sufferer begins to learn to 
walk and without effective treatment, can cause chronic haemophilic arthropathy by 
adulthood. Severely affected patients are subject to serious haemorrhages that may 
dissect through tissue planes, ultimately leading to death as a result of compromise of 
vital organs. Despite the serious haemorrhagic tendency, bleeding episodes are 
intermittent with some patients going for weeks or months without haemorrhage. 
Moderately affected haemophiliacs have occasional haematomas and haemarthroses 
usually associated with trauma. These patients may have l-5U/dl FIX activity, just 
barely enough to limit the frequency of bleeding episodes. Although chronic 
haemophilic arthropathy may occur in moderately affected patients, it is usually less 
disabling than that which occurs in patients with the severe form of the disease.
Mildly affected patients have infrequent bleeding episodes and the disease may go 
undiagnosed for many years and usually discovered because of excessive postoperative 
bleeding, following trauma, or after severe contact sports. Although some carriers of 
haemophilia B have factor IX levels much lower than 50U/dl (extreme examples of 
Lyonisation), most carriers have roughly 50% factor IX activity and experience no 
bleeding episodes.
The progression of arthritis suffered by haemophiliacs occurs in three sequential 
stages, acute haemarthrosis, chronic synovitis and degenerative arthritis. Most patients 
are aware of a bleed before any clinical signs are present and prior to the characteristic 
acute pain. Although symptoms vary between patients, bleeding into the joints results 
in localised swelling causing a reduction in the limbs range of movement.
Chronic synovitis usually occurs after a particularly large haemarthrosis or an 
inadequately treated one. The most frequently affected joints are the knees, ankles and
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elbows or those that have been the target of previous bleeds. Chronic synovitis is 
usually present in persistently swollen joints that are usually painless or only 
periodically painful. This stage can last for months or years with fibrotic tissue 
eventually developing in areas of the synovium affected.
Degenerative arthritis (persistence of chronic synovitis for more than six months) 
produces deformities in joints made more severe in the case of haemophilia by 
muscular contractures. Stiffness and chronic pain in joints are symptoms typically 
presented by older sufferers of the disease (40-60 years old), often associated with 
reduced mobility of the joint. Early radiological signs include loss of joint space, with 
secondary osteoarthritic signs appearing due to loss of cartilage.
1.2.3 The development of conventional treatment
The first major step towards understanding the biochemistry of possible methods of 
treatment occurred when it was found that platelet free plasma, when precipitated with 
water at pH of 5.3 to 5.8, yielded a substance capable of correcting the clotting 
abnormality in affected blood (Bendien 1935; Patek 1937).
This approach was developed further with the introduction of the earliest therapeutic 
plasma fraction, Cohn Fraction IV - a cold ethanol precipitation of plasma containing 
albumin, transferrin and vitamin K-dependent proteins (White 1953). Later 
preparations were improved upon by taking advantage of the property of Factor IX to 
adsorb onto agents such as barium sulphate (BaS04). The subsequent process of 
elution by citrate resulted in the production of a fraction with a considerable increase 
in purity and potency (Blatrix 1959; Didisheim 1959). This fraction (PPB, later 
renamed PPSB for prothrombin-proconvertin-Stuart factor-antihemophilic factor B) 
contained the vitamin K-dependent clotting factors and was used for the treatment of a 
variety of coagulation deficiency states including acquired deficiencies of the vitamin 
K-dependent factors. Although effective, cases of disseminated intravascular 
coagulation (DIC) in patients with liver disease who were treated with PPSB were 
recorded (Menache 1959). This was due to the presence of other vitamin K-dependent 
proteins such as Prothrombin (FII) and FX in the PPSB as well as other activated 
factors, supplementing the normal levels already circulating. The excess of these 
proteins proved thrombogenic in patients with compromised liver function as their
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anti-coagulant capacity such as (protein C and protein S production) was significantly 
reduced.
The treatment of haemophilia A was quickly evolving with methods for the 
purification of clotting factor concentrates being developed and used for small groups 
of patients (Kekwick and Wolf 1957) following the production of cryoprecipitate (Pool 
1964). This product utilised the property of frozen plasma to form precipitates 
containing FVIII when thawed at 4°C (Brinkhous 1954). Within a decade, lyophilised 
coagulation factor concentrates made an appearance offering considerable advantages: 
they could be stored in a domestic refrigerator at 4°C, and permitted the administration 
of a large and assayed quantity of coagulation factor rapidly and in a small volume. 
The large scale production of concentrates followed and was introduced in the early 
1970’s.
Until this time however, the mainstay of treatment for haemophilia B was whole 
plasma (either fresh or fresh frozen). The large volumes of plasma required to stop a 
bleed sometimes resulted in heart failure from fluid and plasma protein overload. To 
overcome this problem, the production of plasma fractions for the treatment of 
haemophilia B was being developed but lagged somewhat behind those of haemophilia 
A. The problems faced were mainly of a technical nature, as the development of 
bioassays required the ability to activate specific clotting enzymes artificially in vitro 
were in the early stages of development at this time.
During the 1960’s and 1970’s, studies were published describing attempts at the 
prevention of bleeding both for long-term management and prior to surgery 
(prophylaxis) which included the introduction of tranexamic acid. The emergence of 
such adjunctive therapy, mainly for mild haemophilia B, has increased effectiveness 
and reduced the cost of some treatment. Clot stabilisation can be achieved with the 
infusion of tranexamic acid (Ingram, Inglish and Bennett 1972; Bennett, Ingram and 
Inglish 1973); (Waly 1995) and the topical application of thrombin is of use in 
gingival/mucosal bleeding (Roberts, Cavanagh, Roberts et al. 1989). Tranexamic acid 
is an antifibrinolytic agent which competitively inhibits the activation of plasminogen 
to plasmin, promoting clot stability. It is particularly valuable in controlling bleeding 
in the mouth in haemophilia as in association with dental surgery.
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The movement towards home treatment of haemophilia vastly improved the patient’s 
quality of life (Rabiner and Lazerson 1973). Drawbacks such as errors in 
administering medication, compliance to the treatment program (including record 
keeping) or the failure to identify unusual bleeding were overshadowed by the benefits, 
especially in children. The normal range of physical activity and school performance 
reported along with the near normal family life indicated that home treatment is 
associated with an overall reduced level of disability from haemophilia (Ekert, 
Moorehead and Williamson 1981).
The possibility of serious thromboembolic events arising from the use of newly 
developed fractions encouraged the formation of high purity preparations of factor IX 
such as Mononine® (Aventis Behring) produced by immunoaffinity chromatography to 
selectively separate FIX from pooled plasma. These high purity FIX concentrates 
contained a much higher specific FIX activity (IU/mg of protein) and appeared to be 
far less thrombogenic than previous concentrates such as PCC (prothrombin complex 
concentrate - which contains factors II, X and variable amounts of FVII), as these 
prothrombotic protein levels were not significantly elevated along with FIX (Mannucci 
1991; Kim, McMillan, White eta!. 1992).
1.2.4 Complications of conventional treatment 
Risk of thrombosis during conventional treatment
The thrombogenicity of factor IX complex or prothrombin complex concentrates 
(PCCs) has been widely reported (Kohler 1999). The clinical spectrum of 
thrombogenicity ranges from superficial thrombophlebitis, deep-vein thrombosis, 
pulmonary embolism and arterial thrombosis to disseminated intravascular 
coagulation. Several risk factors have been identified contributing to these events:
(a) Predisposing clinical factors (underlying disease and clinical condition);
(b) Therapy factors (dosing, concomitant therapy and drug interactions);
(c) Quality of the PCC used.
In haemophilia B, clinical conditions with an increased risk include large muscle 
haematomas, immobilization, surgery (especially orthopaedic surgery), and liver 
disease. Liver disease and/or antithrombin deficiency are considered as major risk 
factors and therapy factors with an increased risk include large, repetitive doses of 
PCC.
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Inhibitor development
The development of an inhibitor, an antibody that blocks procoagulant function, is one 
of the most serious complications of haemophilia A or haemophilia B treatment. The 
incidence of inhibitors complicating treatment of is approximately 30% in haemophilia 
A and 3-5% in haemophilia B patients (Hay 2002).
The clinical impact of inhibitor formation has been recognised for over half a century, 
and only very recently have studies begun to clarify our understanding of inhibitor 
development. Recent studies have focussed on four main areas, a better understanding 
of the incidence of inhibitors following coagulation factor treatment, the identification 
of patients at the highest risk of inhibitor formation, the characterisation of the 
antibodies and the development of better therapies. Treatment of patients with acute 
bleeding episodes can take the form of infusion of FVIIa to bypass the FIX or FVIII 
deficiency, or high doses of factor in an attempt to induce tolerance; however this 
brings with it the risk of anaphylaxis.
The typical bleeding frequency or location of bleeding does not change in 
haemophiliac patients when an inhibitor develops, and joint haemorrhages continue to 
be a major problem. Clinically the development of inhibitors has significant 
implications for the patients, with resulting-decreased life expectancy and increasing 
morbidity.
Transmission of infectious agents
The use of plasma derived blood products has not been without serious consequence. 
In the early 1970’s in the USA, FDA approved production of each batch of clotting 
factor concentrate involved the pooling of plasma collected from up to 10,000 
individuals. The vast majority of the recipients of these concentrates around this time 
developed hepatitis B, since none of the products were treated in any way to kill blood 
bome viruses. The serological testing of donated blood and plasma for hepatitis B 
antigen was not introduced in the USA until 1972 (Kasper 1993).
The emergence of hepatitis C virus (HCV) (Ragni M. V. 1993) and human 
immunodeficiency virus (HIV) (Ragni M. V. 1987) prompted further advances in the 
purification of blood products and the emergence of recombinant technology to the 
production of clotting factor concentrates. Viral attenuation methods were developed
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in the mid 1980’s to inactivate all the main blood-borne pathogens possibly contained 
in concentrates. Such methodologies used in the manufacture of factor IX concentrates 
included dry heating, solvent/detergent treatment, ultrafiltration and hot vapour 
treatment. By using these viral attenuation procedures, enveloped viruses (HBV, HCV 
and HIV) are no longer transmitted by plasma derived factor concentrates
Recombinant human Factor IX (rhFIX)
FIX was successfully cloned and expressed in mammalian cells in 1985 (Anson 1985; 
de la Salle 1985). The complexity of the protein and the need for consistent 
reproduction of several post-translational modifications (Kaufman 1998) delayed 
commercial production. Although recombinant technology offers the opportunity to 
eliminate blood-bome pathogen transmission in its manufacture, recombinant factor 
VIII (rFVIII) and recombinant factor Vila (rFVIIa) concentrates contained human 
plasma and presented a risk of exposure for some time until replaced by a sucrose 
formulation (Abshire, Brackmann, Scharrer et al. 2000). In contrast, rFIX undergoes 
purification procedures that render it free from animal protein (Benefix Coagulation 
Factor IX (Recombinant), Genetics Institute Inc, Cambridge MA). However the 
development of anaphylaxis and/or inhibitors remain at a rate similar to that with 
plasma-derived products (White 1998)
The mainstay of current therapy for haemophilia B is based on intravenous infusions 
of recombinant or high-purity-plasma-derived factor IX concentrates either as 
prophylaxis or in response to a bleeding episode. This approach has the disadvantages 
of high expense, inconvenience and in the case of plasma-derived products, the risk of 
transmission (however small) of blood-bome disease in particular HIV and Hepatitis. 
Also the frequent use of plasma products over a long period of time increases the 
exposure of haemophiliacs to emerging pathogens that are undetectable at the time of 
treatment i.e. the nvCJD prion.
Despite the advances in the purity and efficacy of treatment for haemophilia B, there 
still requires the constant injections of FIX preparations. Disruption to the lives of 
sufferers and the risk of treatment complications has produced the aspiration for a 
permanent, effective treatment that requires minimal intervention.
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1.3 Gene therapy of inherited disease
Gene therapy is a broad term used to describe the use of specifically designed nucleic 
acid based molecules to treat a medical condition. There are a number of different 
conditions that could potentially respond to treatment using such an approach. A 
major application of gene therapy is the administration of a normal copy of a gene to 
correct a chronic inherited disorder caused by the endogenous gene being either 
abnormally expressed or non-functional, the result of which is an aberrant or lack of 
functional protein respectively, giving rise to the disease. This approach to medicine is 
regarded as a potential revolution aimed at treating or eliminating the cause of disease 
at its most fundamental level.
The first clinical studies involving gene transfer began in the early 1990’s (Blaese, 
Blankenstein, Brenner et al. 1995) and so far , all clinical trials have involved gene 
addition rather than correction or replacement of defective genes which is technically 
more difficult. The clinical protocols approved involve somatic cell gene transfer in 
contrast to transformation of the germ-line. Ethical as well as medical issues are raised 
regarding germ-line gene transfer, including the possibility of irreversible damage to a 
lineage, a consequence deemed unacceptable by governing medical, ethical and 
scientific advisory groups today.
Gene transfer to the somatic cells can be carried out in vivo or ex vivo. In the ex vivo 
approach, cells are removed from the patient for transfection and engineering after 
which they are replaced. This usually involves expansion of the transfected cell line, 
which, in turn, would have the effect of increasing the amounts of the therapeutic gene 
product. A notable disadvantage of this technique is that it is largely patient-specific 
as a result of cell immunogenicity and also costly due to the cell manipulation and 
quality control required. The in vivo approach involves direct administration of the 
gene-transfer vector to patients and is therefore not patient-specific. The logistics, cost 
and infrastructure requirements for this type of approach are considerably less in 
comparison.
The number of clinical trials in gene therapy continues to grow and a total of 853 
completed, ongoing or pending trials worldwide between 1989 and 2004 (the majority 
being in the United States) have been identified (Journal of Gene Medicine, 2004
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URL: http://www.wilev.co.uk/genetherapy/clinical/). A majority of the diseases 
addressed in clinical trials are cancers, which is understandable considering 
approximately 1 in 3 adults will suffer from a form of cancer at some point in their 
lives (Cancer Research UK, published literature). Retroviral and adenoviral protocols 
account for over 60% of the clinical trials undertaken. This derives from the first 
generation vectors approved for trials and served to provide the necessary data for the 
design of more effective protocols and novel technologies starting to emerge as well as 
a growing number of liposome-mediated and naked DNA transfers.
Current haemophilia gene therapy
Haemophilia is an ideal candidate for gene therapy as a single-gene disorder. Even a 
relatively small correction of circulating factor IX levels i.e. to 2U/dl, results in a 
significant clinical improvement and increases of up to 150U/dl are still within normal 
limits and therefore unlikely to be detrimental.
Clotting factors, although normally synthesised in the liver, have been shown to be 
biologically active even if produced in endothelial cells (Yao 1994) fibroblasts 
(Axelrod 1990) and muscle cells (Herzog, Hagstrom, Kung et al 1997). This allows 
for a more flexible approach to gene targeting, giving a range of tissues to which gene 
therapy can be easily administered.
Of the 509 trials registered with the National Institute of Health Office of 
Biotechnology Activities (NIH OBA) on 10 February 2005, there are 2 current phase I 
trials for haemophilia B listed. However, this is a pilot scheme to allow easy access to 
data concerning current clinical trials and the reporting of adverse events. Previous 
records show 3 clinical trial protocols for haemophilia B were registered for the 2001/2 
period, one in China (Hsueh 1992) and two in the United States (Glader 1999; Manno, 
Larson, Cohen et al 1999). The Manno phase I trial showed that an increase in the 
circulating factor IX levels of a severe haemophiliac to between 0.5 and lU/dl, 
significantly reduced the requirement for treatment with recombinant factor IX (Kay
2000). This was an extremely encouraging dose-escalation study using adeno- 
associated virus (AAV) injected intra-muscularly, with signs of improvement clinically 
visible rather than detected by biochemical testing.
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The Hsueh phase I/II trial reported plasma hFIX protein in both patients tested 
increased over 2 fold (hFIX activity was about 2U/dl in both patients) after several 
injections of autologous skin fibroblasts genetically modified by retrovirus-mediated 
gene transfer, and persisted for more than 420 days. The report also states blood- 
clotting activity increased significantly in both patients with hemorrhagic tendencies 
being partially corrected after treatment. Further elevation of hFIX was achieved by 
repeating the same treatment 420 days later in one of the patients (Qiu X, Lu D, Zhou J 
et al. 1996). Results of the Glader stage I trial involving injection of AAV into the 
hepatic portal could not be ascertained.
Clinical trials involving AAV predominate for haemophilia B gene therapy and have 
an impressive safety record. It is not without adverse events with a dose escalation 
study in 2002/3 resulting in 2 patients developing elevated liver enzymes. Also the 
feasibility study involving direct intramuscular injection of AAV serotype-2 (AAV-2) 
containing the hFIX gene resulted in the conclusion that the number of injections 
required was unrealistic. From this, two approaches have evolved utilising the muscle 
tissue: the continuing use of AAV-2 but using an intravascular administration method 
to transducer a wider region of muscle cells (Arruda, Stedman, Nichols et al. 2005) 
and the use of AAV serotype-1 (AAV-1) with a tissue specific regulator (Liu, 
Mingozzi, Rodriguez-Colon et al. 2004). The development of a systemic 
administration to target the liver with the same vector was suspended due to a transient 
elevation in liver enzymes observed in a patient, believed to be an immunological 
response to the transduced cells (Kaiser 2004).
1.3.1 The biology of gene delivery: obstructions and mechanisms
In order to successfully obtain a functional gene product from the transfer of a gene to 
a given cell, various processes need to take place. Broadly speaking they are:
Uptake of the nucleic acid or complex by the cell either by direct membrane 
interactions/endocytosis or active uptake by receptor mediated endocytosis; 
Transport of the gene to the nucleus via the endosomal compartment pathway 
(avoiding degradation in the lysosome);
Appropriate expression of the gene in terms of tissue distribution and level of 
expression;
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Correct processing of the gene products (mRNA transport splicing and 
translation) including post-translational modification of the peptide and correct 
positioning of the mature protein e.g. excretion for coagulation factors or 
anchoring within the apical membrane for the cystic fibrosis transmembrane 
conductance regulator (CFTR).
Should any of these components fail or prove inadequate, the process will not be 
successful.
The action of inserting a gene into the nucleus of a eukaryotic cell is unnatural and 
there are no inherent mechanisms to facilitate this process. Viruses overcome this by 
encoding their own machinery (for example retroviruses encode reverse transcriptase) 
to fulfil the task. The gene can be delivered to exist in the cell nucleus as a separate 
entity from the host chromosomes (episome), or integrated into the host genome. In 
this sense, and particularly with regards to viral delivery, it is the carrier vector used 
that defines the ultimate fate of the gene delivered. However, there are cis-acting 
elements (features contained within the DNA primary structure) that can facilitate 
nuclear retention and/or integration which have proven useful in increasing gene 
transfer efficacy.
Blood-borne barriers
The initial barriers facing any method of gene transfer is dependent on the route of 
administration and the location of the target cells. A key issue concerns whether it is a 
requirement of the technology to be injected intravenously or by other parenteral 
routes. A direct injection of a gene complex represents a far simpler task than 
targeting delivery to a specific tissue from a systemic administration. The 
biodistribution of a given DNA/carrier complex is important when considering the 
method of administration. It has been shown that intravenously administered 
liposomes tend to be taken up by the reticuloendothelial (RES) system (Gregoriadis 
and Allison 1974; Oku and Namba 1994), particularly the liver and spleen, a process 
shown to be almost completely independent of size, charge and composition. That 
said the RES system can be suppressed by increasing dose or decreasing the size of the 
liposome as well as pre-saturating the system with ‘empty’ liposomes.
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Different methods have been suggested to achieve a long circulation of liposomes in 
vivo including coating the liposome surface with inert, biocompatible polymers, such 
as polyethylene glycol (PEG) (Klibanov, Maruyama, Torchilin et al. 1990). The 
general opinion is that on the biological level, coating liposomes with PEG sterically 
hinders interactions of blood components with the liposome surface. This would have 
the effect of preventing liposome interaction with opsonins and decreasing the rate at 
which the liposomes are captured by the RES (Allen, Hansen, Martin et al. 1991). A 
similar modification in in vivo behaviour was observed with the inclusion of synthetic 
glycolipids (Wu, Robbins, Bugianesi et al. 1981). Components of the complement 
system are likely to interact with (opsonise) intravenously administered DNA 
complexes. Complement is part of the innate immune system and is activated by a 
wide variety of agents and complement-dependent phagocytosis of liposomes, by 
macrophages has been demonstrated (Wassef, Matyas and Alving 1991). The effects 
of these interactions on gene delivery are discussed further in Chapter 5.
Alternative methods of administration have shown some success on numerous 
occasions including peroral delivery for expression in the gut epithelia (During, Xu, 
Young et a l 1998), direct muscle injection (Wolff, Malone, Williams et al. 1990) and 
aerosolisation for lung epithelial transfer (Alton, Middleton, Caplen et al. 1993). Once 
delivered to the target site, the nucleotide complexes must resist nuclease activity and 
penetrate a physical surface barrier (such as mucus in the case of lung epithelia), in 
order to facilitate uptake by the cell. From intravenous delivery, the complexes must 
cross the endothelium (unless of course, the endothelial tissue is the target).
Extravasation and cell interactions
By far the tightest endothelial barrier is the blood-brain barrier as gaps at sites of cell 
junctions are nanometres wide, even in post-capillary venules, which, in other organs 
are generally relatively permeable. Although the skin, muscle and lung also have tight 
endothelial junctions, the post-capillary venules are slightly larger allowing for greater 
permeability. Tissues of the reticulo-endothelial system such as liver, spleen and bone 
marrow possess a sinusoidal endothelial structure that permits relatively free passage 
of materials without size restrictions up to about lOOnm diameter. For those particles 
with a diameter larger than lOOnm, extravasation is likely to be highly dependent on 
the blood pressure within the liver. If the injection volume is large relatively to the 
animal model, then elevated blood pressure may result in temporary high levels of
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extravasation. A comprehensive imaging study in mice revealed that cationic lipid- 
DNA complexes (lipoplexes) are taken up widely by endothelial tissue, but in a 
complex vessel and tissue-specific manner (McLean, Fox, Baluk et al. 1997).
Binding, internalisation and intracellular processing
When applied to cells, complexes are thought to mediate transfection via a multistage 
process that includes either hydrophobic or cationic binding to the cell membrane and 
subsequent entry into the cytoplasm. This can take the form of receptor mediated 
uptake, non-specific endocytic processes (Zabner, Fasbender, Moninger et al. 1995) or 
membrane fusion, depending on the vector used. The majority of proteins entering 
cells by receptor-mediated endocytosis are found by electron microscopy (EM) to be 
concentrated in coated pits.
These invaginations of the plasma membrane surrounded by electron dense material 
were first described in 1964 (Roth and Porter 1964). Further studies involving the 
purification of these pits found the main protein found in the coat to be clathrin (Pearse 
1975; Pearse 1976), giving rise to the term clathrin-mediated endocytosis. Many 
receptors can be found in the coated pits, even in the absence of a ligand (e.g. 
transferrin receptors LDL receptors), others concentrate there only after ligand binding 
(e.g. EGF receptor). Once assembled as a planar lattice, the clathrin coat progressively 
bends to form a dome and eventually an invaginated, coated bud connected to the 
plasma membrane by a narrow neck. Following this, further constriction of the neck 
leads to the formation of a free vesicle. Newly formed vesicles lose their clathrin coat, 
dock and then fuse with the membrane of the endosome, delivering its content into the 
lumen of the endocytic compartment.
The endosome
The endosomal compartment performs many tasks for the cell. In this case 
internalized material undergoes sorting for subsequent transfer to lysosomes, recycling 
back to the membrane or for transport to the trans-Golgi network (TGN). This 
molecular sorting includes receptor-ligand dissociation and recycling of the receptor 
back to the cell membrane. Endosomes are classified according to their labelling 
characteristics following the introduction of certain molecular tracers:
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Early endosomes are defined as the first target organelles for incoming 
endocytic markers. Typically they are reached by extracellular tracers a few 
minutes after their introduction to the medium. Morphologically early 
endosomes appear as a network of vesicles, tubules and vacuoles which are 
dynamic in nature with incoming membrane flow equilibrated by continuous 
flow to other compartments
Late endosomes are defined as a compartment where endocytic tracers 
accumulate following transit through early endosomes (typically 10-15 
minutes, depending on cell type)
Lysosomes are the final destination of internalized proteins that are not 
recycled and contain a higher concentration of hydrolytic enzymes. Whether 
the transition from late endosome to lysosome occurs by a maturation process 
or by fusion with pre-existing lysosomes remains to be fully understood. Figure 
1.2 shows a schematic diagram of endocytic pathways in mammalian cells.
A variety of ligand-receptor complexes dissociate in early endosomes because of their 
slightly acidic pH (6.0-6.8) generated by the vacuolar proton pump. Dissociated 
receptors are recycled to the cell surface by small vesicular carriers, whereas the bulk 
of ligands and undissociated ligand-receptor complexes are destined for degradation in 
large vesicular elements which proceed further to late endosomes and lysosomes.
The precise mechanism of transport throughout this process remains unclear though it 
is generally accepted that vacuolar elements dissociate and migrate along microtubules 
to the perinuclear region before fusing with late endosomes.
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Figure 1.2 Schematic model of the endocytic pathway
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Many traditional methods for DNA delivery into cells employ endocytic mechanisms. 
Calcium phosphate precipitation is believed to be mainly based on endocytic uptake. 
Cationic lipids were originally proposed to fuse with the plasma membrane however it 
appears that these lipid-DNA complexes enter cells by endocytosis, where they 
accumulate into endosomes. The DNA then escapes into the cytoplasm by an 
unknown mechanism.
Some of the more advanced strategies for the cell-specific introduction of DNA into 
cells use the receptor mediated uptake mechanism. The first system to take advantage
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of this was developed by Wu who linked asialoglycoprotein to polylysine complexed 
DNA for efficient transfer into hepatocytes in vitro and in vivo (Wu and Wu 1987; Wu 
and Wu 1988). Following this study, a growing number of systems employing a 
variety of receptor-ligand interactions (transferring, insulin, epidermal growth factor, 
antibodies (Ab) against surface proteins, carbohydrates and integrins) were designed.
Further developments of such systems includes an addition of special elements for 
improved DNA escape include a section of the influenza virus haemagglutinin protein 
(NH2 terminal of subunit HA-2) (Plank, Oberhauser, Mechtler et a l 1994). The 
influenza virus makes efficient use of the falling pH in endosomal compartments to 
induce a conformational change in proteins to yield an amphipathic a-helix structure 
that is capable of membrane fusion (Klasse, Bron and Marsh 1998).
A peptide fragment of influenza virus has been shown to mediate pH-dependent lysis 
of liposomes and erythrocytes as well as increase the frequency of transfection when 
incorporated into poly-L-lysine(pLL)/DNA complexes (Plank, Oberhauser, Mechtler et 
al 1994; Gottschalk, Sparrow, Hauer et a l 1996) or as part of a peptide delivery 
system (Gottschalk, Sparrow, Hauer et al 1996). It is generally accepted that these 
pH-responsive amphipathic helices act via membrane disruption due to a ‘proton- 
sponge effect’(Boussif, Lezoualc'h, Zanta et a l 1995). This hypothesis has been 
supported by the transfecting activities of cationic polymers such as
TMpolyethanolamineimene (PEI) and Starburst dendrimers whose pKa values are in the 
region 5.5-7.0. The mechanism proposed is that high concentrations of protonable 
groups within an endosome will buffer the fall in pH, increasing the length of time for 
the DNA to reach the lysosome and the likelihood of spontaneous translocation into 
the cytoplasm.
It has been suggested that the increase in osmotic pressure within the endosome causes 
swelling and eventual lysis, releasing the entrapped DNA into the cytoplasm. This 
perceived mechanism is derived from the action of the weak base chloroquine, which 
is known to increase the transfecting activity of polyelectrolytes among many cell 
lines. It is interesting to note that chloroquine does not enhance the activity of
TMPEI/DNA or Starburst dendrimer complexes.
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Disassociation of complexes and transport to the nucleus
It is likely that the cationic component of pLL/DNA complexes (as well as possibly 
other carriers) exert some nuclear localising effect considering the cationic nature of 
the many nuclear-targeting sequences already identified. Additionally, within the 
nucleus the enzymes associated with transcription are readily able to release DNA 
from cationic compounds to allow RNA polymerisation. This is supported by 
experimental evidence that suggests direct injection of pLL/DNA complexes into the 
cytoplasm of Xenopus oocytes resulted in significantly higher expression than the 
equivalent injection of free DNA (Oupicky, Konak, Ulbrich et al. 2000). In contrast, 
cationic lipid/DNA complexes appear to require uncoupling prior to delivery to the 
nucleus. The direct injection of lipoplexes into the cytoplasm or even nucleus of 
Xenopus oocytes resulted in negligible levels of gene expression (Zabner, Fasbender, 
Moninger et al. 1995) implying that the normal endosomal route of entry into the cell 
incorporates an uncoupling stage where DNA is released from the cationic lipid.
Relatively little is known about the uptake of DNA into the nucleus itself, particularly 
since this is not part of normal cell physiology. In non-dividing cells, molecular 
exchange across the nuclear envelope normally takes place through the nuclear pore 
complexes (NPC). These channels regulate the traffic of protein and protein-RNA 
complexes between the cytoplasm and the nucleus (Pante and Aebi 1993) and 
performs distinct roles of passive exchange for small molecules (up to 70kDa) and 
peptide signal-mediated selective transport for larger structures (Gorlich and Mattaj 
1996). The size scales of the NPC make it an unlikely transporter for DNA. The 
upper limit for diffusive passage of colloidal gold particles is approximately 9nm in 
diameter; whereas the nuclear localization signals (NLS) mediated mechanism displays 
an apparent particle diameter limit of 25nm.
A prominent feature of viral mechanisms is their ability to co-opt native protein-import 
machinery by expression of an appropriate NLS (Whittaker and Helenius 1998). The 
basic peptide derived from the simian virus 40 large tumour antigen (PKKKRKV) is a 
nuclear localizing signal that mediates binding of the karyophilic protein to importin-a 
(Adam and Gerace 1991). Complex formation triggers binding to importin-{3, the 
ternary complex is then carried through the nuclear pore complex with the help of a 
GTPase. Several attempts to improve entry of plasmid DNA into the nucleus have 
been published. These include the electrostatic binding of DNA to cationic NLS-
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containing proteins (Kaneda, Iwai and Uchida 1989) or lipids (Remy, Kichler, 
Mordvinov et al 1995) as well other carriers. This “piggyback” approach to nuclear 
transport relies on the unpredictable stability of the complexes within the cytoplasm 
and the fact that the DNA remains associated with the carrier until inside the nucleus.
1.3.2 Potential applications for gene therapy
Gene therapy is a broad term used to describe the use of specifically designed nucleic 
acid based molecules to treat a medical condition. There are a number of different 
conditions that could potentially respond to treatment using such an approach.
Antisense therapy is the administration of specifically designed oligonucleotides to 
inhibit or block the processing of messenger RNA (mRNA) of a specific gene and thus 
its expression. These include RNA ribozymes (Perriman and Gerlach 1990; 
Thybusch-Bemhardt, Aigner, Beckmann et al. 2001), DNAzymes (Li and Sen 1997; 
Sim, Cairns, Saravolac et al. 2000) or a hybrid DNA/RNA molecule (Nesterova and 
Cho-Chung 2000). These oligonucleotides can form complex secondary and tertiary 
structures, which have enzymatic properties, usually exo/endonuclease activity. 
Conversely they can simply be a complementary single stranded oligonucleotide that 
binds to the target mRNA sequence, blocking ribosome attachment and preventing 
further processing.
Cancer (solid tumour) gene therapy by the injection of the tumour with genes to 
stimulate or augment a specific immune response against it (Stopeck, Hersh, 
Akporiaye et al 1997) or induce apoptosis (cell suicide) in the cells forming the 
tumour (Swisher, Roth, Nemunaitis et al 1999). An immune response against tumour 
cells can be stimulated by increasing the levels of tumour-specific antigens displayed 
on the surface of the cells in context with MHC (major histocompatability complex) 
class I. This increased expression can induce or increase CTL (cytotoxic T- 
lymphocyte) responses against such cells.
Gene vaccine treatment by the delivery of naked DNA injection is a method for 
preventative vaccination against infectious disease (Wang, Doolan, Le et al 1998). 
The transfection of antigen presenting cells such as macrophages or, most importantly, 
dendritic cells can lead to the development of an immune response against any cells 
bearing epitopes of the gene introduced. Careful selection of genes associated with
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abnormal cell growth or surface antigens expressed at inappropriate levels on tumours 
is required as autoimmune responses can be easily triggered.
Short-term expression therapy: (e.g. the injection of naked DNA encoding vascular 
endothelial growth factor (VEGF) for localised expression). This gene is applied to 
the affected area to stimulate new vascular growth and relieve ischaemia due to 
inadequate blood supply (Baumgartner, Pieczek, Manor et al 1998). The property of 
naked DNA being expressed only for a limited time is a positive advantage in this 
case, as continual production of vessels could cause circulatory problems.
Long-term correction: is the administration of a correct copy of a defective gene to 
reverse a phenotype (Herzog, Yang, Couto et al. 1999). This approach requires 
sustained expression at therapeutic levels, as well as suppression of any immune 
system activation should repeat administration be required. A person deficient in a 
certain protein from birth will not have had the immune ‘education’ that removes any 
auto-reacting factors early on. The introduction of a novel protein could produce an 
inhibitory immune response as seen in up to 20% of severe haemophiliacs (Lusher, 
Arkin, Abildgaard et al 1993; Bray, Gomperts, Courter et a l 1994).
It is interesting to see that the same approach is used for two very different objectives. 
Naked DNA is used in protocols designed to elicit an immune response and also those 
required to avoid immune stimulation and inactivation. This distinction is determined 
by the method of administration and with the use of a specific vector or adjuvant 
demonstrating the versatility of nucleic acids as therapeutic agents.
Many gene transfer techniques have been developed which can be broadly classified 
into viral (infection) and non-viral (transfection) methods. Desirable features of a gene 
transfer protocol include a high efficiency of transfer, minimal interference with 
normal cell physiology, low toxicity, ease of use and commercial reproducibility.
Most techniques involve compaction of the DNA molecules to facilitate uptake. With 
modified viruses proving the most effective method of gene transfer both in vitro and 
in vivo. This seems appropriate since viruses have eons of evolutionary experience to 
develop the strategy. Used as a tool, however they are not without disadvantages as 
illustrated in Table 1.1. Non-viral gene delivery is an attractive proposition, as it
40
would address many of the concerns associated with administrating live virus particles 
to a subject as a means of therapy.
1.3.3 Viral gene transfer.
Viral gene delivery has always appeared to be one-step ahead of non-viral techniques 
in terms of transfection efficiency, but it is not without drawbacks, most notably 
immunogenicity, where the viral carrier activity is neutralised by the host immune 
system. The mainstay of clinical trials in viral gene therapy falls to three types: (1) 
Adenovirus (Ad); (2) Retrovirus (Rv) and (3) Adeno-associated virus (AAV). Some 
of their characteristics are outlined below.
Table 1.1 Summary of contrasting properties of viral and non-viral
approaches to gene therapy 
Viral
High efficiency of transduction (up to 
100%)
Plasma stability
Some viruses show tissue tropism 
Immunogenic, especially in repeat 
applications
Possibility of reversion to pathogenic 
virulence
Random integration into genome (some 
viruses)
Restrictions on size of gene carried 
Can be concentrated for in vivo delivery 
Complicated, expensive production at 
high doses
Possibility of contamination by other 
viruses
Possible transmission to germ-line
Non-viral
Lower efficiency of transduction
Reduced activity in plasma
Can be targeted with conjugated ligands
Low/absent immunogenicity
No possibility of pathogenicity
Non-integrating
No restrictions on size of gene 
Aggregate at high concentrations 
Cheap, mass production and formulation 
plausible
Synthetic and easily purified 
Negligible risk of transmission
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Adenovirus
Ad gives more-efficient gene transfer compared with other systems, especially in vivo. 
Ad vectors can transfer genes to both proliferating and quiescent cells. Expression of 
the transgene is transient however, being low or undetectable in most tissues after two 
weeks following initial high levels of expression. This is due to the fact that Ad vectors 
do not integrate into the host genome and are disabled for replication. This means 
generally they are not suitable for chronic disease correction but useful for directed cell 
killing, most immunotherapy protocols and some acute diseases.
Ad gives particularly efficient gene transfer to the liver, such that dissemination from 
the site of local injection (e.g. into tumours) can cause consequent liver transfection, 
which is a serious safety concern. This is especially true of individuals with a pre­
existing liver condition such as hepatitis B or C infection, commonly seen in 
haemophiliacs. This can be addressed using tissue specific promoters (Schiedner, 
Morral, Parks et al 1998) or alteration of cell surface proteins (Bilbao, Gomez- 
Navarro and Curiel 1998; Searle and Mautner 1998). A major limitation of Ad vectors 
is their tendency to elicit strong immune responses. This reduces efficacy as 
neutralizing antibody binding prevents proper uptake of the Ad by the target cell. Also 
repeat administrations become ineffective or provoke a strong inflammatory response. 
Indeed the only human death attributed to gene therapy clinical trial occurred from an 
inflammatory response following administration of an Ad vector (Editorial 2000; 
2000; Hollon 2000)
Most Ad vectors are derived from the Ad5 serotype. It has been suggested that 55% of 
adult humans have pre-existing anti-Ad antibodies capable of neutralizing in vitro 
infection by Ad5 (Chirmule, Propert, Magosin et al. 1999). Whether these low titre 
antibodies would interfere with gene transfer upon a first systemic Ad administration is 
not yet clear but investigations such as per oral administration to induce tolerance 
(Ilan, Prakash, Davidson et al 1997) and shielding key epitopes (Chillon, Lee, 
Fasbender et al. 1998) are ongoing.
Current generations of Ad vectors have had nearly all endogenous genes removed. 
These are sometime called “gutted” or helper-dependent vectors and can accommodate 
much larger inserts and have reduced immunogenicity.
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Retrovirus (Rv)
Rv vectors differ from Ad vectors as they facilitate a more-prolonged if lower level of 
transgene expression. A major limitation to this approach is that only proliferating 
cells can be transfected as the provirus only penetrates the nucleus at mitosis.
Rv can be retargeted to bind cell-surface proteins other than its natural receptor, but 
efficient retargeted transfection has not yet been reported. Most first-generation Rv do 
not express residual viral genes, which is partly why Rv are much less immunogenic 
than Ad. However, it is clear that expression of heterologous transgenes leads to 
cytotoxic T-cell (CTL) responses destroying the expressing cells and reducing the 
effectiveness of repeat dosing (Fields, Kowalczyk, Arruda et al. 2000). This occurs 
even in symptomatic AIDS patients (who are seriously immunocompromised), 
indicating that this is a serious problem for gene therapy (Riddell, Elliott, Lewinsohn 
et al. 1996). Additionally Rv are rapidly inactivated by the human complement system 
and therefore gives inefficient gene transfer for most cell types in vivo.
The most extensive use of Rv vectors has been with ex vivo applications, for which 
cells can be cultured to allow efficient transduction from smaller quantities of virus. 
This is an important factor because Rv has presented serious manufacturing problems 
in obtaining high titres and preserving activity through concentration and storage. 
Despite these problems, much clinical experience has been obtained so far with Rv 
largely due to its capability for longer expression. Recent improvements in 
manufacturing processes and the use of envelope proteins from other viruses to 
package the recombinant Rv genomes, enable higher viral titres, greater complement 
resistance, transduction of a wider range of cell types and more-efficient transduction 
in vivo.
Significant progress has been made recently in developing vectors from lentiviruses 
(Lv) such as the human immunodeficiency virus (HIV) (Park and Kay 2001), simian 
immunodeficiency virus (SIV) and feline immunodeficiency virus (FIV) (Stein, Kang, 
Sauter et al. 2001), which are capable of integrative transduction of several quiescent 
(and post-mitotic) cell types as well as proliferating cells. Additionally Lv vectors can 
transfect quiescent haematopoietic stem cells and ultimately might give more efficient 
in vivo transduction than their Rv predecessors.
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Adeno-associated virus
AAV is a small virus capable of integrating into the target-cell chromosome. Wild-type 
AAV integrates exclusively into a single site on human chromosome 19 by a 
mechanism not yet fully understood. Many recombinants show long-term persistence 
in unintegrated forms and appear to give sustained transgene expression following in 
vivo administration.
Long-term correction of haemophilia B has been achieved in both murine and canine 
models of the disease with a single infusion into the liver of an AAV vector expressing 
the FIX gene (Snyder, Miao, Meuse et al. 1999) as well as muscle tissue (Herzog, 
Hagstrom, Kung et al. 1997; Herzog, Yang, Couto et al. 1999). Although the intra­
cellular events responsible and the actual need for integration are not established, these 
examples of sustained expression are a major advantage in treating chronic diseases.
The data available concerning immunogenicity of AAV vectors suggest 32% of adult 
humans possess pre-existing antibodies that neutralize transfection in vitro by the 
AAV2 serotype, from which most AAV vectors are derived (Chirmule, Propert, 
Magosin et al. 1999). Studies in mice suggest injection of AAV type 1 in doses giving 
therapeutic levels of transgene expression leads to the generation of neutralizing 
antibodies that will reduce the effectiveness of repeat dosing (Xiao, Chirmule, Berta et 
al. 1999). The intramuscular injection of an AAV vector expressing FIX failed to 
activate FIX-specific cytotoxic T-lymphocytes (CTLs) in haemostatically normal or in 
hemophilia B mice, resulting in an absence of cellular immune responses against FIX. 
Transgene-derived FIX however, did cause B cell responses (characterized by 
production of T helper cell-dependent antibodies), of a level comparable to those seen 
following protein infusion (i.e. rFIX) (Fields, Kowalczyk, Arruda et al. 2000). A 
cellular immune response to AAV-infected cells is undetectable partly because, in 
addition to the transgene, the vectors contain only short viral sequences required for 
packaging. This undoubtedly contributes to the prolonged expression observed in 
many tissues.
AAV can transfer genes efficiently to both quiescent and proliferating cells. Also 
substantial transfection and long-lasting transgene expression in the epithelial and sub- 
epithelial cells of the upper intestinal tract have recently been reported following oral 
administration of an AAV vector (During, Xu, Young et al. 1998). The main
disadvantages of AAV concern insert size and manufacturing; the virus can only 
accommodate inserts up to 4.5 kb, and early manufacturing processes have required 
the use of helper viruses (usually Ad), which present problems of low titre, 
contamination and costly purification procedures. Now that improved manufacturing 
processes allowing high-titre production without a helper virus have been developed 
(Matsushita, Elliger, Elliger et al. 1998) many more AAV-based therapies are reaching 
the clinic. A phase II clinical study investigating AAV-mediated transfer of hFIX is 
discussed later in this chapter.
1.3.4 Non-viral vectors
The non-viral techniques can be sub-classified further into chemical or physical 
methods, with the chemical approaches characterised by the type of delivery vehicle 
used i.e. liposomal, peptide and polymer based. Although recent advances are 
promising, many suffer from lower transfection efficiencies in vitro and low to absent 
activity in vivo when compared to viral carriers.
DEAE-Dextran
Among the first chemical reagents to be used in the transfection of cultured animal 
cells were DEAE-Dextran (Pagano and Vaheri 1965) and calcium phosphate (Graham 
and van der Eb 1973). These methods involve compaction and precipitation of the 
DNA respectively to facilitate uptake by the cells, presumably by endocytosis. DEAE- 
Dextran transfection is generally for short-term (transient) expression of the introduced 
gene and is not suitable for studies involving integration of the foreign DNA into the 
cells chromosomes. Problems associated with the use of Dextran include high cell 
toxicity requiring reduced exposure of the cells to the solution containing the DNA to 
be inserted.
Calcium Phosphate co-precipitation
The co-precipitation of calcium phosphate with DNA continues to be a popular 
technique. Components are cheap and widely available as well as being easy to use. 
This method is routinely utilised for both transient and stable (long-term) transfection 
of a number of cell types.
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Naked DNA
Naked, supercoiled plasmid DNA has been shown to be expressed in vivo in a number 
of studies (Budker, Zhang, Knechtle et al 1996; Takeshita, Tsurumi, Couffinahl et al. 
1996; Lui, Falo and Huang 2001), suggesting that no co-factors are essential for 
transfection process to take place. It has been suggested that naked plasmid DNA is 
taken up via a scavenger receptor like-mediated mechanism for polyanions (Nakamura, 
Davila-Zavala, Tokuda et al. 1998; Takakura, Takagi, Hashiguchi et al. 1999). A 
number of target tissues have been used for the delivery of naked DNA usually 
involving direct injection into the hepatic portal vein (Budker, Zhang, Knechtle et al. 
1996).
Electroporation and ballistic (gene-gun) delivery
Electroporation for the introduction of foreign genes into cells depends upon the 
original observation that high-voltage electric pulses can induce cell plasma 
membranes to fuse (Zimmermann and Vienken 1982). Subsequently it was found that 
when subject to an electric pulse, the cells take up exogenous DNA from the 
suspending solution through pores momentarily created in the plasma membrane. 
Although most cells die following this treatment, a proportion of the cells can be stably 
transformed (Neumann, Schaefer-Ridder, Wang et al. 1982; Potter, Weir and Leder 
1984). This technique is still in general use for the production of stable transformants. 
Ballistic delivery of nucleic acids into living cells is a completely novel method 
involving high velocity microprojectiles, which carry the RNA or DNA, and are 
literally shot into the cell (Klein, Wolf, Wu et al. 1992). An explosive charge fires 
spherical tungsten particles (average diameter 4pm) into intact cells. This technique 
has proven particularly useful for the stable transformation of plant cells.
Microinjection
The microinjection of DNA into the cell (Kondoh, Yasuda and Okada 1983) involves 
the isolation of a single cell, which is then immobilised and penetrated with a very fine 
needle. DNA is then delivered directly to the nucleus through the needle in what is an 
extremely labour-intensive procedure. As each cell is individually treated, this 
technique is unfeasible for large numbers of cells, but has the advantage of a high rate 
of success. Applications for this technique are mainly in the expansion of a clonal 
cell-line derived from injected cells.
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Peptides as carriers for gene delivery
Individually tailored peptides have been widely described as an approach to gene 
delivery (Sparrow, Edwards, Tung et al. 1998; Morris, Chaloin, Mery et al. 1999; 
McKenzie, Kwok and Rice 2000; Ward, Read and Seymour 2001). Most involve the 
use of pLL or other cationic polypeptides and can vary widely in chain length. These 
pLL/DNA complexes typically measure less than lOOnm in diameter and can be 
targeted to various cell lines in vitro by covalent attachment of targeting ligands to the 
pLL, resulting in transgene expression (Hart, Harbottle, Cooper et al. 1995; Colin, 
Harbottle, Knight et al. 1998; Wagner, Ogris and Zauner 1998; Nishikawa, Yamauchi, 
Morimoto et al. 2000). This has also been the case in vivo with hepatocytes 
successfully targeted with a poly(L-omithine) polymer modified with a fusogenic 
peptide and galactose (Nishikawa, Yamauchi, Morimoto et al. 2000). In this case two 
major barriers of gene delivery (discussed later in this chapter) are overcome by these 
modifications, namely:
• Efficient selective uptake of the complexes facilitated by a terminal galactose 
ligand, necessary for receptor-mediated uptake by the asialoglycoprotein 
receptor (ASGPr) (Wu and Wu 1987).
• Endosome escape by means of a peptide normally found on the amino-terminal 
of influenza virus haemagglutinin subunit HA-2 (Plank, Oberhauser, Mechtler 
etal. 1994).
Peptides have a versatility that allows a wide scope for modification but with it comes 
the possibility of antigenicity, which if designed as a vaccine is desirable, but as a 
carrier for gene delivery, could reduce efficacy and scope for any further 
administrations.
Polymers as carriers for gene transfer
Polyethanolamineimene (PEI) has been reported as a high efficiency gene carrier both 
in vitro and in vivo (Boussif, Lezoualc'h, Zanta et al. 1995). Much of this compound’s 
efficiency is due to the high cationic-charge-density-potential, which conveys the 
characteristic of retaining substantial buffering capacity at virtually any pH. This is a 
desirable property to facilitate release of the complex from the endosome 
compartment, by way of causing osmotic swelling of the endosome and subsequent 
disruption. In this manner PEI acts as a “proton sponge” to the vesicular ATPase-
47
driven H+ accumulation (Nelson 1991), normally lowering pH of the lysosomal 
compartment and degrading its contents.
Liposome mediated gene transfer.
Since the first artificial liposomes used for gene delivery purposes (Fraley, Subramani, 
Berg et a l 1980) and the advancement to synthetic liposomes (Feigner, Gadek, Holm 
et al 1987) several hundred different variations of this technology have been 
developed by different groups. Although the structure of these compounds varies 
widely, they mostly follow an arrangement that includes a cationic or poly-cationic 
head group attached to single or multiple long acyl chains (C l4-20) by a linker. Once 
in contact with negatively charged DNA, electrostatic and hydrophobic forces result in 
liposome formation. Cationic liposomes may contain a neutral fusogenic lipid such as 
dioleoyl phosphatidylethanolamine (DOPE) or cholesterol (Liu, Mounkes, Liggitt et 
al 1997) to facilitate liposome formation or to enhance gene transfer (Farhood, 
Serbina and Huang 1995).
Lipids have been developed with monovalent head groups e.g. DOTMA (Feigner, 
Gadek, Holm et al 1987) or DOTAP (Leventis and Silvius 1990) and others, like 
DOGS and DPPES (Behr, Demeneix, Loeffler et al 1989) contain multivalent head 
groups. Figure 1.3 shows the structures of some commonly used non-viral transfection 
reagents.
Further developments include the incorporation of targeting ligands such as those for 
the asialoglycoprotein receptor found on hepatocytes (Perales, Grossmann, Molas et al 
1997; Bandyopadhyay, Kren, Ma et a l 1998) and integrin binding peptides to facilitate 
endothelial gene transfer (Hart, Harbottle, Cooper et al 1995). Additionally, gene 
construct developments have enabled higher levels of tissue specific expression both in 
vitro and in vivo to be achieved.
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Figure 1.3 Structure of commonly used non-viral transfection 
reagents.
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Dendrimers
Dendrimers are highly branched and reactive three-dimensional macromolecules, with 
all branches emanating from a central core. Since their introduction in the mid 1980s, 
this novel class of polymeric materials has attracted considerable attention due to their 
unique structure and properties. Compared with traditional linear polymers, 
dendrimers have a much more accurately controlled structure such as globular shape 
and a single molecular weight rather than a distribution of molecular weights.
Two distinct synthetic strategies exist for the preparation of dendrimers: the divergent 
approach (Newkome 1985; Tomalia, Baker, Dewald et al. 1985) and the convergent 
approach (Frechet and Hawker 1996). The most obvious difference between the two 
approaches is in the direction of dendrimer growth. In divergent synthesis, dendrimer 
growth starts from a polyfunctional core and proceeds radially outwards with the 
stepwise addition of successive layers of building blocks. Convergent synthesis directs 
the growth of individual segments of the dendrimer towards the core. To compare the 
two approaches, divergent synthesis requires extremely efficient reactions to avoid 
imperfectly formed dendrimers which are very difficult to isolate from their side 
product. In contrast, convergent dendrimers are simple to purity and reactions are not 
required to be stringently efficient, however, a large amount of starting material is 
required and this method suffers from low yield of larger structures.
Figure 1.4 shows a commercially available polyamidoamine (PAMAM) dendrimer 
(Tomalia, Naylor and Goddard 1990) synthesized using a divergent growth approach, 
in which the terminal molecules are extended. PAMAM dendrimers have been 
reported to efficiently transfer genetic material and that the transfection was a function 
of both the dendrimers-DNA ratio and the diameter of the dendrimers (Haensler and 
Szoka 1993). Szoka and coworkers also reported ‘fractured dendrimers’, obtained 
from the heat treatment of intact dendrimers had greatly enhanced transfection 
efficiency (Tang, Redemann and Szoka 1996).
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Figure 1.4 Structure of a 1st generation PAMAM dendrimer 
molecule.
The structure o f a first generation PAMAM dendrimer molecule is illustrated here 
showing the three-lysine structure joined by a central nitrogen atom.
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Highly efficient in vitro transfection has also been shown by a number of groups as 
well as data suggesting that these molecules are not immunogenic or carcinogenic 
(Roberts, Bhalgat and Zera 1996), enhancing their potential as vectors for in vivo 
applications.
Lipidic peptide dendrimers, used for the majority of work described in this thesis are a 
variation of this type of molecule. They are constructed using the divergent approach 
and are discussed in greater detail towards the end of this chapter.
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1.4 Lipidic amino acid dendrimers
The basic structure of lipidic peptide dendrimers (LPD) originates from a previously 
described series of molecules derived from amino acids (Toth 1994). These carriers 
were designed as a versatile method of drug delivery and could also function as a pro­
drug when covalently linked to the appropriate molecule. The LPD were synthesised 
with a number of variations produced to determine the most effective composition for 
a given task (Toth, Sakthivel, Wilderspin et al 1999).
These molecules are described as water-soluble amphipathic branched polypeptide 
dendrimers having three lipidic (C l4) chains derived from a-amino myristic acid 
(AMA) coupled to dendritic lysine head groups. They lack the symmetrical branching 
and high surface charge density that leads to the spherical nature of PAMAM 
dendrimers, but exhibit asymmetrical branching due to the position of the lysine or 
ornithine moieties. Fundamentally they are produced using the divergent method with 
a controlled synthesis procedure yielding compounds with similar properties to 
activated dendrimers, avoiding the chemical variability often seen following 
conventional activation due to partial hydrolysis and subsequent fractionation. A more 
detailed summary of the synthesis is given in Chapter 4 page 104. Figure 1.5 
illustrates the structure of LPD and details the variations produced.
1.4.1 The development of LPD
A number of published studies have followed the development of this family of 
molecules from conception. A lipophilic series of symmetrical polyamide dendrimers 
were investigated in order to define certain characteristics such as the ability to form 
aggregates (Sakthivel, Toth and Florence 1998). This is an important step in 
determining the behaviour of the molecules in aqueous solution and the study found 
that only the 4th generation dendrimer formed tubular supramolecular aggregates 
visible by Transmission Electron Microscopy (TEM). This property of self-assembly 
is widespread in natural occurring membrane lipids as well as an essential part of some 
viral lifecycles and can be utilised.
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Figure 1.5 The structure of LPD and its variations
The LPD available for this study are shown along with details o f the modifications 
developed
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X=GPKKKRKV G*
*Nuclear localisation signal peptide
2 :
As for 1, with Om replacing Lys 
(a-e are variants sis for 1)
\
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3:
As for 1, X = glucose molecule (a-c are 
variants as for 1).
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The interaction of asymmetrical cationic LPD with charged and neutral liposomes has 
been observed both in a previous published study (Purohit, Sakthivel and Florence
2001) and also in this thesis (Chapter 5 page 160). They can either be entrapped 
inside the aqueous phase of the liposomes between the lipid bilayer, adsorbed onto the 
surface or effectively co-exist between two of these states. Although the mechanism is 
unclear, the 32 amino-terminal LPD (and to a lesser extent the 16) appeared to 
solubilise the negatively charged liposomes, indicated by the formation of large 
vesicular structures following ultracentrifugation.
LPD did not show preference for anionic liposomes and adsorbed to all liposomes 
similarly, suggesting a hydrophobic interaction of the respective lipid chains being the 
dominant force at work. The use of co-lipids is widespread for non-viral applications 
with DOPE and cholesterol shown to enhance some delivery systems (Feigner, Gadek, 
Holm et al. 1987; Liu, Mounkes, Liggitt et al. 1997). The fact that some lipids can be 
integrated to confer function to the complexes such as cell targeting (Bandyopadhyay, 
Kren, Ma et al. 1998), in vitro transfection (Farhood, Serbina and Huang 1995) or 
extended biological existence (Klibanov, Maruyama, Torchilin et al. 1990) has been 
previously examined with some success reported and will be examined in the context 
of LPD in this thesis .
Each progressive generation acquires lysine molecules onto the terminal amino- 
groups, increasing the hydrophilic portion of the molecule. It would be expected for 
these higher generation molecules exhibit more classic dendrimer characteristics such 
as higher solubility and an increased overall ionic interaction with DNA, in contrast to 
natural polyamines or cationic lipids possessing smaller polar head-groups. This 
increase in volume as well as hydrophilic nature is likely to somewhat mask the 
hydrophobic region, reducing its influence on the overall structure.
Figure 1.6 shows the structure of two lipidic peptide dendrimers (la  and lb) as a 
space-filling diagram.
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Figure 1.6 Space-filling model showing structure of la  (a) and lb (b)
The black spheres represent nitrogen atoms; the white spheres hydrogen atoms and the 
intermediate shaded spheres, carbon. This model gives an approximate representation 
o f the relative sizes and spatial arrangement o f the molecule. Here. the (b) dendrimer 
shows the lipid component becoming less significant as a proportion o f  the overall 
structure compared to (a). (Shah Sakthivel Toth et al. 2000) © 2000 Elsevier 
Science.
1.4.2 LPD/DNA complex formation
The complex used to transfect cells consists of DNA and LPD. The binding of 
Starburst™ dendrimers to plasmid DNA has been reported to alter the secondary, but 
not primary structure, of the DNA (Tomalia, Naylor and Goddard 1990). Starburst 
dendrimer are a structurally defined, spherical macromolecule composed of repeating 
polyamidoamine subunits and are structurally similar to LPD. These dendrimers 
condense the plasmid with the degree of condensation dependent on the size of the 
dendrimer, the concentration of the DNA and the dendrimer/DNA charge ratio used. It 
is believed that lipidic amino acid dendrimers act in a similar way as the 
electropositive dendrimeric head of Starburst™ dendrimers by interacting with the 
electronegative phosphate backbone of the DNA with the effect of condensing the 
DNA into complexes with the dendrimer. The lipid chains impart a hydrophobic 
component to the interaction further promoting the formation of ordered structures. 
This interaction can be reversed at pH 11.0 (Shah, Sakthivel, Toth et al 2000) and is 
able to produce morphologically different structures depending on concentration and 
other environmental conditions. This property is essential for the DNA to be made 
available to polymerase enzymes for transcription.
1.4.3 Self-assembly and the properties of complexes
All the dendrimers synthesised for this study are amphiphilic and theoretically capable 
of forming micelles or bi-layers in aqueous solution. Bilayers as a rule are formed 
from lipids containing two or more hydrocarbon chains, whereas single chained lipids 
form micelles (Israelachvili, Mitchell and Ninham 1977). This process of self- 
assembly due to hydrophobic effect is ubiquitous as an organisational force in nature, 
with cell membranes being a classic example of a self-assembled bilayer. The super- 
molecular structure and stability of these aggregates is dependent on both internal 
conditions i.e. the relative size of the hydrophobic and hydrophilic components as well 
as external conditions such as temperature and concentration.
Figure 1.7 shows a prediction based on current models as to how the LPD/DNA 
complex could be assembled in the aqueous media used during transfection.
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Figure 1.7 Predicted structure o f LPD/DNA complexes in aqueous 
media
The dendrimer shown below indicates the possible orientation o f the hydrophobic 
(three lipid chains) and hydrophilic domains (branched lysine head-group -  shown 
here as a two tier oval). Not to scale.
The structure shown follows the conventional lipid bilayer assembly with hydrophobic 
forces causing the lipid chains to move away from the aqueous media as hydrophilic 
lysine groups are directed towards. There would be repulsive electrostatic forces 
between the lysine groups, especially in the larger, more densely charged dendrimers 
such as lb and lc, possibly creating wider gaps between individual molecules which 
may be interspersed with the negatively charged DNA. The DNA is compacted in the 
centre of the structure by the lysine groups as seen in cationic lipids.
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Chapter 2 
Aims and Objectives of this Study
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Non-viral gene delivery provides a number of theoretical advantages over the use of 
viral vector systems. However, it is potentially limited by many factors, not least 
inefficiency of gene transfer. As outlined in Chapter 1 page 52, lipidic peptide 
dendrimers (LPD) are a series of molecules derived from amino acids that have been 
developed as a potential method of drug delivery. As the chemistry is relatively simple 
they can be synthesised in many varying forms. These differing forms can therefore be 
tailored to produce a composition that can potentially be designed to perform a specific 
delivery task. Specifically LPD synthesis can be modified to confer cell targeting 
function, in vivo transfections and extended biological half life (see Chapter 1, page 
54).
This thesis developed to explore the premise that, due to this flexibility of synthesis, 
LPD could, potentially, be developed as a versatile vehicle for gene delivery, as well as 
of drug delivery. The overall aim of this thesis was, therefore, to investigate the 
potential of LPD and establish if LPD could deliver a functional gene that could 
correct a model disease phenotype. In this case haemophilia B/factor IX deficiency 
was chosen as a model for LPD based non-viral gene delivery. Haemophilia B has a 
number of features which made it an attractive model single gene disorder: there is a 
simple cause and effect relationship between coagulation factor deficiency and 
symptoms; precise tissue specific expression of coagulation factors is probably 
unimportant, well characterised animal models (small and large) are available and 
factor IX gene manipulation / transgene expression are less complex than factor VIII 
and haemophilia A.
The study was split across two sites, Royal Free Hospital for experimental work and 
School of Pharmacy for synthesis and development of LPD complexes. The project 
was ambitious and to achieve this aim would be a significant achievement given the 
resources and time constraints surrounding the project. Nevertheless it was felt to be a 
valid preliminary study.
In order to examine the potential of LPD for gene delivery, the project was reduced to 
discreet groups of investigations which could be evaluated and any necessary revisions 
or conclusions drawn before progressing further. This would then provide a 
knowledge base to build on as well as a reference point to return to following any
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unsuccessful attempts to progress the study. These specific groups of studies were 
identified as:
Physical and chemical properties of LPD/DNA complexes
As a novel family of molecules designed to deliver a functional gene into the 
nucleus, it is essential understand their interaction with DNA and the properties 
of the complex produced prior to their introduction to cell culture / animal 
models.
In vitro gene transfer experiments (including gene construct development)
Having acquired information about the properties and interaction of LPD with 
DNA, it is essential to examine the capacity of the LPD/DNA complexes to 
deliver genes in cell culture in controlled conditions, to examine potential to 
delivery, efficiency of transfer and expression, cell specificity and any potential 
limitations.
In vivo gene transfer experiments
The final target of LPD/ DNA complexes would be in vivo gene transfer and 
hence exploring routes, potential and efficiency of possible gene transfer would 
be essential.
Immune responses to the complexes
A major concern for a gene-based approach for the treatment of disease remains 
the development of an immune response to the process. This happens in the 
conventional protein based approach for haemophilia. The occurrence of an 
immune response may be anticipated as any transgene product will be seen as 
foreign by a naive host. However, there may also be an immune response to the 
vector per se. As this thesis concerns the development of a vector it will attempt 
to begin to address immunological responses to the LPD/DNA complex.
The rationale as to which experiments were chosen to form this study was developed 
from looking at the published literature over the last twenty years. These studies 
mainly detailed the approaches used to characterise new and established vectors for 
gene transfer. In addition they cited experimental techniques employed and sometimes
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modified to suit this study. On reading a number of these approaches a consensus 
became clear as to the most significant experiments to perform in characterising LPD. 
I have attempted to produce a broad spectrum of investigations from which a more 
complete study on a larger scale can be developed.
These initial studies of the LPD are designed to give an indication as to how these 
novel molecules may behave when introduced to the more complex biological systems 
including cell cultures and live animal models. Perhaps just as importantly they may 
go some way to explaining unexpected results in subsequent experiments due to their 
relative simplicity and provide a basic level of understanding from which to build on.
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Chapter 3 
Materials and Methods
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3.1 Equipment and molecular biology protocols.
All protocols were carried out following COSHH risk assessments according to local 
rules. The Genetic Manipulation Advisory Committee (GEMAC), Royal Free and 
University College Medical School, approved all procedures involving the genetic 
alteration of organisms.
3.1.1 Materials, equipment and suppliers
Chemicals/reagents:
Pipettes:
Microcentrifuge:
Large volume centrifuge: 
Cell culture centrifuge: 
Gel electrophoresis: 
Spectrophotometer: 
General plastic ware: 
Cell culture plastic ware: 
Thermal cycler:
All chemicals and reagents used were molecular biology 
grade, purchased from Sigma UK unless otherwise 
stated.
Gilson Pipetteman: 2, 10,20, 100, 200 and 1000 
Bioline and Bioline Fesco.(Heraeus).
Sorvall RC26 Plus with SLA 1500 rotor.
Functionline Labfuge 400.(Heraeus).
Mini-gel tank and power supply unit (Bio-Rad). 
Ultrospec III. (Pharmacia).
Alphalabs UK.
Nunc (Gibco BRL-Life Technologies, UK).
Perkin Elmer Cetus Thermal Cycler.
Liquid scintillation counter Beckman LS 5000CE.
Cryostat:
Luminometer:
Leica CM3050 
LKB Wallac 1250
3.1.2 Plasmids
pCEP4FIXint.: Childrens Hospital of Philadelphia, PA USA.
PDJC(R/S)dF5: Immune Response Corporation, CA, USA.
pGL3 Control: Promega, UK.
pSVp-Gal: Promega, UK.
pGL3-Control is a commercially available firefly luciferase reporter gene under the 
control of a CMV promoter/enhancer and is used for in vitro transfections in Chapter
5.
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pSVB-Gal is a commercially available p-Galactosidase reporter gene under the control 
of the SV40 promoter/enhancer and is used for in vivo administration in Chapter 6 .
PCEP4FEX (Walter, You, Hagstrom et al 1996) is a modification of the commercial 
mammalian expression vector pCEP4 (Invitrogen) with human FIX cDNA preceded 
by a portion of intron 1 (Kurachi et al, 1995, Yao et.al, 1998) and inserted into the 
multiple cloning site (MCS) (see figure 5.8 page 154). Professor Kathy High 
(Children’s Hospital of Philadelphia, USA) kindly provided this construct which is 
used throughout this thesis.
PDJC(R/S)dF5 is a plasmid containing a proportion of the FVIII gene with additional 
engineered regulatory sequences. Dr. Richard 111 (Immune Response Corporation, 
USA) kindly provided this construct which was the donor plasmid for the sub-cloning 
experiment described in detail in Chapter 5 (see figure 5.9 page 155).
3.1.3 Lipidic amino acid dendrimers
Dendrimers were synthesised as previously described (Sakthieval et al, 1999) and 
stored lyophilised or at concentration of 1 to 5mg/ml in dHiO at 4°C. The dendrimers 
used in this study are as described in Chapter 1 page 52 of this thesis.
3.1.4 Oligonucleotides
Oligonucleotides were synthesized commercially (TAGN, Newcastle UK or Operon, 
Alameda, CA, USA) and designed specifically for the protocol unless otherwise stated. 
The sequence and relevant details of all the primers mentioned in this thesis is 
provided in the following table.
64
Table 3.1 Details of oligonucleotide primers used.
Where no reference is stated, the oligonucleotides were designed specifically for the 
protocol. Nucleotide locations given are the position o f the 5 ’ terminal nucleotide of 
the primer on the target sequence. NM references are accession numbers o f the target 
sequence as recorded in Entrez.
(URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi). Bold sequences are engineered 
restriction sites.
Primer: Target sequence (5’- 3’) and reference. Location
FIXINTU2
FIXINTL2
hFIX
TCACCAGGCCTCATCACCATCTG 
ATCCTTGCAACTGCCGCCATTTA 
Designed in-house
Exon 1- 
Exon 4
LSP-LHP2
LSP-RHP
DDJC(R/S)dF5
GCAGAGATCTGGTATCGATAAGCTTG
GGCTGGTACCGTTTCGTTCTTGTTAT
CC
Designed in-house
2
1 0 0 2
IL-1BU 
IL 1BL
Murine IL-1B mRNA
ATGGCAACTGTTCCTGAACTCAACT
CAGGACAGGTATAGATTCTTTCCTTT
(Norman, Denham, Denham et al. 2000) 
NM 008361
1
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Murine IL-6 mRNA
IL 6 U CTTTTGG AGTTT G AGGT AT ACCT AG 121
IL 6 L GCTGCGCAGAATGAGATGAGTTATC 542
(Salomon, Underwood, Doyle et al. 1992)
NM 031168
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Murine B-actin mRNA
BACTINU GTGGGCCGCTCTAGGCACCA 183
B ACTINL CGGTTGGCCTTAGGGTTC AGGGGG 404
(Norman, Denham, Denham et al. 2000)
TNFa mRNA
TNFaU ATGAGCACAGAAAGCATGATC 298
TNFaL TACAGGCTTGTCACTCGAATT 651
(Norman, Denham, Denham et al. 2000)
3.1.5 DNA/RNA extraction (from tissues), purification and storage
Total cellular RNA, DNA and protein were obtained from cell cultures and animal 
tissues using RNA Isolator™ (Genosys, UK) according to the manufacturer’s protocol. 
For each sample approximately 50mg of tissue was homogenised in a 2mL 
microcentrifuge tube with lmL of RNA Isolator™ using a motorised pellet pestle with 
disposable tips (Sigma, UK). To improve homogenisation, the disposable tips were 
modified by cutting a v-shaped notch into the pestle head with a scalpel blade. The 
homogenate was then incubated at room temperature for 5 minutes after which 0.2mL 
of chloroform was added and combined by inverting the tube repeatedly for about 15 
seconds before incubating at room temperature for a further 10 minutes. Separation of 
the phases was achieved by centrifugation at 12,000g for 15 minutes at 4°C and 
transferral of the top aqueous phase (containing the dissolved RNA) to another tube, 
avoiding removal of the interphase containing DNA.
RNA was precipitated by adding 0.5mL of isopropanol, incubating at room 
temperature for 10 minutes and centrifuging at 12,000g for 10 minutes at 4°C.
Washing the RNA involved removing the supernatant, adding lmL of 75% ethanol 
and inverting the tube several times. The RNA was then centrifuged at 12,000g for 5 
minutes at 4°C before removing the supernatant completely and allowing to dry under 
a vacuum for 10-15 minutes.
66
RNA was resuspended, quantified by spectrophotometry and stored at -80°C in Tris- 
EDTA (lOmM/lmM pH 8.0) with lpL of RNAsin (lOU/pL) (Promega, UK) added to 
every lOOpL TE to inactivate any ribonuclease activity.
DNA was precipitated following complete removal of the aqueous phase (as stated 
above) with the addition of 0.3mL of 100% ethanol followed by mixing by inverting 
the tube several times and incubating at room temperature for 5 minutes. The DNA 
was then pelleted by centrifugation at 2,000g for 5 minutes at 4°C, the phenol-ethanol 
supernatant containing cellular protein was removed before washing the pellet twice 
with 10% ethanol containing 0.1M sodium citrate for 30minutes each wash with 
occasional mixing at room temperature. The DNA was collected at the end of each 
wash by centrifugation at 2,000x g and removal of the supernatant. The DNA was 
then suspended in 2mL 75% ethanol and incubated at room temperature for 20 minutes 
with occasional mixing followed by centrifugation at 2,000x g for 5 minutes at 4°C.
The DNA was briefly dried under vacuum for 10 minutes and slowly dissolved in TE 
(pH 8.0) heated to 50°C before being quantified by spectrophotometry.
DNA was stored at -20°C in TE.
3.1.6 RT-PCR and PCR.
Reverse transcription
Reverse transcription of mRNA from samples of total cellular RNA was performed 
using Omniscript™ Reverse Transcriptase (RT) (Quiagen UK) according to the 
manufacturer’s protocol (04/99) unless otherwise stated. The source of the RT enzyme 
used in this protocol is undisclosed but includes hybrid-dependent exoribonuclease 
RNase H activity to specifically remove RNA in RNA/DNA hybrid molecules.
A typical reaction consisted of (in order of addition):
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Component volume added final concentration
lOx Buffer RT 2.0 pL 
10.7 pL
2.0 pL
lx
RNase free CIH2 O 
5mM dNTPs 0.5mM each dNTP 
lpMlOpM oligo p(dT)i6  primer 2.0 pL
30U/pL RNasin™ 0.3 pL
1 pg/pL Template RNA 2.0 pL
*4U/pL Omniscript™ RT 1.0 pL*
0.5U/pL 
0.1 pg/pL 
0.2U/pL
Total volume 20.0uL
*The RT was only added following a 10-minute incubation at 65 °C to reduce any 
secondary structures formed by the target RNA.
The mixture was then cooled to 37°C and the RT added before incubating at 37°C for 
60 minutes.
Polymerase chain reaction (PCR)
PCR was performed using Bioline ltd. (UK) thermostable DNA polymerase, NH4 
reaction buffer (160mM (NH4)2 S04, 670mM Tris-HCl (pH 8 . 8  at 25°C), 0.1% Tween- 
20). and MgCl2  solution along with a lOmM dNTP stock solution purchased from 
Promega (UK). A typical 50 pL PCR reaction prepared on ice consisted of (in order of 
addition):
Component volume added final conc.
IOXNH4 PCR Buffer 
lOmM dNTPs
5.0 pL
2.0 pL 
x pL
x pL 
x pL
0.5 mM dNTP
lx
50mM MgCl2  
5’ primer (LHP) 
3’ primer (RHP) 
DNase free dH20
a 1-3.0 mM 
b pM 
c pM
(to 50pL final volume)
Thermostable DNA polymerase 0.25 pL 0.025 U/pL
Template DNA x pL approx. 106 copies
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Where applicable, primer sequences were designed using the DNAstar™ software 
(Lasergene, USA) for the Apple Macintosh or obtained from publications/sources as 
cited. The oligonucleotides were synthesised on a 0.2pmol. scale with HPLC 
purification. Upon receipt the freeze-dried oligonucleotides were resuspended in TE to 
lOOpM and stored at -20°C in aliquots. Following addition of all the components 30- 
40pL of autoclaved mineral oil was added to prevent the evaporation of water from the 
reaction during thermal cycling.
The reaction was carried out in a Perkin-Elmer Cetus Thermal Cycler using thin- 
walled 0.5mL tubes for improved heat transfer. See following tables for reaction 
specific variables a, b and c.
Reaction conditions:
All cytokine PCR reactions included 0.1 pM  o f each f-actin primer.
PCR a b c
hFIX 1.5pL FIXINTU2 FIXINTL2
ljuM lpM
Cycling x35
94°C -  30s 94°C -  30s 72°C -  10 mins
57°C -  30s 
72°C -  30s
PCR a b c
LSP 1.5pL LSP-LHP FIXINTL2
lpM lpM
Cycling x30
94°C -  30s 94°C -  30s 72°C -  10 mins
60°C -  30s 
72°C -  60s
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PCR a b c
TNF-a l.OpL TNFaU TNFaL
0.6pM 0.6M
Cycling x35
94°C -  30s 94°C -  30s 72°C -  10 mins
66.5°C -  30s 
72°C -  30s
PCR a b c
IL-ip l.OpL IL-1BU
lpM
IL 1BL 
lpM
Cycling x35
94°C -  30s 94°C -  30s 
57°C -  30s 
72°C -  30s
72°C -1 0  mins
PCR a b c
IL- 6 l.OpL IL 6 U 
0.8pM
IL 6 L 
0.8pM
Cycling x30
94°C -  30s 94°C -  30s 
57°C -  30s 
72°C -  30s
72°C -1 0  mins
3.1.7 Agarose gel electrophoresis and associated protocols
Analytical or preparatory grade agarose (Promega, UK) where appropriate was
dissolved in 0.5x TBE (0.5xTris Borate EDTA: 890mM tris-base, 890mM boric acid,
20mM Na2 EDTA (pH 8.0) to an appropriate concentration and heated to boiling for 2
minutes in a 750W microwave oven. The melted agarose was allowed to cool to
approximately 50°C with stirring before adding ethidium bromide to a final
concentration of 0.5pg/mL. The gel was then poured into a horizontal casting tray
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with combs of the desired size attached and allowed to cool for at least 2  hours at room 
temperature. The combs and any tray sealer were then carefully removed and the set 
gel (in casting tray) placed into an electrophoresis tank containing enough 0.5x TBE to 
just above the level of the gel. Samples were combined with 5x loading buffer 
(Bioline, UK) and loaded into the wells, with an appropriate size standard loaded into 
at least one well of each row. The electrophoresis was performed at approximately 3- 
4V/cm.
Gel retardation assay
10 j l i L  of dendrimer and DNA (pGL3 Control plasmid, Promega, UK) solutions (in 
dH20) were combined, using a constant final DNA concentration of 50ng/mL, with 
increasing dendrimer concentrations accordingly. The charge ratio of NH2 (+ve) to 
P03(-ve) groups (assuming total ionisation) was calculated as follows:
For la: MW=1587.30 and has charge value of 8 +
DNA MW = 660 charge value of 2'
/. 1.587pg of la  combined with 0.66pg of DNA would result in a charge ratio of 8:2 
(4:1).
The samples were loaded onto a 0.8% non-denaturing TBE agarose gel containing Eth 
idium Bromide (EthBr) using sucrose loading buffer without dye. Wells containing 
2.5pg of pure plasmid control and 5pL of molecular weight marker (Bioline 
Hyperladder I) were also included. The gel was then subjected to a constant electric 
field of 3V/cm for 90 minutes.
3.1.8 Preparation of plasmid DNA
Plasmid DNA was prepared from the transformation of E. coli strain JM109 competent 
cells, (high efficiency >108cfu/pg) following the manufacturer’s Standard 
Transformation Protocol.
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Materials
LB medium (IL: lOg Tryptone, 5g Yeast Extract, 5g NaCl pH 7.5, autoclaved)
SOC medium (lOOmL: 2g Tryptone, 0.5g Yeast Extract, lmL 1M NaCl, 0.25mL
0.25M KC1, lmL 2M glucose, lmL 2M MgCVMgSC^ soln.)
LB agar plates (as LB with 15g/mL bacteriological grade agar)
Antibiotic (ampicillin), working concentration = lOOpg/mL,
17 x 100mm polypropylene culture tubes, sterile.
Protocol
One culture tube for each transformation was pre-chilled on ice. Competent cells were 
removed frozen from -70°C and placed on ice for 5 minutes, or until just thawed. The 
cells were then gently mixed by flicking the tube with lOOpL of the thawed competent 
cells transferred to each of the pre-chilled culture tubes.
lOng of plasmid DNA was added (in a volume not greater than lOpL) per lOOpL of 
cells, and mixed in by movement of the pipette tip through the cells while dispensing. 
The tubes were then quickly flicked several times and immediately returned to ice for 
1 0  minutes.
The cells were heat-shocked for 45-50 seconds in a water bath at exactly 42°C without 
shaking and then placed on ice for 2  minutes.
900pL of cold (4°C) SOC medium was then added to each transformation reaction 
and incubated for 60 minutes at 37°C with shaking (250rpm).
1 OOjlxL of undiluted cell suspension and dilutions of 1:10 and 1:100 were transferred to 
antibiotic plates with a sterile glass spreader. The plates were then incubated at 37°C 
for 12-14 hours.
The propagation of transformed cells was carried out using the EndoFree Plasmid 
Mega and Giga kit (Quiagen, UK) and following the manufactures instructions 
(EndoFree Plasmid Mega and Giga Handbook October 1997).
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Materials (Kit contents)
QIAfilter Mega-Giga cartridges 
QUIAGEN-tip 2500 
Composition of buffers per litre:
Buffer PI (Resuspension Buffer) 50 mM TrisCI, pH 8.0; 10 mM EDTA; 1
OOpg/mL RNase A.
Buffer P2 (Lysis Buffer) 200 mM NaOH; 1 % SDS.
Buffer P3 (Neutralization Buffer) 3.0 M potassium acetate, pH 5.5.
Buffer FWB (QIAfilter Wash Buffer) 750 mM NaCI; 50 mM MOPS, pH 7.0;
15% isopropanol
750 mM NaCI; 50 mM MOPS, pH 7.0; 
15% isopropanol; 0.15% Triton®X-100 
1.0 M NaCI; 50 mM MOPS, pH 7.0; 15% 
isopropanol
1.6 M NaCI; 50 mM MOPS, pH 7.0; 15% 
isopropanol 
Undisclosed
10 mM TrisCI, pH8.0; 1 mM EDTA 
pH 8.0
Endotoxin free H2 O for 70% ethanol (add 40 ml of 96— 100% ethanol)
Protocol (continued from transformation of competent cells protocol)
A single colony from a selective plate was picked using a sterile pipette tip and used to 
inoculate a starter culture of 5 mL LB medium containing ampicillin (100pg/mL) in a 
20mL sterile universal container. This was grown for 5 hours at 37°C with vigorous 
shaking (300 rpm).
For each starter culture, a sterile 1L flask was filled with 250mL of LB containing 
ampicillin (lOOpg/mL), with 500pL of the starter culture added to the flask. The 
culture was then covered and incubated at 37°C overnight (approximately 16 hours 
with vigorous shaking at 300 rpm). The bacterial cells were then harvested by 
centrifugation at 6000g for 15 minutes at 4°C (Sorvall centrifuge), following which all 
traces of supernatant was then removed by inverting the open centrifuge bottle until all 
medium had been drained.
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Buffer QBT (Equilibration Buffer)
Buffer QC (Wash Buffer)
Buffer QN (Elution Buffer)
Buffer ER (Endotoxin Removal) 
TE (endotoxin free)
In preparation, the QIAfilter Mega-Giga Cartridge was screwed onto a 45mm-neck 
glass bottle and connected to a vacuum source.
The bacterial pellet was resuspended thoroughly (all clumps dispersed) in 50 ml of 
Buffer PI per 500ml original culture volume. An equal volume of Buffer P2 was then 
added and mixed gently but thoroughly by inverting several times, and incubated at 
room temperature for 5 minutes. 50 ml of chilled Buffer P3 was then added and then 
mixed immediately and thoroughly by inverting several times until a white fluffy 
material had formed and the lysate was no longer viscous. Immediately, the lysate was 
poured into the QIAfilter Mega-Giga Cartridge and incubated at room temperature for 
1 0  minutes without disturbance.
The vacuum source was then switched on and after all liquid has been pulled through, 
switched off. 50 ml of Buffer FWB was then added to the QIAfilter Cartridge and 
gently stirred using a sterile spatula. The vacuum source was switched on again until 
the liquid had been pulled through completely. The QIAfilter cartridge was then 
removed.
12.5 ml of Buffer ER was added to the filtered lysate and mixed by inverting the bottle 
approximately 10 times, and incubated on ice for 30 minutes. (After addition of Buffer 
ER the lysate appeared turbid, but became clear again during the incubation on ice.)
A QIAGEN-tip 2500 was equilibrated by applying 35mL Buffer QBT and allowed to 
empty by gravity flow. The cleared lysate was transferred onto the QIAGEN-tip and 
left undisturbed to enter the resin by gravity flow. The QIAGEN-tip was then washed 
with 2 x 100 ml of Buffer QC. The DNA was eluted with 35 mL Buffer QN and 
allowed to drain.
24.5 ml of room-temperature isopropanol (0.7 volumes) was added to the eluate to 
precipitate the DNA, which was then mixed briefly by vortexing and centrifuged 
immediately at 15,000g for 30 minutes at 40C. The supernatant was then carefully 
decanted to avoid disturbing the pellet. The DNA pellet was washed with 7 ml of 
endotoxin-free 70% ethanol (at room-temperature) and centrifuged at 15,000g for 10
74
minutes. The supernatant was then carefully decanted and discarded without 
disturbing the pellet. This ethanol-washing step was repeated to improve the purity of 
the DNA.
The pellet for was then approximately 10-20 minutes,and redissolved the DNA in a 
suitable volume of endotoxin-free Buffer TE (warmed to 60°C to improve solubility).
3.1.9 Digestion of DNA using restriction endonucleases.
DNA samples were digested in 0.5mL microcentrifuge tubes using the following 
standard reaction unless otherwise stated.
Restriction enzyme 10X buffer 2 pL
BSA, acetylated (lmg/mL) 2 pL
1 pg DNA sample (in dFLO or TE) a pL
Restriction enzyme (2-10 units) b pL
Nuclease-free water c pL
Final volume 20 pL
The value of a, b, and c is variable in order to give the specified final volume.
The reaction was then mixed gently by pipetting and centrifuged for several seconds to 
collect the contents at the bottom of the tube. The reaction was then incubated at 37°C 
for 2  hours.
The enzyme buffers used were in accordance with the manufacturer’s 
recommendation.
3.1.10 Extraction and purification of DNA from agarose gels
Extraction of DNA from agarose gel was performed using the Jetsorb™ kit (Genomed, 
UK) following the manufacturers protocol.
3.1.11 Subcloning: replacement of the CMV promoter on pCEP4hFIXint 
with a liver specific promoter (LSP)
The Liver specific promoter/enhancer sequences were amplified from the plasmid 
vector pDJC(R/S)dF5 using the primers LSP-LHP2 and LSP-RHP. These primers
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were designed with restriction sites for Bgl II and Kpn I respectively 4 bases from of 
the 5’ ends to enable effective enzyme binding. Figure 3.2 shows a map of this 
plasmid and its restriction sites The primers were designed to amplify a lkb fragment 
that, when inserted into the respective sites upstream to the hFIX gene, would directly 
replace the CMV thus conserving the Kozak sequences (Kozak 1986), transcription 
initiation sites and the 5’ untranslated region (5’UTR) of the FIX cDNA. Furthermore 
the promoter/enhancer sequences would be positioned the same distance from the 
transcription initiation site as in the original plasmid. Figure 3.1 shows the plasmid 
pCEP4hFIXint and its restriction sites into which the fragment was inserted.
The amplified fragment contained the following features (111, Yang, Bidlingmaier et al. 
1997):
Component Location on fragment
Alpha Bikunin Protein enhancer. 52-178
Alpha Bikunin Protein enhancer. 185-291
Rabbit p-globin intervening sequence (IVS). 850-975
Human thyroid binding globulin promoter. 305-808
The fragment was then digested with Kpn I (8 Units) and Bgl II (lOUnits) as per 
previous conditions (see 2.1.9) at 37°C for 2 hours before purifying using agarose gel 
electrophoresis and the Jetsorb™ gel extraction method. The vector pCEP4hFIXint 
was also digested with Kpn I (8 Units)and Bgl II (lOUnits) and purified in the same 
manner.
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Figure 3.1 Map of pCEP4FIXint plasmid vector
Components and significant restriction sites are shown.
BamHI
Sail
SV40pA
OriP
hFIXint
pCEP4hFIXint
13407 bp
EBNA-1
PCMV
TKpolyA
Amp/ColE PTK HygB res.
SV40pA: SV40 polyadenylation sequence.
hFIXint: human factor IX cDNA plus intron I sequences.
TkpolyA: thymidine kinase polyadenylation sequence.
HygB res.: Hygromycin B resistance gene.
PTK: Thymidine kinase promoter.
EBNA-1: Epstein-Barr virus nuclear antigen-1
Ori P: Bacterial replication gene.
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Figure 3.2 Map of pDJC (R/S) dF5 plasmid vector
Components and significant restriction sites are shown (III, Yang, Bidlingmaier et al. 
1997).
Xma I
ABP enhancer <x2) 
^ ^ liT B G  P roin eter^ ^ B yl II
rB(j IVS
^ N c o  I
AnipR
E coli ori
BDD FVIII cDNA
Byl II
Kpnl I
Xnia I
ABP: a 1 -microglobulin/bikunin enhancer
hTBG: human thyroid-binding globulin promoter
BDD FVIII: FVIII cDNA (p-domain deleted)
rBg IVS: rabbit p-globin intron 1
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The LSP fragment was then ligated into the pCEP4 backbone in a 4:1 (insertivector) 
ratio in the following reaction which was incubated at 4°C overnight.
pCEP4 backbone 1 pL (160ng)
LSP fragment 5pL (40ng)
1 Ox ligase buffer 1 pL
T4 DNA Ligase (3U/pL) 1
dH20  2pL
lOpL
The plasmid preparation was then used to transform competent E.coli with individual 
successful transformant colonies selected and amplified using standard methods 
outlined previously. Plasmid DNA was extracted and purified using the Quiagen® 
plasmid preparation kits before digesting with Bam HI to confirm the correct insertion 
of the fragment. The plasmid was then synthesised on a larger scale using the standard 
protocol.
3.1.12 Cycle sequencing.
Sequencing was carried out using the ABI Prism® BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit according to the supplied protocols, with the analysis 
of sequencing products carried out on an ABI 310 automated sequencer.
3.2pmoles of primer was added to 8 pL of Terminator Ready Reaction Mix in a thin- 
walled 0.5mL PCR tube. Approximately 300ng of template was added and the 
reaction volume made up to 20pL with dH2 0 . The mixture was vortexed briefly 
before being centrifuged to collect all the solution. 40 pL of mineral oil was added to 
the mix before performing the sequencing reaction.
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Cycling X25
96°C -  30s 94°C -  30s 4°C soak
50°C -  15s 
60°C -  4mins.
The tubes were then centrifuged briefly to collect contents. To purify the reaction 
firstly it was removed from under the oil and placed in a 1.5mL centrifuge tube on ice 
containing the following:
2.0pL 3M sodium acetate (pH 4.6);
50pL 95% ethanol.
The tubes were then vortexed, centrifuged briefly and left at room temperature for 30 
minutes. The tubes were then centrifuged at maximum speed in a microcentrifuge, 
with the supernatant carefully aspirated and discarded. The pellet was rinsed with 
250pL of 70% ethanol followed by centrifuging for 5minutes at maximum speed and 
removal of the supernatant. The pellet was dried on the heat block of a thermal cycler 
at 90°C for 1 minute and resuspended in 14pL of template suppression reagent (TSR), 
being stored on ice prior to sequence data analysis.
The capillary electrophoresis was performed on a short capillary filled with POP6  
polymer with the corresponding module used to control the automated process. Data 
collection and sequence analysis was performed on an Apple Macintosh G4 using the 
ABI Applied Biosystems data collection and sequencing analysis software.
3.1.13 FastTag™ fluorescent labelling of plasmid DNA
Kit available from Vector Laboratories Inc. (USA)
Materials 
FastTag™ Reagent 
Reagent 1, reduction buffer 
Reagent 2, reducing agent 
Reagent 3, maleimide buffer 
Reagent 4, Texas Red® maleimide
80
Protocol
1. To lOOpl of nucleic acid (at 0.5pg/pl) in TE, an equal volume of FastTag™ 
Reagent was added.
Coupling reaction
2. The reaction mixture was overlaid with 0.5 volumes of mineral oil and heat at 95 °C 
for 30 minutes using a heating block.
3. Following coupling, lOOpl of 0.1 M Tris, pH 9.5 was added
4. 200pl of 2-butanol (room temperature) was added to the FastTag™-nucleic acid
solution, vortexed vigorously and centrifuged to separate the phases. The upper 
butanol phase was then removed and discarded. The aqueous phase was re-extracted 
with an additional 2 0 0 pl of 2 -butanol, again discarding the butanol layer following 
centrifugation.
5. Proceed directly to the disulfide reduction reaction or store the FastTag™-nucleic
acid at -20 °C to -80 °C for up to one year.
Reduction of disulphide bridges
6 . To lOOpl of FastTag™-nucleic acid (50 fig total nucleic acid), 12.5pl of 
reduction buffer (Reagent 1) was added.
7. 12.5pl of reducing agent (Reagent 2) was added and incubated at room 
temperature (25 °C) for 10 minutes.
Fluorescein maleimide coupling to FastTag™ thiols
8 . The following components were added in the order shown, to 100pi of 
reduction reaction from step 7 to give a final volume of 200pl, mixed and incubated 
for 30 minutes at room temperature (25 °C).
60pl H20
20pl maleimide buffer (Reagent 3)
20pl fluorescein maleimide (Reagent 4)
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10. The FastTag™ FL-nucleic acid was precipitated from unincorporated fluorescein 
maleimide by adding, in order, the following components:
200pl H20
lOOOpl 10M ammonium acetate 
20pl 1 M MgCl2  
2 pi of 2  mg/ml glycogen 
1250pl 95% ethanol (-20 °C)
11. The mix was incubated at -20 °C for 15 minutes and pelleted by centrifugation at 
13,000g in a microcentrifuge for 15 minutes. The pellet was washed with 70% ethanol 
and centrifuged at 13,000g for 3 minutes. The pelleted nucleic acid was then 
resuspended in H20  or TE.
3.1.14 Detection of Texas Red® labelled DNA 
Materials (supplied in kit)
5x in-situ hybridization (ISH) blocking solution 
Biotinylated anti-rhodamine antibody 
Avidin-Texas Red ® DCS conjiugate 
Vectashield® Mounting Medium
Protocol
The tissues were mounted and sectioned as described on Chapter 3 page 102.
The detection reagents were diluted in lx ISH blocking solution for at least 30 minutes 
before use to further reduce any non-specific
1. Tissue sections were pre-blocked for 30 minutes in lx ISH
blocking solution at 37 °C and washed 2 x 5  minutes in 4x SSC + 0.1% Tween 20.
2. Tissue sections were incubated with biotinylated anti-rhodamine (10 pg/ml) for 30 
minutes at room temperature.
3. Slides were washed 2 x 5  minutes in 4x SSC + 0.1% Tween 20
4. Tissue sections were incubated with Texas Red® Avidin DCS (10 pg/ml) for 30 
minutes at room temperature.
5. Slides were washed 2 x 5  minutes in 4x SSC + 0.1% Tween 20 before 
coverslipping with Vectashield® Mounting Medium.
82
3.2 Mammalian cell culture
Mammalian cells were maintained at 37°C and 5% C02 in a humidified incubator 
(LEEC, UK). All manipulation of live cells was carried out in a Class II cabinet 
(Microflow Biological Safety Cabinet) using aseptic techniques and following local 
biological safety requirements.
3.2.1 Cell lines
Cell lines were obtained from European Collection of Cell Cultures (ECACC), 
CAMR, Salisbury, Wiltshire, UK :
Name ECACC # Description
Hep G2 85011430 Human hepatocellular carcinoma (male).
HEK-293 85120602
Human embryonic kidney, transformed with 
human Ad5 DNA.
C2C12 91031101 Mouse C3H muscle myoblast
COS-7 87021302
African green monkey kidney, transformed
with SV40.
3.2.1 Cell culture materials.
Cell culture media and supplements were obtained from Gibco BRL/Life. 
Technologies pic, except when otherwise stated and all tissue culture flasks and multi­
well plates were obtained from Nunc.
‘Complete’ media contained 10%FBS (heat treated) and lx  Antimycotic/Antibiotic 
solution (Sigma)
Cell line Media details Specific additives*
Hep G2 EMEM NEAA
HEK-293 DMEM/F-12 NEAA
C2C12 DMEM None
COS7 DMEM None
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♦Vitamin K (6 pg/mL) and insulin/transferrin/sodium selenite (1 Opg/1Opg/1 Ong/mL) 
supplements were added to any media used following transfection with a FIX 
construct.
3.2.2 Cell culture maintenance
Growth media was replaced every 48 hours (unless otherwise stated) following two 
rinses with warmed phosphate buffered saline (PBS).
Passage of cell lines was usually carried out at approximately 90% confluency 
according to recommendations from ECACC or ATCC for the particular cell line. 
Briefly, this was achieved by rinsing twice with pre-warmed PBS followed by adding 
lx trypsin/EDTA in PBS (Sigma) to just cover the cells. They were then incubated at 
room temperature (Hep G2 cells were incubated at 37°C) until a few cells started to 
detach. The rest were detached by striking the flask on the bench-top sharply several 
times, mixed with media containing FBS to inactivate the trypsin and centrifuged in a 
sterile tube at lOOOrpm for 5 minutes. The supernatant was discarded and the cells 
resuspended in an appropriate volume of complete media by pipetting several times or 
brief vortexing at low speed. The cells were then transferred into pre-warmed 
flasks/plates.
Terminal differentiation of C2C12 cells was achieved by allowing the cells to reach 
confluency and adding 10% horse serum (Gibco BRL/Life Technologies pic) for 2-3 
days to induce differentiation resulting in a distinct morphology and forming 
contractile myotubes, producing characteristic muscle proteins.
Freezing cells for storage was carried out by following the procedure for passaging 
prior to addition of the complete media following centrifugation. Instead a volume of 
freezing media was added (95%FBS with 5% DMSO) to a cell density of 
approximately 2xl06/mL, mixed briefly and lmL of the suspension placed into sterile 
tubes (suitable for liquid nitrogen storage) and stored at -80°C overnight before 
moving to the vapour-phase of a liquid N2 vessel for long-term storage. Cells were 
revived from storage by warming at 37°C for 1 minute and resuspending in at least 
lOmL of pre-warmed, complete media before centrifuging at lOOOrpm for 5 minutes.
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The supernatant was then removed and complete media added. The cells were then 
placed into a tissue-culture flask with a 25cm2 growth area and incubated as for normal 
maintenance.
3.2.3 Transfection of adherent cells.
24 hours before transfection, growing cells were transferred to 6  or 24 well tissue 
culture plates following the normal procedure. Cells were seeded to reach 50-70% 
confluence at the time of transfection with seeding densities varied according to the 
cell line used. Approximately 2 hours before transfection the media was replaced with 
fresh complete media to stimulate growth.
For each well of a 6 -well plate, the DNA was diluted to 1 OOpL with the appropriate 
solution or media and to a concentration of 0.025pg/pL. The dendrimer was also 
diluted in the same to an appropriate concentration to give the desired charge ratio 
when combined with the DNA (see below for charge ratio calculation). Complexes 
were formed by adding lOOpL of the diluted DNA to lOOpL of the diluted dendrimer 
in one fast action, followed by pipetting several times to mix. The complexes were 
then incubated for 30 minutes at room temperature. The solvents used in the formation 
of complexes included various cell culture media or 150mM NaCl/20mM NaHCC>3 
solution (Escriou, V. et al, 1998) with or without FBS (which was added after the 30 
minute incubation).
800pL of the appropriate media (without antibiotics) was then added. For serum free 
transfections, Opti-MEM™ with GlutamMAX I™ (Gibco BRL -  Cat. no. 51985-042) 
was used, however for transfections in the presence of serum, the media contained 
12.5% v/v FBS to give a final concentration of 10% v/v. The complexes were then 
warmed to 37°C.
Immediately prior to adding the complexes to the cells the media was removed. lmL 
of the complex/media solution was carefully added to the centre of each well drop- 
wise. For HEK-293 cells the solution was added by running down the sidewall of the 
well to avoid detaching the cells. The cells were then incubated as per maintenance for 
up to 5 hours before adding 2mL of fresh complete media. Vitamin K was included in
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the media for FIX expression studies. The cells were then incubated for a further 43 
hours.
Calculation of charge ratio (net charge) of complexes
Molecular weight of dendrimer 1 a ( 8  terminal amino groups) =1587
Molecular weight of 1 base-pair of DNA (2 phosphate groups) ~ 660
1.587pg of dendrimer la  + 0.66pg of DNA gives a charge ratio (+ / -) of 4:1.
For 2.5pg of DNA at a charge ratio of 4:1, the amount of la  required:
f 2.5 ^
 ^ 0.66 j
1.587 = 6.0
pg (to 1 d.p.)
For a charge ratio of 5:1:
6.0
4)
= 7.5pg (to 1 d.p.)
This value is given on the assumption that at physiological pH all s-amino groups (pKa 
~ 10.5) in the dendrimer are protonated and DNA phosphate groups (pKa ~ 1.0) are 
charged.
3.3 Measuring human FIX antigen (ELISA)
Materials and equipment
Diluent for samples, standards and secondary “tag” antibody:
0.01% Tween 20 v/v, 3% PEG 8000 w/v in PBS.
Coating buffer: 0.05M Sodium Carbonate, pH 9.6.
PBS, 0.01% Tween (20 v/v).
lOmg o-phenylenediamine dihydrochloride tablet dissolved in 
15 mL 0.5M sodium citrate, pH 5.0 with 7pL 30% hydrogen 
peroxide added immediately prior to use.
96 well plate: Nunc Maxisorb™ microtitre plates (LifeTechnologies,UK.).
Wash buffer: 
OPD solution:
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Plate reader: MRX microplate reader (Dynex, Billingshurst, UK).
Primary (coat) antibody: polyclonal rabbit anti-human FIX (Dako Ltd, UK).
Secondary (tag) antibody: polyclonal, horseradish peroxidase-conjugated rabbit anti­
human FIX (Dako Ltd, UK).
Protocol
96 well plates (Nunc Maxisorb™) were coated with rabbit anti-human FIX polyclonal 
antibodies (Dako Ltd, UK) diluted 1:500 in coating buffer (lOOpL/well), covered with 
clear plastic and incubated overnight at 4°C.
The plates were then washed 5 times with wash buffer and excess buffer removed. 
0 .1 ml of cell culture media from each sample was added to the plates in duplicate 
along with a range of serial dilutions of an in-house plasma sample pool of 2 0  
individuals with no personal or familial history of thrombotic or haemostatic disorders 
(normal 20 pool - calibrated against international reference plasmas). Additionally the 
abnormal control plasma (reduced FIX antigen), Coag Trol P (Dade, UK) was used 
diluted 1 / 1 0 0  and 1 /2 0 0 , a positive control from the normal 2 0  pool diluted 1 / 1 0 0  and 
1 / 2 0 0  and a negative control: i.e. cell culture media sample from untransfected cells 
was included to give control values.
The plates were sealed and incubated with agitation at room temperature for 1 hour 
and washed five times with wash buffer (removing excess by inverting and tapping on 
absorbent surface). 0.1ml Rabbit anti-human FIX-horseradish peroxidase conjugated 
antibody diluted 1 : 1 0 0 0  was added to each well, which was then sealed and incubated 
with agitation for 1 hour at room temperature. The plate was washed 5 times with 
wash buffer (removing excess) and 0.1ml of an (OPD) added to each well. This was 
followed by 2 0  minutes incubation at room temperature for each sample to effect 
colour development.
The reaction was stopped by adding 0.1ml of 1.5M H2 SO4  to each well at exactly the 
same time interval as the substrate was added followed by a brief shake of the plate. 
The absorbance was measured at 492nm with a microplate reader. FIX levels were
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calculated by comparison with the linear range of a standard curve formed using serial 
dilutions derived from the normal human plasma.
3.4 Measuring human FIX activity (aPTT)
The activated partial thromboplastin time (aPTT) study is a clinical test used to 
investigate the cause of a prolonged blood clotting in patients. Media samples for 
hFIX activity assay were included in a routine assays performed by a working 
laboratory used for clinical tests (Haemophilia Centre - Department of Haematology, 
Royal, Free Hospital) which is rigorously regulated by external bodies namely:
NEQAS (National External Quality Assurance Schemes)
ECAT (European Thrombophilia External Quality Assurance Scheme).
Materials and equipment
ACL Coagulometer (IL)
Including:-APTT and CaCl2 macro reagent reservoirs and magnetic flea
Sample tray and clean rotors
0.5ml and 2ml sample cups
Plastic pipettes
Gilson Dilutor 401
Pipettes P I000 Anachem
Luckhams LP3 plastic tubes
Ice Bath
Reagents
Owren’s buffered saline (OBS)
Factor IX deficient plasma (Technoclone)
APTT Lyophilized Silica (IL)
25mM CaCl2
Reference emulsion (IL) (Provided by IL in APTT kit)
Standards/calibrators
Normal Pooled Plasma - In house Laboratory Standard or Commercially prepared
pooled plasma (Cryocheck- Precision Biologies , Canada) calibrated against FVIII and
FIX British Standard (NIBSC, Potters Bar, UK).
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Internal quality control
Control Plasma (SYSMEX Dade Behring Control Plasma P)
External quality control
NEQAS (National External Quality Assurance Schemes)
ECAT (European Thrombophilia External Quality Assurance Scheme)
NEQAS and ECAT results are subject to review by the Laboratory Management 
Group
Protocol
All samples, standard and QC samples were be placed in an ice bath, e working 
laboratory used for clinical tests and as such is rigorously regulated by to electrostatic 
reAll dilutions were made using a Gilson Dilutor 401. LP3 test tubes were used for the 
sample and placed in an ice bath. Using Gilson Dilutor 401 (Programme 3) dilutions of 
the sample to be tested were prepared in OBS (1/10-1/40). Dilutions of the Standard 
using Programme 1 (1/10), and of the QC material using Programme 6  (1/10 using half 
volumes) were also prepared. As very low intrinsic factor levels were expected, the 
sample dilutions were repeated by starting off with a 1/5, 1/10 and 1/20 dilution 
(Programme 5 on Gilson Diltor 401)
Assay procedure
- The reconstituted appropriate deficient plasma and APTT and CaCU reagent was 
placed into position on the coagulometer.
- One sample cuvette was placed in the “Pool” position, “dil” position and one cuvette 
per sample dilution starting from position 1 , without leaving any gaps
- Diluted (1/10) Standard was added to cuvette in “Pool position”
- OBS was added to cuvette in “Dil” position (Blank and Diluent)
- Diluted samples were added to each cuvette in turn. (At least 250pl of dilution is 
required (sample cups have a dead volume of lOOpl).
- Reconstituted FIX deficient plasma was placed in a 2ml cup and in the appropriate 
position on sample tray.
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Single Factor option and particular assay required (FIX) was selected on ACL. High 
Curve was selected and the value of the standard inserted. The instrument then gave 
instructions for operation and the assay was performed.
Interpretation of results
All ACL series analyser will automatically calculate the result however, to check 
parallelism on assays performed, a graph must be drawn, and the result read off the 
Standard Curve for the Normal Pool. Most intrinsic factor assay curves are drawn 
using Log/Linear graph paper.
F igure 3.3 E xam ple o f a s ta n d a rd  and  para lle l tes t sam ple curve.
Units: x axis (log scale) = FIX concentration, y  axis (linear scale) =time (seconds). 
Substandard, T=test sample.
<D
B
H
FIX Concentration (Log)
Acceptable QC must fall between +/- 2SD for 1/10 dilution, before the results can be 
validated. If the QC is not acceptable the assay must be repeated
On plotting clotting times vs concentration of the dilutions of the standard (as above) 
the 1/10 dilution of the reference plasma is assigned its certified value in IU/dL. The 
1/20 dilution thus contains half of that value.
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Straight parallel lines should be obtained. The value of the test sample can then be 
calculated from the graph according to actual value of the standard. If the sample curve 
is non-parallel (see example below), the result is invalid.
F igure  3.4 E xam ple o f a s ta n d a rd  and  non- para lle l sam ple curve
Units: x axis (log scale) = FIX concentration, y  axis (linear scale) =time(seconds). 
S=standard, T=test sample.
3.5 Animals
C57/BL6 mice were obtained from the Comparative Biology Unit, Royal Free 
Campus, Royal Free and University College Medical School, London, UK, where they 
were bred and maintained.
All procedures carried out have been approved by the Home Office and are licensed 
under the Animals (Scientific Procedures) Act 1985 as stated (project license no. PLL 
70/4916 and personal license no. PIL 70/15643). All mice were killed according to 
Schedule 1 of the Animals (Scientific Procedures) Act 1985 by asphyxiation in a 
closed chamber with increasing concentrations of C02 followed by cervical 
dislocation.
50% 100%
Factor IX Concentration (Log)
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3.5.1 Preparation and administration of dendrimer/DNA complexes to mice.
A proportion of cationic lipid la  was synthesised incorporating a tritium radioactive 
label ([JH] specific activity = 65Bq/ug @ 5 jag/pL in dfhO). Depending on the 
application the dendrimer and DNA were diluted in OptiMEM containing GlutaMAX 
I ™ (Gibco, BRL)
For in vivo expression of (3-Galactosidase
Both the DNA and the dendrimers were diluted to lOOpL (total 200pL per animal) in 
Optimem . Complexes were formed at room temperature by adding lOOpL of the 
diluted DNA (in the same solute as the dendrimer) to 1 OOpL of the diluted dendrimer 
in one fast action, followed by pipetting several times to mix. All reagents were sterile 
and mixing was carried out in a Class 2 biological safety cabinet. Anaesthesia used 
was a variable halothane/ 0 2  mix administered to a closed box for induction and a nose 
cone attached to volatile gas scavenging equipment for maintenance. Depth of 
anaesthesia was checked by a withdrawal response to pain (squeezing the foot pad).
I.V. injection was via tail vein using a tuberculin syringe with a 29 or 31 '/2-gauge 
needle (BDH, UK).
Per oral delivery was by oral gavage using an appropriate brass gavage needle with a 
Luer® fitting and lmL syringe barrel.
3.6 Liquid scintillation counting
Liquid scintillation counting is an analytical technique which is defined by the 
incorporation of the radiolabelled substance to be analysed into uniform distribution 
with a liquid chemical medium capable of converting the kinetic energy of nuclear 
emissions into light energy. A liquid scintillation counter is then used to quantify the 
activity of radioactive the sample emitting B (electrons) and a (Helium nuclei) 
particles.
To ensure efficient transfer of energy between the emitted particle and the medium, the 
substance to be tested is dissolved in a liquid medium called scintillation fluid or a
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cocktail. This fluid is a mixture of 3 chemicals: a solvent appropriate to dissolve the 
test substance which also absorbs excitation energy and emits UV light; a fluor which 
absorbs the UV light emitted by the solvent and emits a flash of blue light and an 
emulsifier to ensure the even distribution of components throughout the cocktail
In the relatively dense liquid, the beta particle travels only short distances before all of 
its kinetic energy is dissipated. Typically a beta particle will take only a few 
nanoseconds to dissipate all its kinetic energy. The energy is absorbed by the medium 
in 3 forms: heat, ionization and excitation. Some of the beta energy is absorbed by 
solvent molecules making them excited (not ionized).
Energy of the excited solvent is emitted as UV light and the solvent molecule returns 
to ground state. The UV light is absorbed by fluor molecules which emit photons as 
blue light flashes upon return to ground state. The total number of photons from the 
excited fluor molecules constitutes the scintillation. The intensity of the light is 
proportional to the beta particle’s initial energy.
In the chamber of the scintillation counter, blue light flashes hit the photo cathode of 
the photo multiplier tube (PMT). Electrons (proportional in number the blue light 
pulses) are ejected producing an electrical pulse that is proportional to the number of 
blue light photons. The number and intensity of pulses is analyzed by the counter to 
provide information about the energy of the radiation or the amount of radioactive 
material dissolved in the cocktail.
Following harvesting, the organs were either frozen in liquid nitrogen-cooled 
isopentane or processed immediately. The total weight of the organ was recorded and 
a sample of organ tissue no larger than 50mg was placed in a 20mL plastic scintillation 
vial (BDH, UK). lmL of Solvable or Soluene-350 (Packard Intemationl, UK) was 
then added (Solvable was used for all tissues except blood, urine and digestive tract 
where Soluene-350 (Packard) was used). The vials were then heated to 50°C for one 
hour with occasional mixing. The solutions were allowed to cool to room temperature 
before 0.2mL of 30% hydrogen peroxide was added in two aliquots of 0.1 mL with 
swirling between additions to allow the reaction to subside. The vials were then heated 
again to 50°C for 30 minutes to complete decolourisation. lOmL of the liquid
93
scintillation cocktail Ultima Gold (Packard) was then added and the caps tightly sealed 
on the vials (and labelled accordingly) before the solution was mixed thoroughly by 
vortexing. The vials were loaded onto appropriate racks and placed in the chamber of 
a scintillation counter (Beckton-Dickenson) for one hour to allow for temperature and 
light equilibration. Counting time was 10 minutes per sample.
All counts were converted to absolute radioactivity (dpm) by automatic quench 
correction. This is done by the counter which generates a scintillation spectra by 
exposing each sample to an external gamma source. This spectrum is then compared 
with an internal library of scintillation spectra derived under a wide range of quenching 
conditions and the counting efficiency is determined. Using this efficiency value in 
conjunction with the observed cpm from the sample, the absolute amount of 
radioactivity in each individual sample is calculated. Samples having a radioactivity 
level of less than or equal to double the background level were considered below the 
limit for accurate analysis and given the value of zero.
The weight of the blood contained in the organ was corrected as for Wu et al (Wu, 
Robbins, Bugianesi et al. 1981) so as to calculate the activity contributed by the blood 
to the total activity calculated for the organ.
Total organ activity (or activity per unit volume for fluids) was calculated:
Weight o f organ (mg) X  dpm counted for sample
Weight o f sample (mg)
The percentage of the total [ H] activity administered present in the whole organ (or 
per unit volume for fluids) could then be calculated:
[3H] activity for organ (dpm) X  100%
[ H] activity administered (dpm)
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3.7 Preparation of Co-lipids
Reagents
Galactocerebrosides and Psychosine (Sigma, UK)
DOPE (Fluka, UK)
Protocol
5mg/mL stock solutions of the lipids were prepared from freeze dried in a 
chloroformimethanol (1:1 vol/vol) solution and stored under nitrogen.Lipids were 
aliquoted into borosilicate glass tubes and dried under a stream of nitrogen. The lipids 
were then hydrated in 500pL 0.15M NaCI with moderate vortexing and warming at 
37°C until the entire lipid had dispersed. The suspension was sonicated (low power) 
for 5 minutes on ice. Lipidic amino acid dendrimers in 0.15NaCl were combined at 
the appropriate molar ratio and the solution dried under nitrogen. Hydration with the 
appropriate medium was carried out on ice with high-speed vortex mixing until a 
homogeneous suspension was obtained. The suspension was again sonicated (low- 
power) for 5 minutes on ice before complex formation with DNA as previously 
described.
3.8 Complement Activation Assay.
Equipment
96 well plate, flat-bottomed: Nunc microtitre plates (LifeTechnologies,UK).
96 well plate, U-bottomed: Nunc microtitre plates (LifeTechnologies,UK).
Plate reader: MRX microplate reader (Dynex, Billingshurst, UK).
Centrifuge: Centaur (with swinging tray rotor for microtitre plates)
Buffers/solutions
EDTA-GVB: lOmM EDTA, 145 mM sodium chloride, 25mM sodium barbital, 1.0% 
gelatin, pH adjusted to 7.4 with hydrochloric acid.
GVB2+: 145 mM sodium chloride, 25mM sodium barbital, 1.0% gelatin, ImM
magnesium chloride, 0.15 mM calcium chloride, pH adjusted to 7.4. 
Human complement serum (Sigma, UK);
Anti-sheep red blood cell stroma (Sigma, UK);
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50mL Sheep erythrocytes (Es) in Alsevers solution (TCS Biosciences, UK)
The procedures described by Whaley (Whaley 1985) were adapted as described by 
Klerx et al (Klerx, Beukelman, Van Dijk et al. 1983) and Plank et al (Plank, Mechtler, 
Szoka et a l 1996). All solutions and reagents were kept on ice throughout unless 
otherwise stated.
The Es were washed once in EDTA-GVB and twice in GVB2+ by suspending the cells 
in 45mL of buffer followed by centrifugation at 2000 rpm at 4°C for 10 minutes to 
pellet the cells. The supernatant was then removed and the cells resuspended for the 
next wash and finally resuspended at approximately 5% solution in GVB2L To 
calculate the cell density, 1 mL of this suspension was added to 29 mL of deionised 
water and the optical density (OD) of the lysate measured using a spectrophotometer at 
a wavelength of 541 nm (OD5 4 1). An OD54 1 reading corresponds to a sheep E 
concentration of lx l0 9 /mL.
The volume of the erythrocyte suspension was adjusted to lxlO9  using the formula:
Volume Es required = Initial volume x OD measured
0.385
The Es were sensitised according to published methods (Whaley 1985) with the anti­
sheep red blood cell stroma reconstituted in cUEO and diluted 1:200 in GVB2+ 
according to the manufacturer’s instructions. Equal volumes of antiserum and sheep 
Es suspension were pre-warmed to 37°C a combined in a 50 mL centrifuge tube. The 
reaction was then incubated at 37°C for 30 minutes with constant shaking (300 rpm). 
The antibody sensitised cells (EAs) were centrifuged (2000g for 5 minutes at 4°C), 
washed once in EDTA-GVB and twice in GVB2+ and finally resuspended in half the 
original volume in GVB2+ to a concentration of 2 x 1 0 9 /mL.
The total haemolytic complement titration (CH50) for the human complement sera
used was determined using several serial dilutions within the range of 1:10 to 1:80. On
ice, 50pL of each dilution was added in duplicate to 2 columns of a round-bottomed 96
well plate, with 50pL of GVB2+ added and mixed by pipetting. lOOpL of EAs at a
concentration of 2 x 109/mL was added to each well. Duplicate controls used included
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“spontaneous lysis” (blank) and “ 1 0 0 % lysis” in which the complement serum was 
replaced with GVB2+ and 2pL 10% Triton X-100 added to the latter. The plate was 
then incubated at 37°C with shaking for 60 minutes and followed immediately by 
centrifugation of the plates at 2000# for 5 minutes at 4°C. The supernatant was 
transferred to a flat-bottomed 96-well plate and released haemoglobin determined by 
the absorbance at 410nm.
Calculation of CH50 of human complement sera.
The proportion of cells lysed (y) in each well is calculated using the following formula.
y  = OD4 1 0  well - OD4 1 0  blank
OD4 10 100% lysis - OD4 1 0  blank
The percentage of cells lysed in each well is obtained by multiplying y  by 100.
When y  (per cent lysis) is plotted against the volume of serum in each well, a sigmoid 
dose-response curve is obtained. The central part of the curve (between 20% and 80% 
lysis) is steep and the proportion of cells lysed is sensitive to small changes in the 
amount of complement in the serum. For this reason the endpoint of the titration is 
taken as a 50% haemolysis.
The sigmoid curve may be mathematically described using the von Krogh equation:
K l/n
Where x is the amount of serum added to the well (pL) and K is the constant which is 
the 50% unit of complement. At the point of 50% lysis 1 —y  =1 and x = K.
The value of K can therefore be obtained by plotting log x  against log y / l —y.
The number of CH50 units/mL = initial dilution x 100.
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Calculation of CH50 of human complement sera following incubation with 
dendrimer/DNA complexes
Dendrimer/DNA complexes were formed in saline as previously described. These 
were then serially diluted in GVB2+ to an appropriate amount of positive charge (nmol 
NH2 per pL). In this case the range tested was to give 10 -  lOOnmol [NH ]/pL in a 
final volume 200pL. 50pL of Dendrimer/DNA complex was added in duplicate to the 
wells of a 96 well round-bottomed plate. The first 2 columns of the plate contained the 
highest concentration for each dendrimer tested, with subsequent columns containing 
the serial dilutions. The last 2 columns contained 50pL GVB2+ only.
50pL of human complement serum in GVB2+ was then added to each well. The 
appropriate dilution was determined in the previous standard experiment as the amount 
of serum that would lyse 50% of the EAs. The plate was then incubated for 30 
minutes at 37°C
After the incubation lOOpL of the EAs were added to each well, leading to a final 
erythrocyte concentration of 1 x 109 /mL. The plates were covered with plastic film 
and then shaken vigorously for lhr at 37°C. Subsequently unlysed erythrocytes were 
pelleted by centrifugation at 2000g and lOOpL each of the supernatants were 
transferred to a flat-bottomed 96-well plate. Released haemoglobin was determined at 
410nm using an ELISA plate reader. Absorbance at 100% lysis was determined by the 
addition of 2pL of 10% Triton X-100 to 2 x 108 EAs in 200pL of GVB2+. CH50 
values for each of the complexes were calculated as previously described.
The CH50 value describes a particular amount of serum that causes the lysis of 50% of 
the erythrocytes in the assay. Its classical definition refers to the volume (in mL) of 
serum that will result in 50% haemolysis of 5 x 108 EAs when incubated at 37°C for 
60 minutes in a final volume of 7.5mL of reaction mixture (Kabat and Mayer 1961).
In this case the CH50 value describes a particular serum dilution:
Addition of 5 0 p L  of this particular dilution to 2 x 1 0 8 EAs in 1 5 0 p L  GVB2+ will result 
in 5 0 %  haemolysis. The concentration effect on C H 5 0  of each compound was 
compared to C H 5 0 max, which is the C H 5 0  value obtained when EAs are incubated with 
untreated serum. Percentage of C H 5 0 max =  ( C H 5 0 sampie /  C H 5 0 max)  x 1 0 0 .
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3.9 Electron Microscopy.
3.9.1 Preparation of biological specimens.
Reagents:
Glutaraldehyde: 20mL 20% paraformaldehyde (Analar BDH) added to 16mL
25% glutaraldehyde (TAAB) made up to 95mL with 59mL 
phosphate buffered saline (Oxoid).
Osmium tetroxide: 1% osmium tetroxide: (Analar BDH); 1.5% potassium
ferricyanide (BDH) in PBS (Oxoid).
Toluidene blue stain: 1% toluidine blue (Raymond Lamb); 0.2% pyronine (Raymond 
Lamb) in 1% sodium tetraborate solution (Analar BDH). 
Reynolds lead citrate: 1.33g lead nitrate (BDH) dissolved in 15mL distilled water 
added to a solution of 1.76g sodium citrate (BDH) in 15mL 
distilled water with the resulting precipitate dissolved by adding 
8  mL of 1 M sodium hydroxide (BDH) and made up to final 
volume of 50mL.
Lemix epoxy resin: 25mL Lemix A; 55mL; Lemix B; 20mls Lemix D. Poured into
resin bottle, 2mL BDMA added and mixed well.
Procedure:
Detached cells were fixed in 1.5% glutaraldehyde for 2 hours. They were then 
detached, transferred to a microcentriguge tube and centrifuged for 1 0  minutes at 
2000g to form a pellet. The preparations were then washed with PBS (Oxoid) and 
post-fixed in osmium tetroxide.
The specimens were then washed using distilled water and then treated with 1% 
Tannic acid in PBS for 1 hour. The cells were then washed with distilled water and 
dehydrated using graded alcohols from 30% to 100%. The cells were left in 50% 
alcohol/50% Lemix (Taab) epoxy resin mixture overnight to infiltrate. They were then 
placed in 100% Lemix resin for a minimum of 6  hours, embedded in fresh Lemix 
Resin and polymerised at 70° C overnight. Semi-thin (1 pm) sections were then cut 
using glass knives on a microtome (Reichert-Jung ultracut) collected on glass 
microscope slides and stained using 1% toluidene blue stain or methylene blue/azure II 
+ basic fuchsin 1:12. Ultrathin sections were cut using a diamond knife (Diatome) and
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collected on 200HS, 3.05mm copper grids (Gilder). Sections were stained using 
saturated alcoholic uranyl acetate (TAAB) for 5 minutes followed by Reynold’s lead 
citrate for 5 mins. Sections were viewed and photographed using a Philips 201 
transmission electron microscope.
3.9.2 Preparation of lipidic peptide dendrimer/DNA complexes for 
TEM
A drop of the sample was placed onto 200HS, 3.05mm copper grids (Gilder, UK) for 1 
minute and then blotted using the comer of a piece of filter paper (Whatman, UK). 
The samples were then stained with 1% (w/v) phosphotungstate for 1 min and blotted. 
All samples were examined with a Phillips 201 transmission electron microscope.
3.10 Histochemistry
3.10.1 Detection of P-Galactosidase activity in tissues 
Reagents
Iron buffer: (2mM MgCl2; 5mM K4 Fe(CN) 6  • 3H2 0 ; 5mM K3 Fe(CN) 6  in
PBS).
20x X-Gal solution: (4% w/v 3-indolyl-p-D-galactopyranoside in DMSO).
Fixative A: (4% w/v paraformaldehyde; 0.01% v/v glutaraldehyde in PBS).
Fixative B: (4% w/v paraformaldehyde in PBS).
Sucrose solution: (20% w/v sucrose; 4% w/v paraformaldehyde).
Liquid-nitrogen-cooled isopentane.
O.C.T. embedding compound (BDH, UK).
Cork mounting discs (Sigma, UK).
Protocol
Small (5mm3) block sections of tissue were harvested and rinsed several times in PBS. 
The sections were then incubated in fixative A for 3 hours at 4°C. The Iron buffer and 
X-Gal solutions were combined to give a lx working X-Gal concentration and warmed 
to 37°C.
The tissue sections were then rinsed in PBS and incubated in the X-Gal/iron buffer 
solution at 37°C overnight (approximately 16 hours), rinsed several times in PBS and
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incubated in fixative B for 12 hours at 4°C. Sections were then incubated in a 
cryoprotectant sucrose solution overnight at 4°C.
The sections were then placed on a cork disc and overlaid with a drop or two of O.C.T. 
mounting media. Immediately after the discs were submerged in liquid nitrogen 
cooled isopentane for 15 seconds and transferred to airtight vials with a few drops of 
isopentane (to prevent drying out) and stored at -80°C. Thin (10pm) sections were cut 
using a cryotome set at -20°C object and cabinet temperature, mounted on PLL coated 
slides (Sigma, UK) and air-dried at room temperature overnight. Mounted sections 
were overlaid with a drop of mounting-media, covered with a glass coverslip and 
sealed with clear nail polish.
3.10.1 Detection of human FIX in harvested mouse tissues.
The reagents used were as described (Herzog, Hagstrom, Kung et al. 1997) with 
modifications to the published protocol for muscle tissue to suit the liver tissue used in 
this study.
Reagents
Liquid-nitrogen-cooled isopentane (Sigma, UK)..
O.C.T. embedding compound (BDH, UK).
Cork mounting discs (Sigma, UK).
Fixative: acetone/methanol 1:1 (v/v) at -20°C
Blocking solution: 2% donkey serum/l%BSA/0.01% Triton X-100 in PBS.
Methanol
Protocol
Sectioning and mounting
Harvested tissue blocks were then placed on a cork disc and overlaid with a drop or 
two of O.C.T. mounting media. Immediately after the discs were submerged in liquid 
nitrogen cooled isopentane for 15 seconds and transferred to airtight vials with a few 
drops of isopentane (to prevent drying out) and stored at -80°C. Thin (10pm) sections 
were cut using a cryotome set at -20°C object and cabinet temperature, mounted on 
PLL coated slides (Sigma, UK) and air-dried at room temperature overnight.
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Fixing and blocking
Using a staining jar, cryosections were fixed for 15 minutes in acetone/methanol at - 
20°C, rinsed in PBS for 5 minutes and blocked with blocking solution for 1 hour at 
room temperature. The sections were then washed in PBS.
Primary antibody reaction
Sections were incubated overnight at 4°C with an affinity purified goat anti-hFIX 
antibody (Affinity Biologicals, Canada), diluted 1:200 in 2% donkey serum/PBS. The 
sections were washed three times for 10 minutes in 1%BSA in PBS.
Secondary antibody reaction
The secondary antibody [flourescein isothiocyanate (FITC)-conjugated rabbit anti goat 
IgG (Dako) diluted 1:200 in PBS/2% donkey serum] was applied for 90 minutes at 
room temperature. After three additional washes in PBS, sections were rinsed in 
distilled water, air dried and covered with Vectorshield™ (VectorLabs).
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Chapter 4
The Properties of Lipidic Peptide Dendrimers
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4.1 Introduction
LPD/DNA complexes have the potential to function as a gene delivery vehicle. In 
order to develop this premise it is important to understand the chemical and physical 
properties of the LPD/DNA complexes. Studies into the properties of LPD/DNA 
complexes have been published (Toth, Sakthivel, Wilderspin et al. 1999; Bayele, 
Sakthivel, O'Donell et al. 2005) and extracts of this thesis contributed to the published 
work.
Preliminary work was performed at the School of Pharmacy, University of London 
prior to commencing this thesis and is outlined below.
Synthesis of LPD
The lipidic peptide dendrimers were synthesised using solid phase procedures where 
the construction takes place on a resin of 4-methyl benzhydrylamine (Toth 1994). 
This method enables the molecule being constructed to be easily manipulated for the 
numerous separate reactions involved in its development. Briefly, the lipid-peptide 
was constructed from commercially available activated amino acids which were 
modified in stages using dimethyl formamide to form the lipid/peptide backbone. 
Deacetylation of the modified dendrimers was performed with hydrazine in methanol 
to enable addition of a glucose or signal peptide. De-protection of the N-termini of the 
amino acids (lysines or ornithines) was then performed using trifluoroacetic acid to 
allow further lysines to be added, forming the dendrimer portion of the molecule. 
The resin containing the peptide was then carefully washed with dichloromethane and 
dried in air before being separated using hydrogen fluoride gas. The LPD was then 
lyophilised in acetic acid and purified using high-performance liquid chromatography. 
Purity was confirmed by mass spectroscopy.
Zeta potential measurements of LPD/DNA complexes and nuclease protection 
assay
The zeta (Q potential or net surface charge density of transfection complexes has been
previously described as a determining factor in gene transfer (Takeuchi, Ishihara,
Kawaura et al. 1996) and also as a means of screening new reagents or formulations
for transfection efficiency (Son, Tkach and Patel 2000). The calculation of zeta
potential has been reported as essential for the prediction of in vitro transfection
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efficiency, because it provided a real measure of the affinity of the gene delivery 
complex for charged cell surfaces (Duguid, Li, Shi et al. 1998). The concentration of 
carrier in solution may serve as a substitute for the zeta potential in predicting affinity 
between the cell surface and the gene delivery complex.
The zeta potential (surface charge density) of the complexes was measured using a 
zeta-sizer. This showed a concomitant change from net negative to net positive 
surface charge as more dendrimer was added to a constant DNA concentration. This 
change had a profound effect on the protection of DNA from DNasel digests. The 
study showed that dendrimer compound la  protected DNA at 10 times the amount of 
dendrimer lb which were tested (Toth, Sakthivel, Wilderspin et al. 1999).
The approaches of the experiments in this chapter are designed to further the study of 
the properties of LPD and LPD/DNA complexes under carefully controlled conditions. 
As an entirely novel family of molecules designed with a view to carry a functional 
gene into the nucleus of living cells, it is essential to obtain information about their 
interaction with DNA and the properties of the complex produced prior to their 
introduction to cells. Additionally, having established that these molecules can 
facilitate the introduction of a functional gene to a cultured cell, a mechanism of how 
this occurs can be postulated.
4.2 Gel-retardation assay of LPD/DNA complexes
When an electrical current is passed through a pre-cast agarose gel (a porous medium 
where the size of the pores can be controlled by altering the concentration of agarose) 
while submerged in an electrolyte bath, it creates a potential difference across the gel. 
Any charged particle within the gel will migrate towards one or other of the electrodes 
depending on the polarity and size of the charge. The speed of the migration through 
the gel is a function of the size of the charged particle and the net charge.
The net charge of DNA complexes for use in gene delivery has shown to be a 
determining factor of efficacy (Ledley 1996; Yang and Huang 1997).
In order for the DNA to be visualised, a labelling molecule must be able to penetrate
the complex. The exclusion of this labelling molecule would produce a reduced signal
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for the DNA and would indicate a decreasingly permeable complex. This could be a 
positive attribute for the protection of the DNA against attack by chemicals that 
degrade DNA, rendering it inactive. The permeability of the complexes would 
indicate the amount of protection afforded to the DNA within the complex
Aims
The gel retardation assay is dependent on the properties of the complexes formed when 
DNA and LPD are combined namely:
- The net charge of the complexes.
- The permeability of the complex to other molecules.
This study was carried out in order to determine the behaviour of the complexes as 
defined by their size and charge.
Experimental design
Agarose was dissolved to a concentration of 2% (w/v) in 0.5x TBE (0.5x Tris Borate E 
ethylenediaminetetraaceticacid - disodium salt: 890mM tris-base, 890mM boric acid, 
20mM Na2 EDTA, pH 8.0) and heated to boiling in a microwave oven. The melted 
agarose was allowed to cool slightly with stirring before adding ethidium bromide 
(EthBr) to a final concentration of 0.5pg/mL. The gel was then poured into a 
horizontal casting tray with combs of the desired size attached and allowed to set at 
room temperature. The combs were then carefully removed and the set gel (in casting 
tray) placed into an electrophoresis tank containing enough electrolyte to just cover the 
gel.
For the gel retardation assay, 10 pL of dendrimer and DNA were combined to produce 
a constant final DNA concentration of 50ng/mL, with increasing dendrimer 
concentrations accordingly. The charge ratio of NH2 (+ve) to PC>3(-ve) groups 
(assuming total ionisation) were calculated (see Chapter 3 page 85) (Shah, Sakthivel, 
Toth et al. 2000). Samples were combined with a sucrose loading buffer to ensure the 
samples sink to the bottom of the well and loaded into the wells. A control sample 
containing 2.5 jug of uncomplexed plasmid and 5pL of molecular weight marker 
(Hyperladder I) were also included. The electrophoresis was performed at 
approximately 3-4V/cm for 90 minutes. Gels were then visualised under UV light.
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Results
Figures 4.1a, b & c show pictures of the agarose gel electrophoresis of LPD/DNA 
complexes viewed under UV light. Different LPD/DNA complexes have migrated 
through an agarose gel preparation under the influence of an electrical charge placed 
across the gel. Under these conditions it appears that the progress of the 
dendrimer/DNA complexes towards the anode (+ve electrode) through the gel is 
retarded as the amount of dendrimer added to form the complexes is increased. This is 
compared to uncomplexed plasmid DNA (labelled neg.).
F igure 4.1a, b & c: A garose gel e lec trophoresis  o f DN A/LPD
com plexes
The figures show the mobility o f plasmid DNA when complexed with increasing 
amounts o f dendrimer. The wells are labelled according to the charge ratio (+/ -) or 
[NH2]: [P04] o f the complex loaded.
4.1a Dendrimer la  (8 terminal amine groups, no modifications)
bl= blank well
Hypl= molecular weight marker
As can be seen in figure 4.1a, the retardation effect is first apparent at a theoretical 
charge ratio of 1 and becomes more noticeable at 1.5 and 2, with total immobilisation 
of the complexes movement through the gel seen at a charge ratio of 4. The EthBr 
marker then becomes weaker in signal at charge ratios of 8 and 16 with the complexes 
mobility completely inhibited.
0 . 2 5  0 . 5  0 . 7 5  1 . 0  1 . 5  2  4  8  1 6  b l  n e g  H y p I
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4.1b Dendrimer lb  (16 terminal amine groups, no modifications)
bl= blank well
0 . 2 5  0 . 5  0 . 7 5  1 . 0  1 . 5  2  4  8  1 6  b l  n e g  H y p I  H y p l =  m o l e c u l a r  w e i g h t  m a r k e r
Figure 4.1b shows that detectable retardation of movement through the gel occurs at a 
charge ratio of 0.75, with total immobilisation occurring at 1.5. The signal of the 
EthBr becomes gradually weaker with complexes at charge ratios of 8 and 16 showing 
signs of movement in the opposite direction out of the wells indicating a change to a 
net positive charge.
4.1c Dendrimer lc (32 terminal amine groups, no modifications)
b1= blank well
Hypl= molecular weight marker
Figure 4.1c shows that significant retardation occurs at a charge ratio of 1, with total 
immobilisation apparent at 2. The EthBr signal becomes gradually weaker with 
complexes at charge ratios of 4, 8 and 16 showing migration in the opposite direction 
out of the wells indicating a change to a net positive charge. At a charge ratio of 16 
the marker is almost completely excluded.
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Discussion
The surface charge of a complex is closely linked to its performance in a gel- 
retardation (mobility shift) assay. The total net charge of the complex determines the 
attraction to a given electrode and the size of the charge determines the strength of this 
attraction. This can be translated and measured by the movement of the complex 
during gel electrophoresis, as the higher net charge will produce greater mobility 
through the gel over a set time. The advantage of this approach is that it allows 
visualisation of the DNA/carrier complex in the context of its mobility through the gel. 
However this is a qualitative assay and no fixed values can be assigned as the complex 
interaction of both electrostatic and steric effects determine the movement through the 
gel.
When EthBr (a planar molecule) is added to DNA in solution, it intercalates between 
the base pairs of the DNA double helix, emitting an intense fluorescence signal at 
618nm when excited at 516nm. If EthBr is introduced to a solution of DNA that is 
pre-complexed with a cationic lipid or other carrier, the fluorescence signal is reduced 
significantly (Gershon, Ghirlando, Guttman et al. 1993). This property may function 
to protect the DNA from chemical attack from nucleases or other harmful molecules.
The LPD/DNA complexes progress through the gel appears to be retarded as the 
amount of dendrimer is added. The EthBr appears to be partially excluded at the 
highest concentration of added dendrimer shown by the decrease in the intensity of the 
band under UV illumination. As the amount of dendrimer accumulating around the 
DNA increases, the intercalation of EthBr into the groves of the helix is progressively 
reduced. It is likely to be fully excluded at higher charge ratios above that seen in this 
experiment. Alternatively the retarded movement towards the cathode could be 
completely reversed in a movement of the complexes towards the anode.
It has been shown that DNA can be displaced from lipoplexes by highly negatively 
charged molecules such as heparin and dextran sulphate (Xu and Szoka 1996). This is 
an essential property of DNA/carrier complexes to be used in gene therapy as the DNA 
must be liberated in the nucleus of the target cell in order to interact with transcription
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factors prior to expression. This assay also provides an indication of the levels of 
EthBr intercalation between the base pairs of the DNA.
The displacement of EthBr at the higher amounts of dendrimer reduces the information 
obtained from the experiment and as such may not be the ideal choice of marker. As it 
is applied to the complexes after they are formed it does not interfere with this process 
and is of use at the lower dendrimer levels. A fluorescent marker such as SYBR™ 
green would not have been excluded as the DNA would be labelled prior to complex 
formation and be detectable at high levels of added dendrimer so it may have been 
advantageous to repeat this experiment with an alternative marker.
In conclusion, the increase in the addition of LPD to DNA changed the net charge 
towards the positive, gradually excluding EthBr from intercalating with the DNA. The 
LPD protects the DNA in this respect and the complexes may benefit from a high 
positive to negative charge ratio when being formed.
4.3 Visualisation of DNA/LPD complexes
The gross structure of the DNA/LPD complexes can be studied using Transmission 
Electron Microscope (TEM). Any subsequent changes to the transfection efficiency 
observed as a result of alterations in the conditions in which the complexes are formed, 
can then be studied in light of any specific variations in the morphology of the 
complexes. Information gained here can then be used in the selection of the most 
effective media for complex formation and determine the effect of additives commonly 
used in cell culture media such as foetal bovine serum (FBS).
Aims
The purpose of this study was to determine the gross morphology of LPD/DNA 
complexes. The effect of variations in the media in which the complexes are formed 
may induce changes to the complexes, which could alter their gene transfer 
capabilities.
Experimental design
The studies, designed to observe the morphology of the complexes, were carried out
using media commonly used in cell culture such as Eagle’s Minimum Essential Media
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(EMEM), Opti-MEM® and a salt solution (NaCl/NaHCC>3 - 150mM/20mM) 
developed to improve the formation of complexes in media containing serum (Escriou, 
Ciolina, Lacroix et al. 1998). 10 pL of LPD and plasmid DNA preparations in the 
different media were combined, using a constant final DNA concentration of 50ng/mL 
and a charge ratio of 5:1 NH2 (+ve) to P0 3 (-ve).
For TEM, a drop of the sample was placed onto copper grids for 1 minute and then 
blotted using the comer of a piece of filter paper. The samples were then stained with 
1% (w/v) phosphotungstate for 1 min and blotted. All samples were examined with a 
Phillips 201 transmission electron microscope.
Results
The results show complexes of LPD 1 a and plasmid DNA viewed by EM. All other 
LPD tested (la, lb, lc, 2a, 2b, 2c and 3a) exhibited similar morphological properties 
when tested. The scanned images maintain the magnification used to view the 
complexes by TEM (85,000x).
In a saline/hydrogencarbonate solution, LPD/DNA complexes form large 
heterogeneous particles. When 10% FBS is added, the complexes form smaller more 
homogeneous particles. The size of these particles is approximately 150-170 nm 
diameter.
Figure 4.2 EM  of com plexes form ed in N aC I/N aH C 03 
(150mM /20mM )
4.2a) +10% FBS 4.2b) No FBS
111
Figure  4.3 E M  o f com plexes form ed in E M E M
4.3a)+10% FBS 4.3b) No FBS
In EMEM, LPD/DNA complexes produce discreet particles with some clumping into 
groups. With the addition of FBS, some electron-dense tubules appear to have been 
formed and are clumped together with some electron dense structures apparent.
Figure 4.4 E M  o f com plexes fo rm ed  in O p ti-M E M d 
4.4a) +10% FBS 4.4b) No FBS
In Opti-MEM® there appears to be small homogeneous particles in the absence or 
presence of FBS. There is relatively little difference in the visible structure of the 
particles when formed in this media preparation.
Discussion
When studying the ‘clumping’ of dendrimer/DNA complexes formed at high 
concentration in physiological ionic conditions, it is important to define the terms used 
in colloidal chemistry. Aggregation or flocculation is used to describe when particles 
become physically associated, yet retain their individual identities. Coalescence refers
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to particles which fuse to form a single larger particle, with a resulting reduction in 
surface area compared to the sum of that of the individual particles (Hiemenz 1986).
Saline/bicarbonate buffer (NaCl/NaHCOs - 150mM/20mM)
It is difficult to absolutely define the process occurring in this case with relation to 
lipidic peptide dendrimers and DNA in saline without further colloidal investigations. 
However, when considering the results of the EM study carried out here, it would 
appear that coalescence rather than aggregation is the more likely process since the 
particles appear larger and amorphous, with no appearance of individual component 
particles forming them. However flocculation could occur with such a close 
association of particles that prevents their interface being resolved and appear as a 
single structure.
The appearance of the particles concur in part to the findings of Escriou et al in that 
serum in the media promotes the formation of small homogeneous 
DNA/lipopolyamine complexes (Escriou, Ciolina, Lacroix et al. 1998). However, in 
contrast to this study the use of the bicarbonate buffer did not result in the morphology 
of the complexes maintaining the larger heterogeneous particle morphology in the 
presence of 10% FBS. This raises the question of whether the hypothesis posed by 
Escriou et al is applicable to LPD/DNA complexes. The activity of the complexes 
could, therefore, be adversely affected by the presence of serum in cell culture media 
during transfection. This hypothesis will be tested in Chapter 5 of this study.
Opti-MEhff
Complexes formed in Opti-MEM® with or without the addition of 10% FBS display 
the least amount of morphological change of the media studied. Optimem® is 
commercially formulated for use as a serum-free cell culture medium with some 
components undisclosed (to protect commercial interests). It is also reasonable to 
assume that some constituents are included to replace the functions normally carried 
out by serum components and could well be proteinaceous in nature. Based on the 
hypothesis that serum has a coating effect on the complexes preventing flocculation or 
coalescence, it is not unexpected to see that Opti-MEM® without the addition of FBS, 
supports the formation of small homogeneous complexes similar to those formed in 
other physiological media containing serum.
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EMEM
Complexes formed in EMEM with FBS added showed no discemable particles as seen 
with the other media. This suggests a disruption in the process or complex formation 
as seen in other media. However without the serum added the complexes formed small 
homogeneous particles with a tendency to aggregate but not coalesce, remaining as 
discreet bodies.
The potential effect o f serum on gene transfer
Serum is the term used to describe the clear fluid remaining from whole blood 
following the depletion of the clot forming agents and cells. It is rich in soluble 
proteins, hormones and immunoglobulins as well as a number of biochemicals. It is 
widely used in cell culture media at various concentrations, the most commonly used 
being 10% FBS. It has been reported that cellular uptake of DNA, in the form of 
DNA-liposome complex is inhibited in the presence of serum (Yang and Huang 1997). 
This inhibitory effect was overcome by increasing the charge ratio of the cationic lipid 
to DNA. This group found that serum inhibited lipofection activity of the lipoplex at 
low charge ratios, whereas it enhanced the lipofection activity at high charge ratios 
(this occurred using DOTAP/DOPE but not lipofectamine). In summary, inactivation 
of cationic liposomes by serum is due to negatively charged serum proteins and it can 
be overcome by increasing charge ratio of cationic liposome-DNA lipoplexes or by 
neutralizing the serum with polylysine.
The published literature describing the effects of serum on the capacity of non-viral 
vectors for gene delivery is varied. Cationic lipid/DNA complexes have been 
examined following pre-incubation with mouse serum but prior to in-vivo 
administration (Li, Tseng, Stolz et al. 1999). This study concluded that lipidic vectors 
underwent dynamic changes in their characteristics after exposure to serum and 
prolonged incubation with serum led to vector disintegration and subsequent DNA 
release. Following in vivo experiments, it was identified that an inverse correlation 
existed between the disintegration rate of lipidic vectors and their in vivo transfection 
efficiency. The mechanism of this uptake appeared to be the accumulation of 
complexes in the microvasculature of the lung followed by interaction with the
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endothelial cells. This result was achieved using cholesterol as a helper lipid to the 
cationic lipid DOTAP.
Other studies have also looked at serum stability of DNA/vector complexes and its 
effect on structure and function (Boukhnikachvili, Aguerre-Chariol, Airiau et al. 1997; 
Yang and Huang 1998). These reports indicate a correlation between the length of 
time the complexes are incubated for prior to administration and their activity.
One detailed study into the effect of serum on lipopolyamine/DNA complexes showed 
that the addition of 10%FBS prevented aggregation, which occurred in serum-free 
conditions (Escriou, Ciolina, Lacroix et al. 1998). However these studies showed that 
the large aggregated particles (observed in cells following transfection) formed in 
serum-free conditions were more effective transfection agents than the smaller discrete 
particles, consistent with other reports. Furthermore, formation of the complexes in a 
hydrocarbonate buffer resisted the inhibitory effects of the serum, retaining a 
heterogeneous morphology and the associated high transfection activity. This proved 
an elegant solution to the problem of serum affecting the efficacy of cationic 
lipid/DNA complexes in transfection but the same principle does not apply to 
LPD/DNA complexes.
As a rule, particles aggregate or coalesce when attractive forces dominate, and 
stabilization results when repulsion is the dominant force. When colloids are of like 
charge, the repulsive forces are predominantly electrostatic and display 
distance/solution dependent behaviour as described for the diffuse electrostatic double 
layer surrounding a charged particle (Hiemenz 1986). Electrostatically stabilised 
complexes generally undergo flocculation upon the addition of a significant amount of 
salt. The diffuse layer extending out from a charged surface is inversely dependent on 
the ionic strength of the electrolyte solution i.e. the electrostatic repulsion is strongly 
reduced with increasing ionic strength. The use of spermidine for DNA condensation 
demonstrates this principal, as the condensates are stable in salt-free conditions but 
aggregate under physiological buffer conditions. The salt concentration at which 
aggregation is observed is sharply defined and is called the critical flocculation 
concentration. This value depends upon the type and valence of the salt, as well as the 
concentration and other properties of the solution (Tang and Szoka 1998).
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Stabilisation against flocculation has been achieved with the use of non-ionic polymers 
such as polyethyleneglycol (PEG). This ‘steric’ stabilisation is thought to occur from 
the polymers adsorbing onto the surface of complexes preventing interaction.
These experiments have shown that FBS alters the morphology of LPD/DNA 
complexes formed in a saline/hydrogencarbonate and EMEM. These changes do not 
appear to occur when the complexes are formed in Opti-MEM®. This may adversely 
affect the ability of the complexes to transfer genes to cultured cells or tissues in vivo.
It is likely that components of serum act to coat the LPD/DNA complexes forming 
small particles that would otherwise aggregate to form larger particles in serum-free 
media. One of the major mechanisms of cell uptake of synthetic DNA complexes 
postulated is that the net positive charge of the complexes causes them to adhere to the 
net negative charge of the cell surface. The coating of the complexes with serum 
components could adversely affect this interaction and reduce gene transfer efficiency.
To test this hypothesis, media with and without serum will be tested in subsequent cell 
transfection studies to evaluate the effect of serum on gene transfer efficiency. The 
incorporation of PEG or other polymers/co-lipids to the complexes at the synthesis 
stage may prove advantageous in the development of LPD to produce a product able to 
withstand the investigations required for pre-clinical studies.
4.4 Intracellular distribution of LPD/DNA complexes
The nature and intracellular fate of the lipid-DNA complexes is still a matter of debate. 
Indeed the method of entry into the cell and the subsequent processing is a major area 
of study in all areas of gene therapeutics.
Aims
This study is designed to visualize LPD/DNA complexes in situ and elucidate the 
possible intracellular pathways leading to transgene expression.
Experimental design
The protocol used is adapted for staining cells transfected with lipidic amino
acid/DNA complexes (Labat-Moleur, Steffan, Brisson et al. 1996). This study
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describes the collection and fixation of transfected cells which are then mounted, 
sectioned and stained before visualisation by TEM. The technique highlights the 
contrast between the dense LPD/DNA complexes and the structures of the cell, 
providing clear images of the complexes.
Hek293 cells were transfected LPD/DNA (LPD type la  was used -  see Chapter 1 page 
51) complexes and were fixed in 1.5% glutaraldehyde for 2 hours. HEK293 cells were 
chosen as they are quite robust when being processed for TEM. They were then 
detached, transferred to a microcentriguge tube and centrifuged for 10 minutes at 
2000x g to form a pellet. The preparations were then washed with PBS and post-fixed 
in osmium tetroxide. Untransfected cells were used as a negative control.
The specimens were then washed using distilled water and then treated with 1% 
Tannic acid in PBS for 1 hour. The cells were washed with distilled water and 
dehydrated using graded alcohols from 30% to 100% and left in 50% alcohol/50% an 
epoxy resin mixture overnight to infiltrate. They were then placed in resin for a 
minimum of 6 hours before being embedded in fresh resin and polymerised at 70° C 
overnight. Semi-thin (1 pm) sections were then cut using glass knives on a microtome, 
collected on glass microscope slides and stained using 1% toluidene blue stain or 
methylene blue/azure II + basic fuchsin 1:12. Ultrathin sections were cut using a 
diamond knife and collected on 200HS, 3.05mm copper grids. Sections were stained 
using saturated alcoholic uranyl acetate (TAAB) for 5 minutes followed by Reynold’s 
lead citrate for 5 mins. Sections were viewed and photographed using a Philips 201 
transmission electron microscope.
For TEM, a drop of the sample was placed onto 200HS, 3.05mm copper grids (Gilder, 
UK) for 1 minute and then blotted using the comer of a piece of filter paper (Whatman, 
UK). The samples were then stained with 1% (w/v) phosphotungstate for 1 min and 
blotted. All samples were examined with a Phillips 201 transmission electron 
microscope.
Results
140 sections of transfected and untransfected cells were examined. The particles 
described were only seen in the transfected cell sections, no particles were seen in the
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negative control (untransfected) cells. The particles resembled those lipid/DNA 
complexes seen in the original study by Labat-Moleur et al in morphology and size and 
no other structures appeared to resemble them in the untransfected cell sections 
viewed.
Figure 4.5 shows LPD/DNA complexes which can be seen within vesicles in the 
perinuclear region of the cell. Localised electron-dense material is apparent at the 
interface of complexes and the compartment membrane. This EM was selected and 
scanned as representative of many serial sections of transfected HEK293 cells 
processed for electron microscopy as described above. The cytosolic (top) and nuclear 
(bottom) compartments are shown divided by the nuclear membrane (B). A indicates 
the endosome, with C showing the LPD/DNA complexes within.
LPD/DNA complexes are seen at the perinuclear region intact as well as showing 
complexes at an earlier stage of endosomal development. Although it can not be 
categorically stated that the particles seen are indeed LPD/DNA complexes, by the 
process of elimination it can be reasonably concluded that the particles are LPD/DNA 
complexes. In addition the particle size, distribution and morphology are in agreement 
with data published in the origin text (Labat-Moleur, Steffan, Brisson et al. 1996).
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Figure  4.5 E M  of serial section o f H EK 293 cell following transfection
(magnification x16, 960.
Figure 4.6 shows a high magnification image of LPD/DNA complexes within an 
endosome. There is an increase in contrast at the interface between the complexes and 
endosome membrane, possibly indicating liposomal fusion taking place. This could be 
the mechanism by which the Complex is released from the endosome in order to be 
taken up into the nucleus.
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Figure  4.6 H igh pow er E M  show ing a seria l section o f H EK 293 cell 
following transfec tion  (magnification x215, 000).
This high magnification EM shows electron dense material localised at the interface o f 
dendrimer/DNA complexes and the endosome membrane. The arrow indicates the 
endosome membrane.
Endosome
compartment
>
Cytoplasm
Discussion
Following entry into the cell by endocytosis, the DNA/carrier complex must be 
released intact into the cytosol in order to enter the nucleus. The mode by which DNA 
complexes gain entry to the cytoplasm has been the subject of extensive studies. It is 
increasingly evident that this process occurs by endocytosis followed by release of the 
complex by one of two mechanisms a) ‘proton sponge’ mediated endosome buffering 
with subsequent rupture and b) fusion with the endosomal membrane.
Proton sponge theory for endosome escape
It would be expected for lipidic amino acid dendrimers to act as a ‘proton sponge’ 
similar to PEI and Starburst™ dendrimers which are the nearest related molecules to 
LPD. The pKa values of the amine groups in LPD in a biological pH are in the region 
5.5-7.0, this means there is a high concentration of amine groups on the LPD that will
accept protons (H*). The effect will be, within the endosome, these amine groups will 
attract the protons generated by the endosome as part of its normal function to degrade 
its contents. The soaking up of these protons by the LPD has an effect of buffering the 
fall in pH, which leads to osmotic swelling and the endosome rupturing releasing its 
contents of intact particles into the cytoplasm. There is no evidence to support this 
mechanism of endosome escape from the lack of intact LPD/DNA complexes in the 
cytoplasm. It is likely that the interaction of the complexes with the endosome 
membrane shown in the above images occurs before sufficient osmotic swelling can 
occur for the endosome to burst.
Fusion with the endosomal membrane as a means to release
The absence of complexes in the cytoplasm could indicate the disassociation of DNA 
and LPD at the point of cytoplasmic entry or immediately following, allowing free 
DNA to enter the nucleus. The ionic interactions that hold the nucleic acid and vector 
together may be weakened if the dendrimer was degraded in the endosome or fuses 
with the endosome membrane, whilst leaving the DNA intact. DNA could exchange 
for another polyanion such as RNA from a large cytoplasmic pool or 
phosphatidylserine present in the outer leaflet of the endosomal membranes (Xu and 
Szoka 1996). EM pictures previously published show lipopolyamine tubes 
disassembling in the vicinity of altered vacuolar structures (Labat-Moleur, Stefifan, 
Brisson et al. 1996) and are in favour of DNA exchanging with polyanions such as 
RNA, anionic proteoglycans or nuclear chromatin in the cytoplasm.
Liposomal fusion with the endosome can result from neutralisation of charged lipid 
species, as induced by changes in pH or the addition of neutralizing multivalent ions 
(Tilcock, Cullis and Gruner 1988; Duzgunes, Goldstein, Friend et al. 1989). Fusion is 
also promoted by the incorporation of lipids bearing unsaturated fatty acyl chains or 
lipids with a small, charged headgroup (Das and Rand 1986). This has already benn 
demonstrated selective inhibition of lipid mixing, whilst not affecting endosomal 
uptake of the complexes, prevents fusion of the liposome and endosome. (Farhood, 
Serbina and Huang 1995; Wrobel and Collins 1995).
The high magnification images of LPD/DNA complexes in the endosome and absence 
of intact complexes in the cytoplasm support the theory that an interaction with the
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membrane is taking place. The increase in electron density at the point of contact of 
the complexes and the membrane may reflect the incorporation of the dendrimer into 
the membrane, releasing the free DNA to interact with other cationic moieties in the 
cytoplasm as mentioned above. This conclusion, if correct, will provide a positive 
development towards the aims of this thesis as it is widely accepted that a non-viral 
gene delivery system that can mimic the DNA delivery mechanisms of viruses by 
fusing with the plasma or endosomal membranes will enhance the clinical 
development of clinical gene therapy (Feigner 1997).
Summary
These investigations have been carried out in order to determine the physical nature of 
the lipidic amino acid dendrimers when complexed with DNA. Prior to or in 
conjunction with in vitro studies, the data gained here could prove invaluable in 
attempting to account for unexpected events, or support expected results as the study 
progresses. Points raised include:
LPD form discreet complexes with DNA, the morphology of which depends on the 
media they are formed in, that are resistant to nuclease attack.
The complexes can be formed with different overall net charges depending on the ratio 
of LPD to DNA that is combined.
They are taken up by cells intact, localised to the nucleus and display an interaction 
with the endosome membrane.
It is possible that serum will affect the function of the LPD/DNA complexes to deliver 
genes, making the use of a protective co-lipid a consideration in future experiments. 
Opti-MEM® shows the least variability in the morphology of the LPD/DNA 
complexes and will be used as the media within which to form the complexes.
It is unclear whether plasmid/carrier disengagement takes place in the cytoplasm or in 
the nucleus. Although the last stages of the transfection mechanism are not elucidated 
in this study, it is likely that a major barrier which hampers in vitro gene delivery with 
cationic vectors is nuclear translocation. The results described in this section will go 
some way towards optimising conditions such as the net charge of the complexes, prior 
to the introduction into cultured cells, reducing the amount of time-consuming 
preliminary transfections. Also the characterisation of properties of the complexes
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(such as morphology in certain media) under controlled conditions, will give a 
reference point that could be used to explain otherwise unexpected results when used 
to transfect living tissue.
This study can be extended by using longer time points at which to fix and study the 
cells post-transfection. Other cell types could also be used to determine any cell-type 
specific processing features of the complexes.
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Chapter 5 
In vitro Gene Transfer
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5.1 Introduction
The first conclusive evidence that any system is capable of gene transfer into living 
tissue is obtained through the in vitro transformation (or transfection) of cultured cells. 
As well as a proof of principle this process allows the evaluation of a number of 
properties of a gene transfer system through experimental manipulation of the 
conditions. The development of an optimised protocol for gene therapy can then be 
developed through the advances made at this stage of development. In vitro gene 
delivery is also a powerfiil tool to study the functioning and regulation of genes or 
proteins, which can then be expressed at levels desirable for the protocol. Although a 
precursor of in vivo applications for an overall gene delivery strategy, in vitro 
behaviour may not predict in vivo behaviour. As long as these limitations are 
recognised, comparing the factors controlling the efficiency of transfection in vitro 
may give valuable insights into the mechanisms underlying transfection, which can be 
then used to develop an in vivo protocol. This chapter follows the principle that the in 
vitro activity of LPD/DNA complexes observed in the following investigations can be 
used to form a hypothesis to test in an in vivo environment.
5.1.1 Non viral gene transfer into cultured cells
Many parameters govern the transfection activity of a synthetic carrier/DNA complex 
including: the size of complexes (as determined by charge ratio and plasmid size), the 
presence of salts or serum in the immediate environment, the cell type studied and the 
toxicity of particles or aggregates to normal cell activity. Naturally there are many 
factors affecting transfection efficiency involving the nucleic acid expression 
component and subsequent processing of the gene product and these will also be 
discussed.
The major problems to overcome for successful in vitro application of non-viral 
vector-mediated transfection are mainly:
• Low efficiency of transfection;
• Instability in biological fluids;
• Lack of targeting to specific cells.
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As with the development of any new technology, it is advisable to approach these 
deficiencies systematically as they can be notoriously interrelated, with a trade-off 
between desirable properties likely to produce the most effective end product. In this 
work I have pursued a number of approaches with a view to developing LPD as gene 
transfer agents. Each aspect of the gene transfer process was examined with a view to 
developing improvements in the performance of LPD/DNA complexes and is outlined 
below:
Problem: Low targeting efficiency for delivery to specific tissues.
Approach: Use of galactocerebroside (Gc) as a targeting co-lipid (Bandyopadhyay, 
Kren, Ma et a l 1998).
Galactocerebrosides are naturally occurring lipids found in the membrane of cells 
forming the mammalian central nervous system and can be used to target the 
asialoglycoprotein (ASGP) receptor found exclusively in liver cells. The lipid contains 
a terminal galactose molecule on its polar head group, which acts as a ligand for the 
receptor, facilitating receptor-mediated endocytosis. This method of cell entry has 
been shown to be a more effective mechanism than the passive uptake of DNA 
complexes by electrostatic attraction and non receptor-mediated endocytosis 
(Nishikawa, Yamauchi, Morimoto et al. 2000).
Problem: Inefficient entry into the cell nucleus from the cytoplasm.
Approach: Modification of LPD to incorporate a nuclear localization signal (Zanta, 
Belguise-Valladier and Behr 1999).
Translocation of exogenous DNA through the nuclear membrane is a major concern of 
gene delivery technologies. To take advantage of the cellular import machinery, this 
study utilized a single nuclear localization signal peptide (PKKKRKVEDPYC) 
attached to a luciferase reporter gene construct. Transfection enhancement (10- to 
1,000-fold) as a result of this signal peptide was observed irrespective of the cationic 
vector or the cell type used. The hypothesis formulated here is that the 3-nm-wide 
DNA present in the cytoplasm is initially docked to and translocated through a nuclear 
pore by the nuclear import machinery. As DNA enters the nucleus, it is quickly 
condensed into a chromatin-like structure, which provides a mechanism for threading 
the remaining worm-like molecule through the pore. The study concluded that a single
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NLS signal is thus sufficient, whereas many signals on a gene would actually inhibit 
entry, the same DNA molecule being threaded through adjacent pores.
Problem: Low levels of expression of the delivered transgene.
Approach: Use of a strong transcription enhancer such as CMV and tissue specific 
regulatory sequences (Boshart, Weber, Jahn et al. 1985).
A strong transcription enhancer was identified in the genomic DNA (235 kb) of the 
human cytomegalovirus (hCMV), a ubiquitous and severe pathogen of the herpesvirus 
group. The study showed that the hCMV enhancer, reported to have little cell type or 
species preference, is several-fold more active than an alternative regulator, the SV40 
enhancer. It is the strongest enhancer the study analysed, a property that makes it a 
useful component of eukaryotic expression vectors. Despite the age of this study, the 
CMV regulatory sequences are still widely used as a strong director of expression and 
are included in the hFIX expression vector used in this study (Walter, You, Hagstrom 
etal. 1996).
A tissue-specific, non-viral regulatory sequence was investigated with a view to 
utilising it for pre-clinical studies as an alternative to the CMV enhancer. The 
promoter/enhancer fragment used utilises the human thyroid binding globulin 
promoter which has been shown to act strongly in directing expression in a liver 
specific context (Hayashi, Mori, Janssen et al. 1993)
Problem: Inefficient processing of mRNA, reducing levels of gene product.
Approach: Use of cw-elements consistent with efficient processing i.e. Intron I for 
hFIX (Kurachi, Hitomi, Furukawa et al. 1995).
The first intron (intron I) of the human factor IX gene has been studied for its potential 
enhancer activity. Factor IX minigene expression vectors with the same factor IX 
promoter were then constructed containing various portions of intron I. The results 
indicated that the expression enhancing activity of intron I is not due to specific 
enhancer elements present in the intron subsequences, but is due to functional splicing 
sequences present in the precursor mRNAs. The study concluded that being efficiently 
assembled into spliceosome complexes, transcripts with splicing sequences may be 
better protected in the nucleus from random degradations than those without such 
sequences.
127
This is not an exhaustive list by any means, but indicates the processes I have 
determined that could be realistically applied in developing LPD. However it assumes 
the properties conferred to the gene-delivery systems in the original work will be 
transferable to LPD and will have to be tested to confirm this hypothesis.
5.2 Mammalian cell transfection
Transformation is the process by which free DNA is incorporated into a recipient cell 
and brings about genetic change. The classical meaning of the term transfection is the 
process by which bacteria are transformed by the DNA of a bacterial virus. As the 
term transformation in mammalian cells is used to describe the conversion of cells to 
the malignant state, the introduction of DNA into mammalian cells has been termed 
transfection to avoid confusion.
The introduction of foreign DNA to cultured cells falls into two broad categories, 
determined by the ultimate fate of the introduced DNA. Stable transfectants are cells 
in which the foreign DNA has integrated into the cells genome or are retained in the 
nucleus as a stable episome i.e. resides within the nucleus but outside the genome, 
resulting in sustained levels of expression. As only a fraction of cells treated actually 
take up the DNA and express it successfully, they are selected by the addition of a 
cytotoxin to the culture media to which the inserted DNA confers resistance. These 
resistant cells are then expanded to produce a significant number of stable 
transfectants. The site at which the DNA is integrated is random so this process could 
disrupt essential genes and alter the cells characteristics rendering any results difficult 
to validate. Transient transfectants are cells in which the introduced DNA exists as an 
episome and although initially expressed, the levels of gene expression soon drop off 
with the foreign DNA silenced or destroyed. In contrast to stable transfection, this 
method retains the cells characteristics (save for the conferred gene) but is at the loss 
of sustained expression of the transgene. This study follows protocols for transient 
transfection as main focus is the ability of the LPD carrier to transfect the cells rather 
than the retention of the transgene by the cells.
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As previously described, gene delivery in vitro and in vivo requires uptake of DNA 
into target cells, release from intracellular vesicles and transport to the nucleus where 
expression of the gene takes place. Some studies have suggested that for the synthetic 
carrier mediated transfection, high levels of reporter gene expression are only obtained 
in actively dividing cells (Zabner, Fasbender, Moninger et al. 1995; Wilke, Fortunati, 
van der Broek et al. 1996). Wilke et. al. studied transfection using growth arrested or 
growth-cycle synchronised cells and showed that although all cells took up the DNA, 
the gene expression was limited by mitotic activity. This hypothesis will be tested 
with LPD/DNA complexes in terminally differentiated C2C12 myothubes which are 
terminally differentiated myeoblasts and are not actively dividing.
In general, for all systems tested (with the exception recombinant adenovirus), there is 
a clear and comparable difference in transfection efficiency between cells transfected 
shortly after their next cell division (cells in late S/G2 phase) to cells that are just at the 
beginning of the cell cycle at the time of transfection (G1 phase) (Brunner, Sauer, 
Carotta et al. 2000). This suggests that transport of DNA into the nucleus is very 
inefficient so that only the disruption of the nuclear membrane allows inclusion of 
sufficient amounts of DNA for high reporter gene expression. The hypothesis is 
supported by the use of signal peptides that facilitate nuclear transport, which 
significantly enhances expression when included in the complexes (Kaneda, Iwai and 
Uchida 1989; Zanta, Belguise-Valladier and Behr 1999).
Preliminary work on LPD at The School of Pharmacy, University of London has 
determined that LPD/DNA complexes are most effective at a 5:1 +/- charge ratio, with 
a transfection efficiency of up to 20% (Shah, Sakthivel, Toth et al. 2000). The 
LPD/DNA complexes are optimised to 5:1 on the basis of the above work. This 
optimal charge ratio is applied to all the dendrimers tested in this chapter which should 
allow differences in activity between the variants to be definable.
5.2.1 Measuring luciferase reporter gene expression in cells 
transfected with LPD/DNA complexes
When mammalian cells are transfected with the reporter gene firefly luciferase, the
transgene can be easily detected and quantified using commercially available kits. The
level of transgene expression corresponds to the number of cells transfected and is a
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good reporter system for the efficiency with which the gene is transferred. It also 
provides data regarding the transfection conditions (in this case the presence of serum) 
and the effect altering these conditions has on the expression of the transgene. These 
studies are an essential part of any prospective gene therapy protocol as they provide a 
proof of principle that the LPD/DNA complexes are able to transfect cultured 
mammalian cells.
For this study the following LPD molecules were tested to give an indication as to the 
efficiency with which they can transfer the reporter gene to a transfected cell. Also by 
direct comparison, the effect of the structural modifications included in variations of 
LPD such as the addition of a short peptide that has been shown to bind to the nuclear 
import machinery of cells (nuclear localising signal -  NLS) (Zanta, Belguise-Valladier 
and Behr 1999) or a glucose molecule to take advantage of glucose uptake 
mechanisms.
Table 5.1 Table of lipidic peptide dend rimers used in transfection 
studies
la  -  8 amino groups - Lysine 3 a -  (as for la) plus glucose molecule
lb -  16 amino groups - Lysine 3b -  (as for lb) plus glucose molecule
lc -  32 amino groups - Lysine 3c -  (as for lc) plus glucose molecule
I d -  (as for la) plus NLS 2a -  8 amino groups - Ornithine
Dendrimers 2b and 2c were not used in these experiments due to their poor solubility. 
Aim
The aim of this study is to determine the levels at which the different LPD molecules 
are capable of transfecting cultured mammalian cells when complexed to a reporter 
gene. It is a useful preliminary study as it will indicate which LPD is the most 
promising for gene transfer as shown by the highest levels of reporter gene expression.
Experimental design
LPD/DNA complexes were prepared with 2.5jug of the luciferase reporter plasmid 
pGL3 Control (Promega Inc.) in Opti-MEM® (Gibco BRL) with and without 10%FBS
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at a 5:1 charge ratio. For a positive control, Lipofectamine (GibcoBRL), a 
commercially available cationic lipid transfection reagent was used. COS-7 cells were 
chosen as they are robust, easy to maintain and have been shown to be transfected by a 
number of different methods.
Cells were seeded to reach 50-70% confluence at the time of transfection. 
Approximately 2 hours before transfection the media was replaced with fresh complete 
media to stimulate growth.
For each well of a 6-well plate, the DNA was diluted in lOOpL of the appropriate 
media to a concentration of 0.025pg/pL. The dendrimer was also diluted in the same 
to an appropriate concentration to give the desired charge ratio when combined with 
the DNA. Complexes were formed by adding lOOpL of the diluted DNA to lOOpL of 
the diluted dendrimer in one fast action, followed by pipetting several times to mix. 
The complexes were then incubated for 30 minutes at room temperature. The 
LPD/DNA complexes were formed in media with and without serum before being 
added in duplicate to each well of a 6 well tissue culture plate containing the cells. 
Transfected cells were incubated for 48 hours before being lysed and the cell debris 
collected. The debris was then tested for luciferase expression using a commercially 
available kit (Luciferase Detection System, Promega Inc.) by adding a substrate, 
briefly vortexing and inserting immediately into the chamber of a luminometer 
(Wallac). The total cell protein was then measured using a commercially available kit 
(Bio-Rad Protein Assay) in a microtitre plate assay calculated against a standard curve 
of bovine serum albumin (BSA).
Results
Figure 5.1 shows the levels of luciferase activity detected COS-7 cells 48 hours after 
being transfected by various LPD molecules complexed with a luciferase reporter 
gene. The transfections were all performed in duplicate (n=2), as were the 
luminometry measurements and the mean of each reported with the standard deviation 
from the mean indicated.
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The results are interpreted as: a) a comparison in the amount of reporter gene product 
produced following transfection in the presence of serum (dark coloured bars) or 
without serum (light bars) and b) a comparison between the individual dendrimers.
Comparison with and without serum
When serum is added to the transfection media (10%FBS), the reporter gene activity is 
drastically reduced in all dendrimers tested as well as with Lipofectamine™. For 
example la  shows levels of 1.0 xlO5 RLU/mg some 8 times less than without serum.
Figure 5.1 Firefly luciferase expression in COS-7 cells following 
transfection by LPD/ DNA complexes
Luciferase activity is tested following lysis o f  the cells and combining with a 
commercially available substrate. The reaction is measured in a luminometer in terms 
o f relative light units (RLU), corrected for background luminescence and normalised 
to RLU per mg o f  total cell protein. The mean is shown with standard error bars. For 
LPD composition see table 5.1 on page 130.
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Comparison o f different dendrimers
Immediately noticeable is that in media without serum, dendrimer la  (the smallest 
unmodified dendrimer with 8 terminal amino groups) shows the highest mean level of 
luciferase activity at 7.7x105 relative light units (RLU) per mg of total cell protein. 
This is greater than the commercial preparation Lipofectamine™ which shows 
luciferase activity at 6.5 xlO5 RLU/mg. Dendrimer 2a shows third highest levels at 5.4 
xlO5 RLU/mg with the other LPD 3a and 3b showing levels at 3.3 xlO5 RLU/mg or 
lower.
The LPD with the nuclear localising signal (NLS) Id shows low levels of luciferase 
activity 1.1 xlO5 RLU/mg compared with its unmodified analogue la.
Discussion
The results of the assay are not corrected for transfection efficiency i.e. the percentage 
of cells expressing reporter gene, as this in itself can lead to systematic error if co­
transfecting with a reporter such as p-Galactosidase (Huszar, Mucsi, Terebessy et al. 
2001) and has been shown not to be effective in normalising the analysis of enzymatic 
transient gene expression assays (Hollon and Yoshimura 1989). To attempt 
consistency in the transfections and assays they were duplicated and the reagents 
pooled as far as possible with cells obtained from the same passage and stage of 
growth for comparable data series. The coefficient of variance (a measurement of the 
spread of data) was calculated for each dendrimer to determine reproducibility of the 
results and is shown in table 5.2.
The coefficient of variation was calculated as a percentage of the ratio of the standard
deviation to the sample mean i.e. 4  x  100% where s= the standard deviation and
x
x = mean of the sample.
The effect o f serum on transfection
The lower levels of expression following the addition of media containing serum to the 
complexes in vitro suggests that serum proteins reduce the levels of transgene 
expression, a property which could prove detrimental for in vivo trials. This is an 
important factor, as some non-viral approaches have proved ineffective in vivo due to
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rapid clearance or inactivation by serum components (Yang and Huang 1997; Escriou, 
Ciolina, Lacroix et al. 1998; Li, Tseng, Stolz et al. 1999).
Table 5.2 Table showing the coefficient of variance of transfection 
data (Expressed as a percentage o f  the transfections for each dendrimer (COS-7 
expression o f  luciferase).
10%FBS No FBS
la 4 la 3
lb 7 lb 17
2a 5 2a 6
2b 6 2b 19
3a n/a 3a 20
3b 11 3b 14
Lip. 14 Lip. 6
Neg. 0 Neg. 0
The serum used in this case is heat-inactivated FBS (Gibco BRL) which has the heat- 
labile fractions such as complement, vitamins and growth factors removed but it is 
apparent the serum contains factors that inhibit the transfection process. The data 
obtained from cells transfected in the presence of serum also showed a lower variation 
as compared to cells transfected without serum indicating that the process appears 
more reproducible when serum is used in the cell culture media.
Following the inadvertent use of FBS that had not been heat-treated (to inactivate heat 
labile fractions) all LDP/DNA complexes were rendered ineffective for gene transfer 
to all cells used in this study (data not shown). This is a significant development and 
brings into question the effectiveness of the complexes in vivo if  they come into direct 
contact with serum components following systemic administration. As the serum was 
not heat-inactivated it contained the heat labile fractions possibly the most significant 
being complement, a series of proteins forming part of the primary immune response 
in vertebrates and has been reported to inactivate gene/carrier complexes (Wassef,
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Matyas and Alving 1991; Plank, Mechtler, Szoka et al. 1996). The possibility of 
complement inhibiting LPD/DNA complexes is investigated in Chapter 7.
As shown previously, complexes formed in Opti-MEM® do not appear to alter their 
morphology if 10%FBS is added (see Chapter 4 page 111). The reduction in 
transfection activity can therefore be attributed to the serum effects on the process of 
gene transfer and not changes in the LPD/DNA complex prior to adding them to the 
cells.
The efficiency of gene transfer was not measured in these cases and it is assumed that 
the number of cells transfected is as previously reported i.e. a maximum of 20% for la 
with reduced efficiency reflected in the reduced levels of gene product. This is a 
limitation to the study as transfection results can be inconsistent due to variables such 
as the reagents; sources of cell line and user technique and in hindsight should have 
been investigated.
The effect o f  the modifications on LPD and their ability to transfect cells 
The effects o f the modifications to the LPD complexes were disappointing but will 
provide data that can be used in their continued development. The NLS modified 
dendrimer (Id) performed poorly, producing a 7 fold decrease in reporter gene activity. 
The need for a stero-chemical or molecular modelling input into the study is apparent 
in order to determine what modifications to the structure of the LPD would be 
functionally beneficial. It would appear attaching a functional group such as an NLS 
or receptor ligand is unpredictable, without first determining to some extent the 
availability of these functional groups to their relevant targets.
The glucose-modified dendrimers (3a, 3b) both showed reporter gene levels around 
3.2x105 RLU/mg total cell protein, around half of that seen for LPD la  which is the 
unmodified analogue of 3a. The effect of glycolipids to liposomes has been 
investigated in an in vivo environment (Wu, Robbins, Bugianesi et al. 1981), however 
the mechanism by which a single glucose molecule added to the LPD would affect the 
properties of the complex is undetermined in vitro and requires further investigation.
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The unmodified LPD complexes performed well in these initial transfection activity 
studies. In summary: for reporter gene expression levels in COS-7 cells la>2a>lb>lc.
la  and 2a posses only 8 terminal amine groups, with 2a constructed with ornithine 
instead of lysine. Ornithine has the same functional groups as Lysine with the only 
difference being one extra carbon atom in its backbone. This could have the effect of 
increasing the size of the dendrimer, while the net charge remains constant, reducing 
the charge density of the complex The dendrimers lb and lc contain 16 and 32 
terminal amine groups respectively and as a result increase in size. They are highly 
charged and the distance between LPD in the complex would increase for these 
molecules due to electrostatic repulsion. This could increase the complexes 
permeability to other molecules, reducing its transfection activity.
Studies have shown the use of an NLS enhances expression of transgenes. This 
hypothesis was tested for LPD by covalently attaching an NLS (dendrimer Id). 
It has been found to have a negative effect on transfection as seen in this study and has 
been published (Toth, Sakthivel, Wilderspin et al. 1999). Recent evidence concerning 
the mechanism of NLS facilitated nuclear entry (Zanta, Belguise-Valladier and Behr 
1999) suggested that ‘straddling’ of the nuclear envelope pores could occur if more 
than one NLS peptide is utilised on a given complex by the nuclear pore transport 
machinery. This hypothesis could be tested by using the LPD with the NLS combined 
at various ratios with its analogue without the NLS peptide. This would reduce the 
number of NLS signal peptides displayed on the complex which may decrease the 
likelihood of this straddling effect if that is the limiting factor in this case.
The need for a stero-chemical or molecular modelling input into the study is apparent 
in order to determine what modifications to the structure of the LPD could be 
functionally beneficial. It would appear attaching a functional group such as an NLS 
or receptor ligand is unpredictable without studying to some extent the availability of 
these functional moieties to their relevant targets.
The results here show that LPD are capable of delivering a functional gene to cultured 
cells with varying degrees of success. However in all cases the presence of serum 
drastically reduced the activity levels of reporter gene product. One dendrimer in
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particular (la) exceeded the reporter gene expression levels seen in the commercial 
preparation Lipofectamine™ and is a good candidate for further investigation.
5.2.2 Measuring hFIX gene expression in cells transfected with 
LPD/DNA complexes
In order to produce functional hFIX, the gene must be taken into the nucleus intact 
before being transcribed and the mRNA correctly transported and translated into the 
nascent peptide. The polypeptide must then be correctly processed in order to be 
secreted undergoing appropriate post-translational modifications, specifically for FIX -  
Vitamin K-dependent y-carboxylation of the Gla domains. COS-7 cells are derived 
from African green monkey kidney cells and would not normally be the first choice of 
cell-line to produce and secrete hFIX. However they have been used for initial hFIX 
expression experiments as the next logical progression from the previous reporter gene 
transfection experiments and are capable of fulfilling the task. Later studies in this 
thesis use human Hep G2 (hepatocellular carcinoma) cells which would be expected to 
be capable of producing clotting factors in situ as part of normal liver function.
Aim
The aim of this study is to determine if LPD/DNA complexes can deliver a hFIX gene 
which is active and produces measurable hFIX secreted into the cell culture media. In 
addition the study aimed to examine the capacity of different cell types to produce 
hFIX, three actively dividing: COS-7, Hep G2 and C2C12 myoblasts and one 
terminally differentiated and quiescent cell type: C2C12 myotubes.
Experimental design
Cells were seeded to reach 50-70% confluence at the time of transfection. 
Approximately 2 hours before transfection the media was replaced with fresh complete 
media to stimulate growth. For each well of a 6-well plate, the DNA -  the hFIX 
expression vector pCEP4hFIXint was diluted in IOOjuL of Opti-MEM® to a 
concentration of 0.025pg/pL. The dendrimer was also diluted in the same to an 
appropriate concentration to give the desired charge ratio when combined with the 
DNA.
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Complexes were formed by adding lOOpL of the diluted DNA to lOOpL of the diluted 
dendrimer in one fast action of the pipette plunger, followed by pipetting the mixture 
up and down several times to mix. The complexes were then incubated for 30 minutes 
at room temperature. The complexes were formed in media with and without serum by 
adding a then added in duplicate to each well of a 6 well plate containing COS-7 cells 
at a stage of growth of 60-70% confluency. The cells were incubated for 48 hours 
before the media was drawn off and a sample analysed for hFIX Ag levels using an 
ELISA.
Testing FIX Ag levels
For the ELISA 96 well plates (Nunc Maxisorb™) were coated with rabbit anti-human 
FIX polyclonal antibodies (Dako Ltd, UK) diluted 1:500 in coating buffer 
(100pL/well), covered with clear plastic and incubated overnight at 4°C. The plates 
were then washed 5 times with wash buffer and excess buffer removed. 0.1ml of cell 
culture media from each sample was added to the plates in duplicate along with a range 
of serial dilutions of a normal 20 pool. An abnormal control plasma (reduced FIX 
antigen), Coag Trol P (Dade, UK) was used diluted 1/100 and 1/200, a positive control 
from the normal 20 pool diluted 1/100 and 1/200 and a negative control were included: 
i.e. cell culture media sample from untransfected cells.
The plates were sealed and incubated with agitation at room temperature for 1 hour 
and washed five times with wash buffer (removing excess by inverting and tapping on 
absorbent surface). 0.1ml of rabbit anti-human FIX-horseradish peroxidase conjugated 
antibody diluted 1:1000 was added to each well, which was then sealed and incubated 
with agitation for 1 hour at room temperature. The plate was washed 5 times with 
wash buffer (removing excess) and 0.1ml of the substrate OPD added to each well.
The absorbance was measured and Factor IX Ag levels were calculated by comparison 
with the linear range of a standard curve formed using serial dilutions derived from the 
normal human plasma. The amount of hFIX was then adjusted for the total volume of 
cell culture media and total number of cells.
Testing FIX activity levels
The activated partial thromboplastin time (aPTT) study is a clinical test used to 
investigate the cause of a prolonged blood clotting in patients. It can determine if the
138
cause is a deficiency of one or more factors or an inhibitor, in this context it will be 
used to determine the activity of the hFIX produced by transfected cells as compared 
to a normal standard of pooled plasma and a commercial FIX depleted control sample. 
A review of the test can be found in Triplett et al. (Triplett 2000). In this mixing study, 
platelet-free, normal plasma that is replete with all coagulation factors (near 100% 
activity for each) is mixed with the patient sample. For example, in a 1:1 mix, one part 
patient sample is mixed with one part normal plasma and the mixture are tested. In this 
case the lowest possible concentration for any individual factor in the mixture would 
be approximately 50% (in the case of a patient with a factor concentration of zero and 
the normal pool has an activity of 100%.
The test can also be used to detect inhibitors to the coagulation process as, in the 
absence of inhibitors, this mixture will produce a normal clotting time. When 
additional of normal plasma fails to correct the clotting time into the normal range, the 
cause of the abnormal test is likely an inhibitor. The performance and interpretation of 
mixing studies is described in more detail in Chapter 3 page 89.
Human FIX activity was not tested for COS-7 or C2C12 cells and vitamin K was not 
added to the media. This also determined that the ELISA (which uses a polyclonal 
antibody) was capable of detecting hFIX protein in vitamin K absence (PIVKA). 
Human FIX activity was only tested for Hep G2 cells for the reasons outlined above.
Results
Comparison o f cell types
The following cells were tested for hFIX antigen. hFIX activity was also measured for 
Hep G2 cells by the aPPT.
Cell type: Description:
Hep G2 Human hepatocellular carcinoma
C2C12 Mouse C3H muscle myoblast
African green monkey kidney, transformed
COS-7
with SV40
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COS-7 cells are commonly used for transfection experiments to test a new technology 
such as LPD. Hep G2 and C2C12 cells (dividing myoblasts and terminally 
differentiated myotubes) were used to a) investigate differences between tissues and b) 
the effects of different stages of cell division (C2C12 only) on transfection with 
LPD/DNA complexes and hFIX expression. The amount of hFIX detected is 
expressed as ngFIX/106 cells/24hours, that is to say, the mean was calculated (along 
with the standard deviation from the mean - shown in figures as error bars) from the 
duplicate samples tested. The levels measured were then standardised to reflect the 
amount produced for a sample of 106 cells over a 24 hour period.
hFIX expression COS-7 cells
The results can again be interpreted as a) a comparison in the amount of hFIX 
produced following transfection in the presence of serum (dark coloured bars) or 
without serum (light bars) and b) a comparison between the individual dendrimers.
Figure 5.2 shows the levels of hFIX Ag detected in the media of COS-7 cells 48 hours 
following transfection.
Figure 5.2 hFIX expression in COS-7 cells following transfection
Various LPD/DNA complexes were used in the presence and absence o f  serum. 
hFIX antigen (Ag) in the cell culture media was measured 48 hours following 
transfection (n=2). For a table o f  dendrimers used see Table 5.1 on page 130.
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LPD la  shows the highest levels of hFIX Ag at 42ng in the absence of serum, 2a and 
lipofectamine show levels of 36ng and 35ng respectively. These levels drop 
dramatically when serum is added to the transfection media, with la  falling to 18ng, 2a 
to 14ng but Lipofectamine™ appears to have retained some of the activity seen in the 
absence of serum at 24ng.
The remaining dendrimers show levels between lOng and 22ng without serum with a 
drop of approximately half when serum is added, except for 3a where FIX Ag is 
detected at background levels.
hFIX Ag expression and activity in Hep G2 cells
Some dendrimer variations were not used for this study as they did not perform well in 
initial transfection experiments. LPD variations used were those containing only 8 
terminal amine groups and selected to produce a range of transfection activity i.e. 
la>2a>3a.
la  -  8 amino groups - Lysine 
2a -  8 amino groups - Ornithine 
3a -  (as for la) plus glucose molecule
hFIX Ag levels in cell culture media following transfection
Figure 5.3 shows the levels of hFIX Ag measured in cell culture media following 
transfection with LPD/DNA complexes with Lipofectamine™ as a control.
The transfections were all performed in duplicate (n=2), as were the hFIX assay 
measurements and the mean of each reported with the standard deviation from the 
mean indicated.
LPD la  shows the highest levels of hFIX Ag at 38ng in the absence of serum, 2a and 
lipofectamine show levels of 25ng and 20ng respectively with 3a at 20ng. It is 
interesting to note that 3a now shows detectable levels of FIX in Hep G2 cells, 
whereas in COS-7 cells only background levels were detected (see Figure 5.2 page 
140). These levels drop for all dendrimers when serum is added to the transfection 
media, with la  and 2a falling to 15ng, 3a to 9ng and Lipofectamine™, falling to 12ng. 
No hFIX was detectable in the culture media prior to the transfection.
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Figure 5.3 Measuring the levels of hFIX Ag in the cell culture media 
of HepG2 cells following transfection
The results show the levels o f  hFIX Ag detected in the media o f  transfected HepG2 
cells after 48 hours (n=3). It was measured using an ELISA developed and routinely 
used to measure patient circulating FIX Ag levels. A pool o f  20 samples from  
individuals with a normal clotting profile is used in serial dilutions to produce a 
standard curve.
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hFIX activity in cell culture media following transfection
The activity of hFIX secreted into the cell culture media was investigated using the 
aPPT assay. Results for hFIX activity are presented as IU/dL, (human plasma normal 
range being 50-150 IU/dL). Table 5.3 shows hFIX activity levels in media samples for 
the dendrimers tested along with the controls used in assay. Trol P (Dade, UK) is a 
commercially available FIX-depleted plasma and Normal indicates the pooled samples 
of plasma from 20 individuals with no abnormal clotting history and acts as a positive 
control.
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Table 5.3 Results of aPTT assay
Cell culture media samples taken 48 hours following transfection o f  HepG2 cells with 
the dendrimers indicated. The results seen are those taken from cells transfected in 
the presence o f  serum. The normal range is 50-150IU/dL and determined by a 
standard curve (see Chapter 3 page 89).
aPTT for dilutions (seconds)
Sample 1/5 1/10 1/20 1/40 IU/dL
la 59.2 64.8 73.8 - 30
2a 73.3 78.9 84.8 - 8.0
3a 84.2 93.0 - - 3.0
TrolP 85.4 84.9 88.7 - 4.0
Blank - 98.8 102.1 - <1
Normal - 56.4 55.1 66.1
Normal - 55.1 61.3 58.5
A level of 30 IU/dL is seen in the media of cells transfected with dendrimer la with 
very low levels of activity seen in the dendrimers 2a and 3 a. These levels of activity 
correspond to the levels of antigen seen in Figure 5.3. Although the level is a 
relatively low production, it shows that a functional hFIX gene can be delivered in 
vitro by LPD/DNA complexes and is expressed to produce FIX protein capable of 
normal protease function.
hFIX expression in C2C12 cells
Figure 5.4 shows the expression of hFIX Ag in C2C12 muscle cells at both the 
exponential growth phase and terminally differentiated. 10% horse serum (Gibco 
BRL) was included with fresh cell culture media when the myoblasts reached 
confluency in order to promote the formation of myotubes. The dividing myoblasts 
and quiescent myotubes were transfected with dendrimers la, 2a and 3a.
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hFEX Ag was measured using an ELISA developed and routinely used to measure 
patient circulating FIX Ag levels. A pool of 20 samples from individuals with a 
normal clotting profile was used in serial dilutions to produce a standard curve.
Figure 5.4 Expression of hFIX in dividing C2C12 myoblasts and 
terminally differentiated myotubes
The results show the levels o f hFIX Ag detected in the media o f  transfected C2C12 
myoblasts and myotubes in the presence o f serum (10% FBS) after 48 hours (n=3).
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Similar levels of expression were detected for muscle myoblasts (C2C12) between the 
dendrimers, however terminally differentiated myotubes were refractory to transfection 
with LPD/DNA complexes. Levels of hFIX Ag were lower than observed in COS-7 
cells and Hep G2 cells.
Summary of transfection results
The sensitivity of the ELISA assay used is determined by the standard curve generated 
by serial dilutions of pooled normal plasma. These dilutions were included on each 
plate of samples and were calculated for each plate read. From this, the lower limit for
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the assay above which results can be determined as reliable was measured at 6.25 
U/dL.
Figure 5.5 shows the levels of FIX Ag detected in the cell culture media 48 hours 
following transfection in the presence of 10%FBS. The results are presented as a 
comparison of the cell types showing for levels of expression la>2a>2b>lb>3a>3b.
This comparison between cell types shows that for hFIX expression levels 
COS-7>HepG2>C2C12, however there is one exception in that 2a (8 amino terminals 
-  ornithine) showed similar levels in HepG2 cells to those seen in COS-7 cells, albeit 
with a larger standard deviation of data from the mean. This indication that the sample 
data has a wider distribution could be the reason why the results for 2a follow the 
pattern shown above.
LPD 3a (8 amino terminals - showed only background levels of hFIX Ag in COS-7 
cells expressed detectable levels in Hep G2 and C2C12 cells.
Figure 5.5 Comparison of hFIX expression by cell type with 10% 
FBS added to the transfection media.
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The coefficient of variance was calculated for each dendrimer to determine 
reproducibility of the results and is shown in table 5.4.
The variance of the samples is greatest for the Hep G2 cells rising to a maximum of 
24% for dendrimer 3a. As the range of data is at the low end of the tests sensitivity (7- 
1 Ing/mL) any variation between samples will be reflected as a significant increase in 
the variance coefficient as compared to higher values seen in COS-7 cells.
Table 5.4 The coefficient of variance of transfection data using 10% 
FBS in the transfection media.
Expressed as a percentage for each cell type used, the dendrimers are shown with 
Lipofectamine™ with the coefficient o f  variance shown in the adjacent column.
Hep G2 C2C12
n/a
Lip. Lip.
Figure 5.6 shows the levels of FIX Ag detected in the cell culture media of HepG2 and 
COS-7 cells, 48 hours following transfection without serum. The results are presented 
as a comparison of the different dendrimers for levels of hFIX Ag detected in the 
media following transfection without serum and can be summarised as 
1 a>2a>2b> 1 b>3a>3b for both COS-7 cells and Hep G2 cells. This finding is
consistent with the data obtained when serum was added to the transfection media. 
However, the amount of FIX Ag seen expressed by C2 C12 cells are at a relatively low 
and uniform level for dendrimers la, 2a and 3a.
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Figure 5.6 Comparison of hFIX expression by cell type without 
serum added to the transfection media
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The comparison between cell types shows that for hFIX antigen levels in media 48 
hours following transfection COS-7>HepG2>C2C12.
The coefficient of variance was calculated for each dendrimer to determine 
reproducibility of the results and is shown in table 5.4. Calculations were performed 
as for table 5.4
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Table 5.5 The coefficient of variance of transfection without serum 
added
The coefficient is expressed as a percentage for each cell type used.
COS-7 Hep G2
la 3 la 5
lb 17 lb -
2a 6 2a 12
2b 19 2b -
3a 20 3a 30
3b 14 3b -
Lip. 6 Lip. 4
The variance of the samples is greatest for dendrimer 3a in both cell types tested. The 
range of data is at the low end of the tests sensitivity (13-24ng/mL) so variation 
between samples will be reflected as a significant increase in the variance coefficient.
Discussion
In the comparison between cell types, the results show that for hFIX antigen levels in 
media 48 hours following transfection COS-7>Hep G2>C2C12. This is likely due to 
the individual characteristics of the cell-type and the efficiency by which they perform 
the necessary processes involved namely: take up the complexes, transport them to the 
nucleus, express the gene and process the gene product correctly.
The fact that myotubes do not appear to express the transgene indicates that the 
LPD/DNA complexes require cells to be actively dividing in order to transfect them. 
The mechanism behind this deficiency involves the disruption of the nuclear 
membrane during mitosis. This destabilisation allows the complexes to enter the 
nucleus and deliver the transgene. As myotubes are not dividing, the nuclear 
membrane remains intact and could inhibit migration of the complexes into the nucleus
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The effect or serum on transfection has been discussed previously in this chapter (see 
page 133). It appears to have an attenuating effect on the levels of expression, with the 
most obvious effect on COS-7 cells which showed the highest levels of transgene 
expression without serum. The relative reduction in expression when serum is added 
to the media is approximately 50% for each cell type tested. This indicates that the 
serum has a similar effect on the transfection process for Hep G2 and COS-7 cell types 
and that the activity of the complexes is being affected by the serum. The distinction 
between plasma and serum on the activity of LPD/DNA complexes must be 
considered. The absence in serum of coagulation factors and other associated 
molecules that are depleted following clot formation may be significant for in vivo 
studies. Also the component cells of blood may affect their activity.
Reproducibility between transfection results could be improved by using a higher 
number of duplicates i.e. n=4 or n=6 in smaller tissue culture plates containing more 
wells.
The results show that LPD/DNA complexes are able to deliver a gene to cultured 
mammalian cells which is expressed and produces a detectable, functional protein. 
The LPD variant that has shown the highest levels of transgene expression is la  (8 
amino terminals, lysine, unmodified) and was true for all cell types tested. Although 
serum reduced the detected levels of gene product by 50% it did not inhibit gene 
transfer using LPD/DNA complexes.
These results are very promising for the development of LPD as potential gene 
delivery agents for the treatment of haemophilia B and provide useful data with which 
to progress to the next stage of developing a gene therapy protocol.
5.23 Investigating the effect of chloroquine on the transfection 
activity of LPD
As suggested in Chapter 4, following uptake by the cell, LPD/DNA complexes
facilitate escape from the endosome by interactions with the membrane in contrast to
other dendrimers that burst the endosome by acting as a proton sponge (see Chapter 4,
page 120). Chloroquine (a lysomotropic agent) is well documented as providing
149
assistance towards escape from the endosomal compartment and into the cytoplasm. 
Chloroquine is a weak base that is able to diffuse into areas of low pH whereupon it 
buffers the drop in pH by taking up protons. This property can be applied to disrupt 
the normal endosomal pathway that applies to most substances (including gene/carrier 
complexes) taken up by cells. If chloroquine is included at the time of transfection in 
the cell culture media, it is taken up into an endosome along with the gene complex. 
As the endosome matures and starts to decrease the pH of the compartment by actively 
introducing protons (Hydrogen ions), the chloroquine acts as a ‘proton-sponge’ 
effectively neutralising the effect of the proton pump. This in turn causes rupture of 
the endosomal membrane resulting in a loss of contents into the cytoplasm. As this 
occurs prior to lysosome formation, the contents (i.e. LPD/DNA complexes) can be 
preserved and become available to enter the nucleus from the cytoplasm. The use of 
chloroquine as an adjunct is examined in this study to determine any effect it may have 
on enhancing the activity of LPD/DNA complexes as gene carriers.
Aim
This investigation was carried out in order to determine whether the migration from the 
endosomal compartment into the cytosol (and ultimately the nucleus) was a limiting 
factor for LPD/DNA complexes. Chloroquine can enhance expression by facilitating 
endosome escape, increasing the availability of DNA to be transported to the nucleus. 
However if this is not a limiting factor of the DNA/carrier complexes used, it can 
appear to reduce expression due to its cytotoxicity causing increased cell mortality.
Experimental design
Preparation of the cultured cells followed standard techniques (see Chapter 3 page 84), 
However, the cell culture media was supplemented with chloroquine immediately prior 
to the addition of the LPD/DNA complexes. Following sampling of the cell culture 
media for hFIX content, total cell protein was measured in order to give an indication 
as to the cytotoxicity of the chloroquine. A concentration of 50mM chloroquine 
(Haensler and Szoka 1993) was used during the transfection of Hep G2 cells with 
lipidic amino acid dendrimer la  complexed to a human FIX gene construct.
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Results
Figure 5.7 shows that the addition of chloroquine to the transfection media does not 
enhance transgene expression. The decrease in expression of hFIX is likely to be due 
to the toxicity of the chloroquine causing increased cell death.
Figure 5.7 The effect of chloroquine on transgene expression when 
used in the cell culture media during transfection of Hep G2 cells.
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The total cell protein recovered at time of assay was approximately 25% less in cells 
with chloroqine added (+Ch) as compared to no chloroquine.
Discussion
The failure of chloroquine to enhance the expression of the transgene by means of
facilitating endosome escape, indicates endosome escape is not a limiting factor of
LPD mediated transcription. The reduction of total cell protein accounted for
following removal of media for hFIX assay is expected due to the cytotoxicity of the
chloroquine. This also supports the hypothesis that LPD/DNA complexes facilitate
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their own escape from the endosome by means outlined previously (see Chapter 4 page 
120).
5.2.3 Investigating the regulation of expression of hFIX by different 
promoter/enhancers
The most widely used regulatory sequences are derived from viral genomes, with the 
cytomegalovirus (CMV) proving the most popular in early pre-clinical studies 
(Nishikawa, Yamauchi, Morimoto et al. 2000) (Walter, You, Hagstrom et al. 1996) 
(Kay 2000). However the need for more specialised regulatory sequences seems to 
arise towards the late pre-clinical/clinical trial stage usually derived from eukaryotic 
species (Hagstrom, Couto, Scallan et al. 2000) (Wilson, Grossman, Wu et al. 1992) 
(111, Yang, Bidlingmaier et al. 1997).
The concern is raised for using CMV regulatory sequences for gene expression in the 
murine liver, as transcriptional silencing occurs after several weeks. (Nakai, Herzog, 
Hagstrom et al. 1998) (Loser, Jennings, Strauss et al. 1998). Although this regulatory 
sequence is compatible with these preliminary studies, the need for a more suitable 
regulatory element at a later stage is addressed with the replacement of the CMV 
derived sequences with a mammalian liver specific promoter/enhancer.
Aim
The aim of this study was to create an alternative hFIX expression vector which is 
driven by a strong tissue specific promoter/enhancer and test it efficiency by 
measuring the levels of hFIX Ag secreted by transfected cells.
Experimental design
This aspect of the study was possible due to the kind gift of the FIX construct 
pCEP4hFIXint regulated by the human Cytomegalovirus (CMV) immediate-early 
promoter/enhancer (Walter, You, Hagstrom et al. 1996) (see figure 5.8). These 
sequences have been widely reported as being extremely strong directors of expression 
in vitro since their characterisation (Boshart, Weber, Jahn et al. 1985).
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Figure 5.8 Map of pCEP4FIXint plasmid vector
Components and significant restriction sites are shown.
Bam HI
SV40pA
OriP
hFIXint
KpnBBNA-1
P CMV
BglTKpolyA
Amp/Col E
PTK HygB res.
Legend:
SV40pA: SV40 polyadenylation sequence.
hFIXint: human factor EX cDNA plus intron 1 sequences.
TkpolyA: thymidine kinase polyadenylation sequence.
HygB res:. Hygromycin B resistance gene.
PTK: Thymidine kinase promoter.
EBNA-1: Epstein-Barr virus nuclear antigen-1
Ori P: Bacterial replication gene.
This large vector (approx. 13.5kb) is derived from the commercial vector pCEP4 
(Invitrogen, UK) with the hFIX cDNA that includes a proportion of intron I inserted 
into the Bam HI -Kpn I site. The vector also contains various other standard features
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designed to enhance transfection by means of nuclear retention (EBNA-1: Epstein- 
Barr virus nuclear localisation antigen) in transformed cell lines, or to facilitate 
resistance to selective media when expanding transfected cells.
The CMV promoter was replaced with a liver-specific promoter/enhancer (LSP) (111, 
Yang, Bidlingmaier et al. 1997) (Wang, Takabe, Bidlingmaier et al. 1999) with the 
view to produce maximal expression in the organ.
The promoter/enhancer fragment was removed from the plasmid vector (a generous 
gift from C. R. Ill, The Immune Response Corporation CA, USA - see figure 5.9). It 
utilises the human thyroid binding globulin promoter which has been shown to act 
strongly in directing expression in a liver specific context (Hayashi, Mori, Janssen et 
al. 1993). The promoter/enhancer fragment was removed from the plasmid vector (a 
generous gift from C. R. Ill, The Immune Response Corporation CA, USA - see figure 
5.9). It utilises the human thyroid binding globulin promoter which has been shown to 
act strongly in directing expression in a liver specific context (Hayashi, Mori, Janssen 
etal. 1993).
The Liver specific promoter/enhancer sequences were amplified from the plasmid 
vector pDJC(R/S)dF5 using the primers LSP-LHP2 and LSP-RHP (see below).
LSP-LHP2 GC AGAG ATCTGGT ATCG AT AAGCTTG
LSP-RHP GGCTGGTACCGTTTCGTTCTTGTTATCC
These primers were designed with restriction sites for Bgl II and Kpn I respectively, 4 
bases from of the 5’ ends to enable effective restriction enzyme binding. The primers 
amplify a lkb fragment containing the full complement of the promoter/enhancer 
sequences contained in the pDJC vector. When this fragment is then inserted into the 
accommodating sites of the pCEP4 vector, upstream to the hFIX gene it would directly 
replace the CMV thus conserving the Kozak sequences (Kozak 1986), transcription 
initiation sites and the 5’ untranslated region (5’UTR) of the FIX cDNA.
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Figure 5.9 Map of pDJC (R/S) dF5 plasmid vector
Components and significant restriction sites are shown (III, Yang, Bidlingmaier et al. 
1997).
Xnia I
E coli
ABP: a 1 -microglobulin/bikunin enhancer
hTBG: human thyroid-binding globulin promoter
BDD FV m : FVIII cDNA (p-domain deleted)
rBg I VS: rabbit p-globin intron 1
Table 5.6 summarises the individual steps involved in the subcloning procedure. Each 
process was confirmed using gel electrophoresis and sequencing where possible.
liTBG Piom otei
pDJClRSHlFS
AmpR
Xma I
BDD FVIII cDNA 
II
Kpnl I
ABP eiihoncei 1x2)
iByIVS
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Table 5.6 Outline of the processes involved in the sub cloning 
procedure
Process Rationale
Amplify a lkb fragment within 
pDJC with LSP-LHP2 and 
LSP-RHP.
Liberates fragment containing the desired 
promoter/enhancer sequences (prior to the rBg 
IVS) and creates Bgl II and Kpn I restriction sites.
Digest fragment with Bgl II 
and Kpn I.
Modifies ends of fragment to be compatible with 
PCEP4 plasmid.
Digest pCEP4 fragment with 
Kpn I and Bgl II.
Liberates the CMV promoter region, creating 
linear vector containing hFIX and backbone with 
compatible ends.
Ligate lkb LSP fragment with 
pCEP4 vector.
Creates circular expression vector containing 
hFIX cDNA and LSP promoter sequences.
The fragments were then purified using a commercial kit before being used in the next 
manipulation. Figure 5.10 shows the digestion confirming the successful insertion of 
the LPS sequences.
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Figure 5.10 Digestion of LSP pCEP4FIXint ligations with Bam HI.
Plasmid preparations extracted from 11 transformants are shown. Plasmids 
incorporating the fragment bearing the Liver-specific promoter will produce 2 bands 
o f 3.8 and 9.6 kb when digested with Bam HI. Lanes 4 and 6 show plasmid 
concatamers. The original pCEP4FIX vector (CMV promoter) is shown in lane 12 as 
a negative control. Hyperladder I  (Bioline, UK) is used as a weight marker in lanes 1 
and 14.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
3kb
lkb
Results
Figure 5.11 shows the levels of hFIX Ag following transfection of Hep G2 cells (n=3) 
with LPD (in Optimem +10% FBS) complexed with hFIX expression vectors driven 
by either the CMV promoter or a liver specific promoter/enhancer. The vector shows a 
decrease in the amounts of detected hFIX Ag when the LSP is used as compared to the 
CMV promoter in both of the LPD/DNA complexes tested (la  and 2a).
Ii
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Figure 5.11 Comparing the levels of expression of hFIX Ag in HepG2 
cells
Measured following transfection with LPD/DNA complexes with a CMV promoter and 
a liver specific gene promoter (LSP).
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Discussion
The original study that used the liver specific promoter/enhancer elements utilised in 
this investigation controlled a FVIII expression vector and reported a 2.3 fold increase 
in expression when using the CMV promoter as compared to the human thyroid- 
binding globulin promoter (TBG) alone (111, Yang, Bidlingmaier et al. 1997).
The promoter/enhancer fragment was inserted into the hFIX vector in a precise 
position which conserved the upstream regulatory sequences (Kozak 1986) and the 
transcription initiation site. This was done to increase the efficiency with which the 
gene was transcribed by offering an optimised leader sequences.
The LSP regulatory sequences also contain 2 al-microglobulin/bikunin enhancer 
motifs which contains a cluster of hepatic nuclear factor elements, common to many 
liver-specific genes. When multimerised, this enhancer, like many others, shows
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incremental activity and functions in either orientation in the gene (Rouet, Raguenez, 
Tronche et al. 1992).
When the ancillary enhancer sequences were included i.e. 2 al-microglobulin/bikunin 
(ABP) enhancer motifs, and the rabbit p-globin intron 1 (rBg IVS), the expression 
levels increased to 2.1 fold from that seen in the TBG promoter alone. If the 
difference is expressed as a ratio of LSP/CMV, it is 0.91. The detected hFIX Ag 
reported in this study when the two regulatory sequences are compared, produce a ratio 
of 0.75 for la  and 0.77 for 2a. The rabbit P-globin intron 1 was not included in the 
regulatory sequences removed from the donor plasmid pDJC(R/S)dF5. As the 
recipient plasmid pCEP4hFIXint already contained an optimised portion of hFIX 
intron 1 (Kurachi, Hitomi, Furukawa et al. 1995; Walter, You, Hagstrom et al. 1996) 
additional sequences could disrupt the message processing. It is possible that the 
preserved hFIX intron 1 sequences are less efficient at processing the FIX mRNA than 
the rBg IVS is with FVIII mRNA, when used in conjunction with the LSP elements. 
Further study would be advantageous to test this hypothesis by including the rBg IVS 
in the hFIX construct and investigating the effect on gene expression.
5.2.4 Investigating the incorporation of a liver specific targeting 
colipid into LPD/DNA complexes and its effect on gene transfer.
As outlined earlier in this chapter, this study used the addition of galactocerebrosides 
(Gc) to facilitate targeting to the asialoglycoprotein (ASGP) receptor expressed solely 
by liver cells (see page 126). Galactocerebrosides are naturally occurring lipids found 
in the membrane of cells forming the mammalian central nervous system and can be 
used to target the asialoglycoprotein (ASGP) receptor found exclusively in liver cells. 
Studies have shown the use of these particular co-lipids increase transgene expression 
through increase uptake of the gene/carrier complexes (Bandyopadhyay, Kren, Ma et 
al. 1998).
Aim
The purpose of this study is to investigate the use of a targeting co-lipid to facilitate 
uptake of the LPD/DNA complexes by a specific cell type to improve the uptake of the
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complexes by the cell and determine if the complexes can be modified to target a 
specific cell type.
Experimental design
The Gc lipids were aliquoted into borosilicate glass tubes and dried under a stream of 
nitrogen. The lipids were then hydrated in 500pL 0.15M NaCl with moderate 
vortexing and warming at 37°C until the entire lipid had dispersed. The suspension 
was sonicated (low power) for 5 minutes on ice. LPD dissolved in dH20 were 
combined at the appropriate molar ratio and the solution, warmed and dried under 
nitrogen. Hydration with the appropriate medium was carried out on ice with high­
speed vortex mixing until a homogeneous suspension was obtained. The suspension 
was again sonicated (low-power) for 5 minutes on ice before complex formation with 
DNA. Transfections were performed in duplicate with Opti-MEM® and the CMV 
driven hFIX gene construct as outlined previously.
Results
As shown in figure 5.12, the inclusion of a Gc co-lipid significantly increased the 
levels of hFIXAg expressed in transfected Hep G2 cells (mean = 34.4 ng/hFIX Ag/106 
cells/24 hours with Gc and 15 ng/hFIX Ag/106 cells/24 hours without Gc, n=3) as 
compared with COS-7 cells. This is likely due to the increased uptake of the 
complexes by the Hep G2 cells which uniquely express the receptor for the ligand 
contained in the complexes.
No significant increase in hFIX Ag production is observed when Gc targeting co-lipids 
are added to the LPD la  and used to transfect COS-7 cells. This contrasts to the 
HepG2 cells, which show over a 2 fold increase in the levels of hFIX produced.
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Figure 5.12 Comparing the effect the addition of galactocerebrocide 
targeting lipids (Gc) on the levels of expression in COS-7 cells.
The hFIX vector driven by the CMV promoter was used was used in these studies to 
determine i f  the Gc were acting in a cell specific manner and facilitating uptake in 
liver cells. These transfections were performed in the presence o f  serum.
1a C0S7 1a/Gc C0S7
Discussion
The ASGP receptor is expressed solely in liver cells and recognises molecules that 
contain terminal galactose moieties for receptor-mediated endocytosis. The 
galactocerebroside when used as a co-lipid appear to enhance the effectiveness of 
LDP/DNA complexes to target liver cells as shown in the increase in expression seen 
only in the Hep G2 cells expressing the receptor. The terminal galactose moiety, 
which acts as the ligand for the asialoglycoprotein (ASGP) receptor, is a small 
molecule when compared to the poly-lysine dendrimer head group of the LPD. Most 
other cationic lipids used with co-lipids also contain small cationic head-groups but in 
this case stearic hindrance doesn’t appear to affect the galactose availability to the 
receptor. Were the larger LPD variations tested such as 2a or 3a this may become an 
issue with a possible way to overcome this is to covalently link the galactose to the 
LPD in a way that it is presented to the receptor on the outer side of the complexes, 
again a look towards molecular modelling would benefit this area of study.
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A significant increase is seen with the addition of the galactocerebroside co-lipid along 
with the CMV promoter to la  compared to the same conditions with 1.
This particular study would benefit from the additional assay of adding a direct 
competitor to the asialoglycoprotein receptor such as asialoorosomucoid with the 
LPD/DNA complexes which would then provide supporting evidence that the increase 
in expression of FIX Ag by the liver cells is due to uptake by this receptor and not by 
another mechanism.
5.3 Summary of results
The LPD/DNA complex la  shows an improvement on Lipofectamine™ for expression 
of both the luciferase reporter gene and the hFIX gene in COS-7 cels and Hep G2 cells.
The different LPD variations show different levels of gene expression when compared 
in the same cell type and conditions. Generally la>2a>2b>lb>3a>3b.
Levels of expression are greater in the absence of serum as seen in most if not all 
synthetic gene delivery systems.
LPD/DNA complexes can transfect other cell types such as C2C12 myoblasts that are 
actively dividing but cannot transfect terminally differentiated myotubes.
Chloroquine does not increase the expression of the transgene for LPD/DNA 
complexes as seen in some non-viral vectors. This indicates that endosome escape is 
not a limiting factor in the mechanism by which LPD/DNA complexes deliver the 
transgene to the cell nucleus
The addition of a cell-specific targeting co-lipid improved the levels of transgene 
expression in the target cell type that was not seen in a cell type which does not 
express the targeted receptor. The studies used here to improve the efficiency of 
LPD/DNA complexes in vitro offer versatility as the modifications can be applied or 
omitted for a particular protocol and may prove beneficial for in vivo studies.
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Chapter 6 
In vivo Gene Delivery
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6.1 Introduction
In vivo gene transfer studies utilise the “whole body” system of selected animals as a 
prelude to clinical trials. These pre-clinical studies are essential in order to obtain 
information regarding the pharmcokinetics of any given substance when administered. 
Also provided is further proof of principle since evidence of in vitro gene transfer does 
not automatically lead to in vivo success.
A major consideration in the development of in vivo gene transfer is the route of 
administration, i.e. the question of systemic or local application of the therapy. Each 
method has particular features which contribute towards determining the behaviour of 
a gene/carrier complex as it enters the body through to its ejection or metabolism. 
These factors include stability in serum and interaction with the blood components in 
the case of systemic administration or, for local administration, distribution concerns 
that could include leakage to other sites causing an adverse reaction. These factors 
contribute significantly to the determination of both the immediate and long-term fate 
of a gene therapy protocol.
Administration o f gene therapy
Although theoretically any tissue or organ could be utilised in the administration of a 
gene/carrier complex, certain routes are clearly advantageous in the treatment of 
specific conditions, e.g. direct transfer into solid tumours (Makinen, Loimas, Kosma 
et al. 2000) or aerosol into the lung for CFTR gene transfer (Alton, Stem, Farley et al 
1999) are classic examples where the gene is physically introduced directly to the site 
of interest. For conditions in which the target of the therapy is less well defined or a 
choice or targets is available, a program of study to determine the most suitable 
method and route of administration is essential to obtain the best possible performance.
Although Factor IX is primarily synthesised in the liver, a number of other tissues are 
capable of carrying out the necessary post-translational modifications to the protein to 
ensure correct function, such as the gut epithelia (Lozier, Yankaskas, Ramsey et al. 
1997) and skeletal muscle (Herzog, Hagstrom, Kung et al. 1997). It is also interesting 
to note that functional Factor VIII has reportedly been expressed in the epidermis of 
mice following a skin graft (Fakharzadeh, Zhang, Sarkar et al. 2000).
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Skeletal muscle is now being directly injected with AAV particles containing the FIX 
gene in clinical trials, with results indicating a reduction in the use of self-administered 
recombinant FIX in patients following treatment (Kay 2000). Skeletal muscle is not a 
tissue one would expect to be initially considered as the target for gene therapy to 
replace a blood coagulation factor. However, when taking into consideration all the 
alternatives currently available, multiple intra-muscular injections would appear a 
more desirable procedure than cannulation of the hepatic portal vein for directed 
delivery to the liver followed by patial hepatectomy (Wilson, Grossman, Cabrera et al 
1992). As the disease to be treated is a bleeding diathesis, the least invasive means of 
administering the therapy is a very important factor in deciding a strategy for its 
treatment. Although not overlooking the potential of ex vivo treatment by autologous 
grafts following gene transfer to excised tissue, this work has focused on direct 
systemic administration.
Vectors for in vivo delivery
The successful performance of a gene transfer system in vitro, success in vivo does not 
necessarily follow. Careful consideration has to be given to the vector, in particular 
the regulatory sequences, to ensure the most effective expression is obtained. An 
optimised vector also allows a reduction in the dose of the gene/vehicle complex 
administered an important factor in the case of synthetic carriers, but an essential one 
for the safe administration of viral vectors.
6.2 Investigating the tissue distribution of LPD complexed 
with DNA following administration into mice
Bioavailability
The bioavailability of an administered drug is usually defined as a fraction of the 
active drug that reaches the systemic circulation whatever route of administration was 
applied. This is a generalised principle for systemic drug delivery and as such it is a 
useful term to use when discussing the effective levels of drug available to the target 
tissues. Gene delivery is a process more akin to carrier mediated drug delivery and 
therefore a more complex issue to determine bioavailability since so many more 
processes are involved beyond merely entering the circulation.
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To be effective, intracellular delivery of DNA/carrier complexes is required followed 
by the transport of the DNA to the nucleus when only then is the DNA considered 
bioavailable. There are several methods of administration such as aerosolisation for 
delivery to the lungs, per-oral delivery to the digestive tract and localised application 
to areas such as the skin.
Liposomes with a specific affinity for an affected organ or tissue are believed to 
increase the efficacy of liposomal agents. Immunoglobulins, primarily of the IgG 
class, and their fragments are widely used as targeting moieties for various drugs and 
drug carriers, including liposomes. However, pharmacokinetic properties of 
immunoliposomes in many cases are still far from desirable. Despite evident success in 
the development of an antibody-to-liposome coupling technique and improvements in 
the targeting efficacy, the majority of immunoliposomes still ended up in the liver, 
which was usually a consequence of insufficient time for the interaction between the 
target and the targeted liposome (Wang and Huang 1987). This is especially true in 
cases when a target of choice has diminished blood supply (ischemic or necrotic 
areas), and only a small number of liposomes pass through the target with the blood 
during the time period when liposomes are present in the circulation. The same lack of 
targeting occurs if the concentration of the target antigen is very low so that the 
number of productive collisions between target antigens and immunoliposomes is 
insufficient. In both cases, much better accumulation can be achieved if liposomes can 
stay in the circulation long enough. This will increase the total quantity of 
immunoliposomes passing through the target, and the number of collisions between 
immunoliposomes and target antigen.
Anatomical and physiological considerations
The capillary endothelium comprises a dynamic interface adapted for the exchange of 
endogenous and exogenous substances between the blood and the interstitial fluids. 
The basic structural features of capillaries are diverse among organs there are three 
main types of blood capillaries: continuous fenestrated, and discontinuous. The 
continuous capillaries are the most widely distributed in mammalian tissue and are 
found in skeletal, cardiac, and smooth muscles, as well as in the lungs, subcutaneous 
tissues, and serous and mucous membranes. The transport pathway is important in
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macromolecule exchange and in these capillaries includes pinocytotic vesicles, 
intercellular junctions, and transendothelial channels. Physiological estimates of 
transport pathways for macromolecules have revealed small pores with radii of 6.7-8.0 
nm and large pores (20-28 nm). As serum albumin, with an effective diameter of 7.2 
nm (molecular weight 67 OOODa), can barely pass through the pores, the substantial 
transport of macromolecules across the continuous capillaries is negligible. The brain 
capillaries utilise this property as a blood-brain barrier for highly restricted 
macromolecular transport
Fenestrated capillaries are generally found in the intestinal mucosa, the endocrine and 
exocrine glands, as well as the glomerular and peritubular capillaries of the kidney. 
Macromolecules can move across the endothelial barrier in the same fashion as 
described for continuous capillaries. In addition, macromolecules can also move 
through the fenestrae, the circular openings with radii of 20-30 nm. In glomerular 
capillaries, macromolecules can cross the fenestrated capillaries more easily, however, 
the continuous basement membranes function primarily as a size and charge selective 
barrier for glomerular filtration of macromolecules. The shape and flexibility of 
macromolecules are also important factors (Taylor and Granger 1983).
The distribution of the discontinuous type of capillary wall is more limited than that of 
the other types; they are found only in the liver, the spleen, and bone marrow and are 
characterized by intercellular junctions with diameters ranging between 100 and 1000 
nm as well as an absence of a basement membrane. In these capillaries, the openings 
are extremely large and do not restrict the passage of macromolecules between plasma 
and the interstitium. In addition to these features that exist under normal conditions, 
capillary permeability to macromolecules is enhanced in pathophysiological states 
such as cancer and inflammation. Capillary vessels in a human tumour inoculated into 
SCID mice are permeable even to liposomes of up to 100-400 nm in (Yuan, Dellian, 
Fukumura et al. 1995).
The typical molecular weight of plasmid DNA is more than 1000 kDa and its size is 
relatively very large (>100 nm) (Ledley 1996). Although the size of plasmid DNA and 
DNA/carrier complexes depends greatly on its structure, the extravasation of both
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naked and complexed DNA via both continuous and fenestrated capillaries should be 
very low. Glomerular filtration of DNA and carrier complexes should also be 
negligible. On the other hand, permeation of DNA into organs with discontinuous 
capillaries and tumor tissues might be significantly higher. Therefore, condensation of 
plasmid DNA is one of the most important factors for in vivo gene delivery (Ledley 
1996).
In a preliminary study carried out at the London School of Pharmacy, the oral 
administration of the precursors of LPD to Sprague-Dawley rats was investigated 
(Florence, Sakthivel and Toth 2000). Maximum levels of dendrimer observed were 
15% in the small intestine, 5% in the large intestine and 3% in the blood at 6 h after 
administration, while 1.5% reached the liver, 0.1% the spleen and 0.5% the kidneys. 
The study concluded that “if particles flocculate or otherwise aggregate in vivo, 
determination of the influence of particle diameter becomes difficult. Aggregation of 
dendrimers units and partial dendrimers can result in supramolecular assemblies and is 
likely to alter its distribution in vivo”. This gives an indication of the possible levels of 
LPD seen in tissues following oral delivery; however, the LPD in this study is 
complexed with DNA and may display properties differing from a similar 
uncomplexed molecule.
Aim
The purpose of this study was to investigate the fate of LPD/DNA complexes 
following administration into mice by means of a tail vein intravenous injection or per- 
orally.
Experimental design
The LPD la  was labelled with [ H] at the synthesis stage and purified using published 
methods (Florence, Sakthivel and Toth 2000). This dendrimer was chosen as it has 
performed most favourably in previous investigations of transgene expression as 
previously described (see Chapter 5). By using a radiolabelled LPD ([Tlj specific 
activity = 65 Bq/ug = 3900 dpm), it was possible to determine the uptake of the 
complexes by various organs of the body by harvesting them and processing them to
168
determine the amount of radioactivity they have taken up by liquid scintillation 
counting (LSC).
Of a total of lOug DNA (pCEP4hFIXint) administered to each animal half of which 
was covalently labeled with a fluorescent tag (FasTag™) prior to complex formation 
with the LPD. This was in order to determine if any dissociation of the DNA and LPD 
had occurred following administration and allow them to be detected separately. 30ug 
of LPD la was used for each animal, giving a total dose of 119,000dpm administered.
The labelled LPD/DNA complexes were formed using Opti-MEM® as previously 
described (see Chapter 5 p i30) to a charge ratio of 5:1 (+ : -). Complexes were 
administered to a total of 20 animals (including two negative controls who were 
administered the injection vehicle alone) 16 of which were intra venous and 2 per oral. 
The animals were then sacrificed in duplicate at time points, as shown in table 6.1 and 
6.2 below, according to Schedule 1 of the Animals (Scientific Procedures) Act 1986. 
The tissues were harvested and then frozen by snap cooling in liquid nitrogen cooled 
isopentane and stored in the vapour phase of liquid nitrogen filled vessels. Intestinal 
sections were perfused with saline to remove contents prior to freezing.
Animals used were C57BL/6 strain, which have been previously used in gene transfer 
applications (Hortelano, Al-Hendy, Ofosu et al. 1996). Animals were fed and given 
water ad lib leading up to and following administration except for the mice 
administered the complexes perorally, which were starved overnight.
Results
Tissues were harvested and stored as described above. Sections of the tissues were
TMthen processed either for LSC or FastTag label detection (See Chapter 3 page 93 and 
82 respectively). The weight of the blood contained in the organ was corrected as for 
Wu et al (Wu, Robbins, Bugianesi et al. 1981) in order to calculate the activity 
contributed by the blood to the total activity calculated for the organ.
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Liquid scintillation counting for detection o f fH J labelled dendrimer.
Tables 6.1 shows the raw data in terms of levels of radioactivity detected in various
•  ' X  •sampled tissues following administration of radiolabelled [ H] dendrimer la 
complexed to the hFIX DNA construct pCEP4hFIXint.
Table 6.1 Tissue distribution of [3H] labelled LPD/DNA complexes 
following intravenous administration into mice
Values shown are the raw data indicating the percentage (activity) o f  total dose 
administered (117,000 dpm per animal). The tissues were harvested at the time point 
indicated. Blood samples shown as * indicates the sample could not be counted due to 
an incompatibility with the solvent used, n/a = background levels detected, nt = not 
tested.
Time Animal Liver Spleen Heart Lungs Kidney Blood
2 mins a n/a n/a n/a n/a n/a ♦
ff b n/a n/a n/a n/a n/a *
5 mins a 9.2 n/a n/a 1.0 3.2 *
ft b 15.3 n/a n/a 1.2 6.1 *
15 mins a 6.3 n/a n/a 1.1 n/a ♦
ft b 6.5 n/a n/a 1.1 0.7 *
30 mins a 9.8 n/a n/a 1.0 0.4 5
?? b 2 4 .5 2 .1 0 .7 2 .3 0 .8 15
2hours a 17.1 1.5 0.8 1.0 0.9 *
ft b 15.6 n/a n/a n/a 0.5 *
24 hours a 8.4 n/a n/a n/a 0.7 *
ff b 6.8 n/a 4.9 n/a 1.6 *
4days a 6.6 n/a 1.5 n/a n/a *
b 3 9 .6 n/a n/a 2 2 .6 1 3 .5 *
7days a 2.9 n/a 1.5 n/a 0.9 *
ff b 6.5 n/a n/a n/a 5.8 *
*5
The levels of radioactivity detected indicate that the majority of the [ H] label is 
accumulated in the liver. A high proportion of the administered dose remained 
undetected, however not all tissues were examined and any of these could have 
retained the complexes.
170
There are two statistical outliers in the sample data and are shown above in bold. They 
show a high increase in the amounts of [3H] labelled dendrimer detected for individual 
animals at time points of 30 minutes and 4 days and are likely to be due to unavoidable 
variations in the administration technique.
No radioactivity was detected in the brain and testes for all time-points (data not 
shown).
Tables 6.2 shows the raw data in terms of levels of radioactivity detected in various
'y
sampled tissues following administration of radiolabelled [ H] dendrimer la 
complexed to the hFIX DNA construct pCEP4hFIXint and administered per -orally.
Table 6.2 The tissue distribution of [3H] labelled LPD/DNA 
complexes following per-oral administration into mice.
Values shown are the raw data indicating the percentage (activity) o f total dose 
administered (110,000 dpm per animal). The small intestine (SI) was divided into four 
equal sections with (i) being the most proximal to the stomach (St.) and (iv) the most 
distal section.
Time Liver Spleen Heart Lungs Kidney St. Sl-i Sl-ii Sl-iii Sl-iv Colon
24h 5.2 0.3 n/a n/a 1.0 2.1 0.3 1.2 2.4 0.8 0.3
24h 2.7 0.2 1.0 1.5 0.8 1.3 n/a n/a 0.5 0.5 2.4
As seen in the intravenous study, a high proportion of the administered dose remained 
undetected, however as not all tissues were examined and any of these could 
theoretically have retained the complexes. A  maximum of 5.2% was seen in the liver 
of one animal, with the other tissues detected measuring between 2.4% and 0.2%. No 
radioactivity was detected in the brain and testes for all time-points (data not shown).
Detection o f Fast Tag™ labelled DNA
The presence of fluorescently labelled DNA was not detected in the tissues tested.
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Discussion
There were technical difficulties in the collection and processing of tissues for LSC. 
With the small volumes of blood involved it proved difficult to obtain sufficient 
sample to measure. Also the blood reacted violently with the scintillation cocktail, 
resulting in loss of the sample on many occasions. The difficulty in testing blood has 
been reported previously (Counting Solutions, Packard Inc. 1996). The type of
3 *dendrimer and label used was determined prior to this study and as [ H] is a low 
emitter there was difficulty in administering sufficient radioactivity to be analysed 
coupled with the amount of LPD/DNA complexes required and the total volume of 
fluid administered to the mice. A high emitter such as 1311 or 32P would be the label of 
choice in subsequent experiments.
Restrictions on the project licence at the time restricted the oral administration of the 
complexes to a dosed food particle whereas oral gavage would be preferable as a more 
direct and accurate method. This oversight was addressed in the next part of the study 
following amendments to the conditions of the licence (see page 180).
The animals could not be placed in metabolic cages for this study due to lack of 
suitable equipment during renovation of the animal facilities used, which would enable 
the measurement of radioactivity in excreta and other metabolic products.
The data gives an overview as to the fate of the complexes when administered to mice 
however, the data does not appear to be sufficiently reliable to provide conclusive 
evidence. The duplicates are not consistent and difficult to draw quantitative statistical 
conclusions from. This could have been due to the aggregation of complexes when 
administered differing from animal to animal, resulting in the circulation of varying 
levels of radioactivity. Such aggregation would also explain the low proportion of the 
total dose of radioactivity detected as accumulation of aggregates in capillary beds 
would prevent distribution throughout the body.
The reticulo-endothelial system (RES) is a term used to describe cells of the immune 
system whose predominant role is to remove particulate antigens and include mainly 
phagocytic macrophages together with the endothelial cells of the vasculature and
172
polymorphonuclear cells. These cells are found in many organs such as the liver 
(Kupffer cells), brain (microglia) and lung so therefore are not just confined to the 
circulation, but can be resident in tissues or fixed to the endothelial layer of the blood 
capillaries. Kupffer cells in particular have been shown to be responsible for the 
majority of the uptake of poly(l-lysine)/DNA vectors in the liver (Ward, Read and 
Seymour 2001). It is likely that a majority of the complexes are taken up and detected 
in cells of this nature. To differentiate between LPD/DNA uptake by parenchymal 
liver cells and Kupffer cells would require the collection and breakdown of the tissue 
architecture followed by cell sorting and analysis. The interaction of the RES and 
LPD/complexes is investigated in Chapter 7)
It cannot be determined as to the exact nature of the [3H] source detected in the tissues 
sampled. It is possible, although unlikely, that the LPD/DNA complexes became 
dissociated in the circulation. The purification of the LPD following synthesis 
removes unincorporated label so this can be discounted..
However, qualitatively it is encouraging that it does not appear to permeate the blood- 
brain barrier and or testes. The complexes also appear to have m inim al toxicity when 
administered as no adverse reactions were seen in the animals.
Overall there is a relatively low proportion of radioactivity present in the tissue 
samples tested. On all samples except the liver, the vast majority of the tissue was 
used for testing which would preclude the asymmetrical distribution of complexes 
throughout the organ. The liver and lungs seem to frequently contain the highest 
amount of radioactive label as would be expected since these tissues contain the largest 
capillary networks and hold a large volume of blood at any given time. The spleen 
also appears to retain a significant level of radioactivity in some samples tested. It is 
possible that the complexes aggregated in capillary beds in various parts of the body, 
rendering them undetectable.
There are two noticeable outliers in the sample data where the radioactive dose appears 
disproportionately large compared to its duplicate. In the case of one animal during 
the tail vein injection, a proportion of the complexes was inadvertently delivered sub­
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cutaneously indicated by a raised pool of fluid under the surface of the skin, 
presumably due to the needle not entering the lumen of the vein. The data series from 
this anim al was included as it could provide evidence for a different administration 
approach. There was nothing remarkable about the administration procedure of the 
complexes to the other animals.
A published study that determined the biodistribution of [3H] labelled dendrimer 
PAMAM (see Chapter 1 page 50) delivered to mice (Nigavekar, Sung, Llanes et al 
2004). It showed that the dendrimer was cleared rapidly from the blood, with 20% of 
the administered dose cleared within 5 minutes. The recovery of these dendrimers 
were comparable to the results seen in this study, however, a much broader tissue 
distribution was seen, including the brain and heart. As this study investigated the 
dendrimers as drug deliver agents, this would be a positive attribute. The study also 
reported the clearance of 48% of the dendrimers administrated via the urine within 7 
days of injection.
The instant a foreign substance is introduced in vivo, mechanisms to remove the 
substance either actively or passively are operating. The most significant pathways for 
the clearance of long-circulating drugs and drug carriers are extravasation, renal 
clearance and uptake by cells from the blood which are all are independent processes. 
It is the rate at which these processes take place that determines bioavailability. 
Phospholipid liposomes, if introduced into the circulation, are very rapidly sequestered 
by the cells of the RES and therefore have a biological half-life < 3 0  min. Liver 
Kupffer cells are primarily responsible and the sequestration is mostly independent of 
size, charge, and composition of the liposomes (Senior 1987). Suppression of RES 
uptake can be achieved by a number of methods which include decreasing liposome 
size, increasing liposome dose, pre-saturating RES with ‘empty’ liposomes or other 
particles, or modifying the liposome surface with certain ‘protective’ polymers.
Due to the limited synthesis of the LPD and budget constraints, only dendrimer la  was 
labelled. It then follows that other dendrimers should undergo the same scrutiny in 
order to determine any tissue tropisms or characteristics not seen with la. To go some 
way to address this, additional dendrimers were tested in the oral delivery of a reporter
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gene following revision of the project licence determining the methods used to 
administer the complexes to mice.
6.3 Investigating hFIX transgene expression in mice 
administered LPD/DNA complexes
By far the most popular method of delivering DNA/carrier complexes in vivo is by 
intra-venous injection (Litzinger, Brown, Wala et al. 1996); (Li, Rizzo, Bhattacharya 
et al. 1998)}; (Ward, Read and Seymour 2001).
This delivers the gene/carrier complex directly into the bloodstream, allowing systemic 
circulation and the bioavailability of the complexes to the widest range of tissues.
Aims
The aim of this study is to detect any activity of a delivered hFIX gene in mouse 
tissues following systemic delivery of an LPD/hFIX gene complex.
Experimental design
The delivery of the complexes to the tissues has been examined earlier in this chapter 
(see page 166). As gene delivery by LPD/DNA complexes has not been tested in vivo 
prior to this investigation, it is essential to cover the eventuality that the complexes 
may fail at one or more of the processes required to take place for a transgene to be 
expressed as a function protein. Detection of gene expression was by the following 
methods corresponding to three stages of the gene expression to protein production 
process as shown in table 6.3.
Table 6.3 Investigative methods used to detect transgene activity 
and subsequent stages towards protein production
Investigation used Substance tested for
RT-PCR of cellular mRNA hFIX mRNA
Immunohistochemical staining of tissue sections intracellular hFIXAg
ELISA of blood plasma secreted hFIXAg
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hFIXRT-PCR and T-vector cloning
An optimised RT-PCR was performed using specific primers to detect transcripts of 
the hFIX gene. The primers were designed to distinguish between murine and human 
FIX, with the 3’ terminal base of the sense primer being located at a variation in the 
nucleotide sequence. This means that the primer is does not get extended in the 
polymerase reaction if it anneals to the similar murine FIX sequences. Figure 6.1 
shows the region of the hFIX sequence the primers are designed to anneal to and 
illustrates the difference in the two nucleotide sequences.
Amplified products obtained from liver tissue or transfected Hep G2 cells were then 
purified from the agarose gel and cloned into a commercial T-vector cloning kit 
(pGEM®-TEasy, Promega UK) according to the manufacturer’s protocol. The samples 
were then sequenced in both directions using Sp6 and T7 primers supplied with the kit. 
Cells transfected in vitro with the same hFIX construct complexed with LPD were 
used as a positive control.
Immunohistochemistry
Harvested tissue was snap-frozen in liquid nitrogen-cooled isopentene and stored at - 
80° C until the sections were ready to be analysed. Cryosections (5-6 pm) were 
prepared and stained with a goat anti-human FEX for immunofluorescent detection.
ELISA
The ELISA was performed as previously mentioned to detect circulating hFIX Ag (see 
Chapter 3 page 86). According to the manufacturers of the antibodies used (DAKO, 
UK), the test would not cross-react with murine FIX, producing a false positive. To 
monitor any possibility of cross-reaction producing a false positive result, negative 
control samples of murine plasma were incorporated into the assay.
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F igure 6.1 C om parison  o f hum an  and  m urine  m RNA sequences 
indicating  p rim e r annealing  sites.
The upper (sense) primer-annealing site is shown in the green box, the lower 
(antisense) primer-annealing site is shown in a yellow box. Note the 3 ’ terminal 
nucleotide o f the upper primer (G) is not complimentary to the murine sequence (T) 
and as such should not amplify murine FIXDNA. All non-homologous sequences are 
indicated by a blue square over a red letter corresponding to the differing nucleotide.
T A T G C A G C G C G T  G A AC AT  GAT C A T G G C A G A A T  C A C C A G G T C T C A T C A C C A T  C T T C C T T T T A G G A T A T  C T A
1 0  2 0  3 0  4 0  5 0  6 0  7 0
h u m a n F I X m R N A  T A T G C A G C G C G T G A A C A T G A T C A T G G C A G A A I TCACCAGG C T C A T C A C C A T C T  j C C T T T T A G G A T A T C T A  7 0  
m u r i n e F I X m R N A  GC T f T f A T f A C C A T C T T f C T T T T A G G A T A T C T A  3 3
C T C A G T  G C T  G A A T G T  G C A G T T T T T  C T T G A T C G T  G A AA AT G C C A C C A A A A T T C T T A C T C G T C C A A A G A G G T
8 0  9 0  1 0 0  1 1 0  1 2 0  1 3 0  1 4 0
h u m a n F I X m R N A  C T C A G T G C T G A A T G T A C A G T T T T T C T T G A T C  TG A A AA  GC CA  C A A A A T T C T  A A T C G  C C A A A G A G G T  1 4 0  
m u r i n e F I X m R N A  C T C A G T A C  G A A T G T G C A G T T T T  C T T G A T C G T G A A A A T G C C A C C A A A A T T C T T A C  C G T C C A A A G A G * T  1 0 3
A T A A T T C A G G T A A A T T G G A A G A G T T T G T T C G A G G G A A C C T T G A G A G A G A G T G T A T  G G A A G A A A G G T G T A G
150 160 170 1 8 0  1 9 0  2 0 0  2 1 0
h u m a n F I X m R N A  A T A A T T C A G G T A A A T T G G A A G A G T T T G T T C A A G G G A A C C T T G A G A G A G A A T G T A T G G A A G A A A  G T G T A G  2 1 0  
m u r i  n e F I X m R N A  A T A A T T C A G G  ' A A A  T ‘ G A A G A G T T T G T T C G A G G " A A C C T T G A ' A G A G A G T G T A T ' G A A G A A A G J T G T A G  1 7 3
T T T T  G A A G A A G C A C G A G A A G T T T T T  G A A A A C A C T G A A A G A A C T A C T  G A A T T T T G G A A G C A G T A T  G T T G A T
2 2 0  2 3 0  2 4 0  2 5 0  2 6 0  2 7 0  2 8 0
h u m a n F I X m R N A  T T T T G A A G A A G C A C G A G A A G T T T T T G A A A A C A C T G A A A G A A C A A C T G A A T T T T G G A A G C A G T A T G T T G A T  2 8 0  
m u r i  n e F I X m R N A  T T T T G A A G A A G C A C G A G A A G T T T T T G A A A A C A C T G A A A  A A C T A C T G A A T T T T G G A A G C A G T A T G T T G A T  2 4 3
G G AG AT C A G T G T  G A G T C C A A T C C T T  G T T T A A A T G G T G G C A T T T  G C A A G G A T  GAT A T T A G T T C C T A T  GAAT
2 9 0  3 0 0  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
h u m a n F I X m R N A  GGAG AT C A G T G T  G AGT  C C A A T C C  T G T T T  A AAT  GG G G C A G T T  G C A A G G A T  GA A T T A  T T C C T A T  G AAT  3 5 0  
m u r i n e F I X m R N A  G G A G A T C A G T G T G A A T C A A A T C C T T G T T T A A A T G G T G G A A T 4 T G C A A G G A T G A T A T T A G T T C C T A T G A A T  3 1 3
Results
Figure 6.2 shows the amplified products from the RT-PCR using hFIX specific 
primers as visualised using agarose gel electrophoresis. It includes both mRNA 
obtained from murine tissues and Hep G2 cells transfected with the same hFIX
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construct complexed with LPD. According to the published sequence, the primers 
should amplify a 300bp portion of the hFIX DNA. As seen below the murine mRNA 
gave rise to a 500bp band indicating extra sequences being amplified in the reaction. 
To determine which sequences were being amplified by the primers, automated 
sequencing was performed.
Figure 6.2 Photograph showing agarose gel electrophoresis of hFIX 
RT-PCR using in vivo and in vitro gene transfer
Total cellular RNA was isolated from the liver o f mice administered the gene via 
various routes. Cells transfected with the hFIX gene were used as a control. The RNA 
was then subjected to RT-PCR using primers specific for hFIX cDNA. The picture 
shows a 500bp band for mRNA derived from murine tissue and a 300bp band from  
control transfected cells. A lOObp molecular weight marker (Bioline) is also shown.
500bp 
300bp
SC IP IV -ve Hep H ep+velV -ve
Li Li Li Li Li PCR
Legend:
Li=liver; IV=intravenous; IP=intra peritoneal; SC=sub-cutaneous
Hep=transfected Hep G2 cells (+ve control); -ve=no template DNA in reaction (-ve
PCR control)
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Verification of RT-PCR amplification by sequencing.
The PCR products shown in figure 6.2 were purified and sequenced in both the 
forward and reverse direction to confirm the sequence of the DNA amplified by the 
forward and reverse primers respectively. The sequence extended by the forward 
primer is shown in figure 6.3 and corresponds to the hFIX sequence. This confirms 
the presence of hFIX mRNA in the murine liver cells.
Figure 6.3 Sequence data of sampled mRNA extracted, reverse 
transcribed, amplified and cloned into a T-vector (forward primer 
sequence)
The sequence below is obtained from the mRNA isolated from a sample o f murine liver 
tissue following administration o f an LPD/hFIXDNA complex. It shows the sequence 
o f hFIX and not murine FIX, confirmed by the nucleotides (highlighted in pink) at 
which point the murine FIX sequence differs (see figure 6.1 for a comparison o f the 
two sequences). The forward primer annealing site is highlighted in blue.
Forward primer site.
C A  c ca  o g c t • c A ( J
10 70 30 40 50 60 70
. f  ( (  : C '  G C C T '  T T A G G A 1 A I C T A C 1  C A G !  G C T  C  A  A T  G T  A C  A  G T 1 f J T C T T G A T  C A T  G A A A A C G C C a A C  
80 00  100 110 170 130 140 150
A A A A  T C T  G A A T C C G G C  C A A A G A G G T A T A A f  (  C  #  C  C  7  A A A '  : G G A A G A G  T G T T C A A G G G A A f
160 170 180 190 700 710
C T T  G A G A G A G A . V T G T A T  G G A A G  A A A A G T  G T A G  T T f  f G A A N  A  A N  C  A  C T  6  A G A A G !  T  T T  T G A A A  
770 730 740 750 760 770
A C A  C T G A A A G A A C A A C  T  G A A T  t  1 I G G A A  G C N  G T A T T  G '  I N G A '  G  G  A G A  T C A G G G A G  C C A C
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The sequence data from the reverse primer indicated a mismatch had occurred in the 
PCR annealing step as the extended sequence did not follow that of hFIX. This 
mismatch of sequences occurred also for the commercial in vivo transfection reagent 
(Sigma, UK) used (data not shown). The larger than expected (approx. 500bp) 
amplified products seen in figure 6.2 are likely to be due to mis-priming of the reverse 
primer to an upstream sequence, producing a larger fragment than seen in the 
transfected cell control.
The same procedure used to extract and sequence mRNA from murine liver tissues 
was used to extract cellular mRNA from HepG2 cells following in vito transfection 
with LPD/hFIX DNA complexes. This sequence data is shown in figure 6.4.
Figure 6.4 Sequence data of control mRNA extracted, reverse 
transcribed, amplified and cloned into a T-vector
The control mRNA sequence data below is derived from a sample o f HepG2 cells 
transfected with LPD/hFIX DNA complexes (see figure 6.1 for a comparison o f the two 
sequences). The forward primer annealing site is highlighted in green.
! U T T C U  CACCC CT CAT CA C M l  Cl  ( I  I I '  U  C AT A T C U C  T CAGT GC r Cl  r  C r AC 4 G 1 1 *  I I. 
w  t>3 ICO 119 173 lif t 141!
A A 4 I I ( T & A I <CCC< (  A A U  AC C T A T A 4
198
T C
( C a C A A C T T T T T  CAAJ i A C 4 (  T C A A A C A A ( A A ( 1 ( , h  t  * T T T C C A A C C A C T  A T CT T CAT C G A C A ' 
7*0 ?<» 373 lie  W!
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The sequence obtained follows the consensus of hFIX in both primer directions and 
serves as a positive control. These cells were further confirmed as being successfully 
transfected with a hFIX gene by the presence of hFIX in the cell culture media.
Detection o f circulating hFIX  antigen (hFIX:Ag) using an ELISA.
All ELISA tests of sampled plasma following administration of LPD complexed with a 
hFIX construct showed no evidence of circulating hFIX:Ag. Tests for anti-hFIX 
antibodies also proved negative. Advice obtained from the manufacturers of the 
antibody used (DAKO) suggest that the levels of hFIX produced during this study 
would likely fall below the sensitivity threshold of the assay.
Immunohistochemical analysis
None of the sections viewed tested positive for hFIX:Ag. It is entirely likely that, as 
for the ELISA discussed earlier in this chapter, any levels of intracellular FIX 
produced may be below the sensitivity of this test.
Discussion
The limitations of the techniques used in this study are apparent. An example of this 
would be the PCR detection of hFIX mRNA used. The reverse primer for hFIX 
which, although performed well in experiments using RNA derived from cultured 
cells, mis-primed when murine RNA was used as the template and initiated the 
extension of an alternative section of DNA. As the reverse primer was not designed to 
differentiate between human and murine FIX, it is possible that the primer is 
preferentially including additional nucleotide sequences present in the murine FIX 
mRNA. As a non-specific primer was used for the reverse transcription (oligo-dT 
oligonucleotides), all cellular mRNA in the murine tissues collected would be 
converted to a double stranded template. It would follow that the native murine FIX 
templates would be present at much higher concentrations as compared to the hFIX 
templates derived from the transgene. This would present a bias towards amplification 
of the murine FIX in the susbsequent PCR step and away from the human FIX 
sequences. Although this was partially corrected with the hFIX specific forward 
primer, the reverse primer did not benefit from this specificity. Although the 
sequencing of the detected DNA using forward primer conclusively foil wed the hFIX
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sequence, the absence of a reverse-sense confirmation reduces the impact of the 
results. A hFEX specific reverse primer would be beneficial in this study to ensure 
conclusive detection of hFIX in the PCR stage. Alternatively or even in conjuction 
with this, the inclusion of a hFIX specific primer at the initial reverse transcription 
stage would ensure the production of hFIX templates albeit at a very low concentration 
which would require the addition of a carrier molecule prior to the PCR reaction to 
ensure its stability.
Alternative methods of nucleotide detection such as the northern blot (for RNA) or 
Southern blot (for DNA following reverse transcription) could be applied in future 
studies affording a greater sensitivity and confidence in the detection of transcripts.
The ELISA, although used with success in the detection of hFIX expressed in cultured 
cells did not detect circulating hFIX. It is possible that any hFIX produced would be 
below the sensitivity of both the ELISA assay and the immunohistochemical analysis 
of the tissue sections which, in retrospect, have appeared to be inadequate for the 
purposes of this study.
The study of systemic administration of LPD/DNA complexes proved disappointing in 
that no hFIX. Ag could be detected. Notwithstanding the shortfalls of the analytical 
methods, this lack of apparent activity of the complexes could be explained by the 
inactivation of the complexes due to an interaction with blood components. This 
explanation is supported by the fact that the LPD/DNA complexes were inactivated in 
10%FBS that had not been heat-treated (see Chapter 5 page 135). Taking this 
hypothesis further would be to say that specifically the heat-labile fraction of serum is 
responsible for this characteristic. The possibility that these serum components 
interfere with the activity of LPD/DNA complexes administered systemically is 
investigated in Chapter 7.
6.4 Investigating the expression of a reporter gene in mice 
administered LPD/DNA complexes per-orally
This straightforward method of delivery would appear to be ideal for delivery of a 
gene therapy in diseases such as haemophilia due to its minimally invasive nature. It
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could be easily self-administered by patients, although pre-clinical trials realistically 
require an oral gavage. Oral gene delivery strategies have been few and far between 
until recently, mainly due to the perceived difficulties such as overcoming acid pH in 
the stomach (which leads to depurination of DNA), the nucleases, lipases and 
peptidases present in the gastro-intestinal (G.I.) tract and the poor permeability of both 
genes and gene vectors across the epithelium due to size and charge incompatibilities. 
Despite the apparent hurdles, oral delivery has been reported as being quite successful, 
in some cases with significant levels of expression seen using liposomes to deliver a 
reporter gene (Schmid, Weidenbach, Draenert et al 1994). Mechanisms of uptake that 
have been elucidated include: transcytosis across enterocytes (Wiwattanapatapee, 
Carreno-Gomez, Malik et al. 2000) and endocytosis by epithelial cells (Duncan, 
Pratten, Cable et al. 1981). However, as these studies discuss, there is still conflicting 
evidence as to the upper size limit for particle uptake via these routes, an important 
consideration when developing synthetic carriers.
Anatomically, the gut epithelium presents a large surface area for transduction with a 
therapeutic gene with the capillaries very close to the cell layer. This allows the 
secretion of proteins into the systemic circulation and may also facilitate the movement 
of exogenous DNA complexes by trans-cellular (transcytosis) or para-cellular (via 
temporary disruption of tight junctions) across the epithelium and provides an 
attractive target for gene therapy.
Aims
The aim of this study is to determine if an LPD/reporter gene can be delivered per 
orally in order to target the gut epithelia to express the transgene.
Experimental design
The protocol used was adapted from published studies (Schmid, Weidenbach, Draenert 
et al 1994; Lozier, Yankaskas, Ramsey et al 1997). The LPD used are la, 2a and 3a 
in duplicate administrations to C56BL/6 mice by per-oral gavage. The complexes 
were formed as described (see Chapter 5 page 137) using Opti-MEM® (without the 
addition of serum), with an equal volume of 1 0 % sucrose solution added to the 
complexes prior to administration.
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Results
The LPD 3a (8 amino groups with a glucose molecule added) showed expression of 
the reporter gene in areas of the proximal jejunum epithelia. Other areas of the tract 
did not show reporter gene expression. Figure 6.5a and 6.5b show a section of the 
proximal jejunum harvested from two separate animals respectively, administered 
LPD3a/DNA complexes followed by G.I. tract tissues being harvested and processed 
for p-galactosidase activity.
The reporter gene activity was not detected in other LPD/gene complexes or the 
negative control samples derived from animals that were administered the injection 
vehicle. This control was added to preclude a false positive result caused by 
constitutive expression of a native enzyme with the same P-galactosidase activity 
(figure 6.5c).
F igure  6.5a D etection of P-galactosidase activ ity  in m urine  
gastro in tes tina l tra c t sam ples following oral delivery  o f LPD//DNA
This figure is o f a slide-mounted frozen section o f the jejunum o f an animal which has 
been administered LPD/DNA complex (LPD 3a, reporter gene construct pSV/3-Gal) 
visualised by an inverted microscope and camera. (Olympus CK2 and OM 4Ti with 
Fuji T64 film.). Magnified x250
o
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F igure 6.5b D etection of P-galactosidase activity in m urine  
gastro in testina l tra c t sam ples following o ral delivery of LPD//DNA
This figure is o f a slide-mounted frozen section o f  the jejunum o f another animal which 
has been administered LPD/DNA complex (LPD 3a, reporter gene construct pSV/3- 
Gal). Magnified x250.
.
- v  i ' \-v
' f ' U
Figure 6.5c D etection o f p-galactosidase activity in m urine  
gastro in testina l tra c t sam ples following o ral delivery o f LPD//DNA -  
negative contro l
This figure is o f  a slide-mounted frozen section o f the jejunum o f a negative control 
animal. The tissue was processed as the previous two samples shown. The lower left 
portion o f the sample displays an artefact (air bubble). Magnified x400.
5  -
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Discussion
The in vivo data indicate that the cationic lipids can deliver a functional gene when 
administered per-orally. Expression was only been observed in this study of a reporter 
gene, (3-Galactosidase delivered in conjunction with LPD 3a. This was seen as the 
positive staining of (3-Galactosidase in the gut epithelia of animals administered the [3- 
Gal reporter gene construct and confirmed by its absence in the negative control. 
Dendrimer 3a is a variation of la  which has been used for the majority of this study 
due to its apparent increased activity of gene transfer as compared to the other 
variations. The modification of 3a involves the addition of a glucose molecule to the 
amino acid backbone of the molecule (see Chapter 1 page 53).
The absorptive processes for glucose is sodium (Na+) dependent - i.e., one Na+ 
molecule is translocated across the brush border membrane of the epithelial cells with 
each glucose molecule. It is therefore unlikely, a large molecule such as LPD/DNA 
complexes are taken up by this mechanism. More likely is an absorption mechanism 
for large molecules, with the glucose modification of the LPD either facilitating uptake 
or providing a protective function from gastric secretions. The presence of receptors 
that trigger endocytosis are well documented as providing mediation of uptake, with 
many enteric pathogens exploiting this method (Yersinia targets the M cells of Peyer’s 
patches). Lectin modifications to liposomes and polymers for targeted drug delivery 
via the glycoproteins of the G.I. tract have been extensively studied (Woodley 2000) 
and similar techniques could be applied to other easily modified synthetic carriers such 
as LPD.
This study would benefit from a more comprehensive investigation involving several 
dendrimers, each modified covalently or otherwise and combined with co-factors such 
as PEG, cholesterol, receptor ligands or other helper-lipids. Variation of 
administration methods should also be undertaken to fully optimise what appears to be 
a promising system for the oral administration of DNA complexes.
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6.5 Summary of results.
In this chapter the LPD/DNA complexes were administered to mice with the following 
results.
The tissue distribution showed most of the labelled LPD that was detected was found 
in the liver. However, the majority of the LPD remained undetected. Attempts to 
differentiate between the radioactively labelled LPD and fluorescently labelled DNA 
resulted in the failure of DNA to be detected in any tissues tested. This is likely due to 
the sensitivity of the label and assay being inadequate for this application.
The per-oral administration of a reporter gene complexed with a glucose-modified 
dendrimer resulted in the expression of the gene in epithelial tissue lining the gastro­
intestinal tract. This determines that the complexes are able to deliver a function gene 
in vivo by oral administration of LPD/DNA complexes.
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Chapter 7
Immunogenic Properties of Lipidic Peptide
Dendrimers
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7.1 Introduction
A major concern for a gene-based approach for the treatment of a human disease is the 
development of an immune response to the vector or gene product. This happens in 
the conventional protein replacement based treatment for haemophilia where an 
immune response results in antibody mediated humoral responses to the infused 
clotting factor protein. The development of such a response may be anticipated since 
the introduction of any new protein (or transgene product), will be seen as foreign by a 
naive host and therefore trigger the immune system to respond whether humoral, cell 
mediated or both. For a gene based approach to be successful, gene expression must 
continue and not be down regulated by an immune response. If this were to occur, gene 
expression may be lost and the treatment aims fail. The mediators of this response 
may be cellular based (CD4, CD8 ) or humorally based (immunoglobulins, complement 
etc.) and there are several components of the treatment process where an immune 
response may occur. These components may broadly be divided into external factors 
(characteristics of the vector and the transgene) and internal factors (characteristics of 
the host to receive gene therapy).
As this study concerns the development of a vector it will focus on the external 
characteristics of the LPD/DNA complex.
7.1.1 Components of the immune system affecting gene therapy
Processes of the host immune system known to be involved in the disruption of 
therapeutic gene transfer are:
• The complement system (Wassef, Matyas and Alving 1991; Plank, Mechtler, 
Szoka et al. 1996);
• Antibody production by B-lymphocytes (Krieg, Yi, Matson et al. 1995; Zhou, 
Liu and Liang 2004);
• Cytotoxic T-lymphocyte (CTL) responses (Klinman, Yi, Beaucage et al 
1996; Wang, Doolan, Le et al. 1998).
All of these immune responses are capable of reducing the effectiveness of the therapy 
by attacking either the gene-carrier complex, the target cells containing the transgene
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or the secreted product. These interactions are not discrete in their actions, with aspects 
of all being involved in some common processes.
Antibodies
Antibodies (Ab), also called immunoglobulins (Ig) are vertebrate immune proteins 
secreted by B-Cells circulating in the blood stream. These proteins bind foreign 
macromolecules in a high specific fashion and facilitate their inactivation or removal 
from the body. All antibodies have the same basic structure, but are diverse in a region 
that binds to the target also known as the antigen (Ag). As a rule, each antibody can 
bind specifically to just one antigen. Antibodies can form against the vector (Lee, 
Partasarathy and al. 2001), the DNA/vector complex (McLachlan, Stevenson, 
Davidson et al 2000) or the gene product (Dai, Schwarz, Gu et al. 1995). Antibody 
production against the gene product is of particular concern in haemophilia gene 
therapy. As previously discussed, some antibodies raised to clotting factors 
(inhibitors) can reduce or eradicate anticoagulant activity (Hay 2002). Antibodies like 
complement components can also act as opsonins in that they coat the antigen which is 
then ingested by circulating macrophages.
Complement
The complement system (also called the heat labile fraction of serum) is part of the 
natural immune system that protects vertebrate species from invasion by foreign 
organisms. It is a group of about 20 serum proteins primarily synthesized in the liver 
whose overall function is the control of inflammation. The two mechanisms of 
activating complement are the classical and the alternative pathways.
Agents as diverse as immune complexes, fungi, bacteria, viruses, heparin and 
polysaccharides are capable of activating complement which can result in a number of 
effects.
1. Formation of the multi-component complex capable of disrupting membranes 
(such as those found on bacteria) and causing cell lysis.
2. Attraction of phagocytes and increased blood-flow to the site of activation 
along with increased permeability of capillaries to plasma molecules.
3. Coating of organisms or molecules for uptake by phagocytes (opsonisation).
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Additionally, the activation cascade causes the proteolytic cleavage of certain 
precursors that, when activated, link the activation of complement with the recruitment 
of other components of the immune system.
The clearance or opsonisation of particles (which have activated complement) is 
regulated by the reticuloendothelial system (RES) and is mediated by an interaction 
with the C3b/C4b components of the complement system. Opsonisation has been 
previously described for liposomes, therefore it can be expected that activation of the 
complement system by DNA complexes would severely limit their efficacy when 
administered intravenously. (Plank, Mechtler, Szoka et al 1996). The processes and 
components of the RES are outlined later in this introduction.
The classic pathway begins when complement proteins Cl is activated by antibody- 
antigen complexes, splitting both C2 and C4. The small fragment C4a and C2b are 
lost with the major fragments combining to form C4b2a. This combination triggers a 
splitting of the C3 complement protein into C3a, an anaphylatoxin and C3b which 
combines with C4b2a to create C5convertase. Anaphylatoxins increase vascular 
permeability by triggering degranulation of mast cells and the release of histamine.
The alternative pathway begins when microbes react with the C3 protein. Following 
the cleavage of Factor B by Factor D, a C5 convertase is generated by the combination 
of Bb to pre-existing C3b. This combination also causes other C3 proteins to split into 
an anaphylatoxin C3a and C3b, which again combines to form C5 convertase 
C3bBb3b, creating a positive feedback.
The two pathways converge and follow the lytic pathway with the formation of C5 
convertase. This enzyme causes the C5 protein to split, creating another anaphylatoxin 
C5a, with the other fragment C5b- triggering a reaction that causes C6  + C7 + C8  +C9 
to assemble into the Membrane Attack Complex (MAC). A schematic diagram of the 
components of the complement system is shown in figure 7.1.
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Figure 7.1 Illustration of the complement cascade.
The two major pathways, the classical (from component Cl) and alternative (from 
component C3) pathways are indicated. The major protein components (but not 
regulators) involved are shown. The processes are a multi-component response to 
foreign particles and are mainly adapted to removing bacteria or other foreign 
particles from the bloodstream. ©Jason Dyer1998: 
http: //cord, ubc. ca/steeves/ikd/ikd-main. html
The reticuloendothelial system (RES)
Phagocytic macrophages are cells of the immune system whose predominant role is to 
remove particulate antigens. Together with the endothelial cells of the vasculature and 
polymorphonuclear cells they form what is sometimes termed the reticuloendothelial 
system. These cells are found in many organs such as the liver (Kupffer cells), brain 
(microglia) and lung so therefore are not just confined to the circulation, but can be 
resident in tissues or fixed to the endothelial layer of the blood capillaries. Kupffer 
cells in particular have been shown to be responsible for the majority of the uptake of
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poly(l-lysine)/DNA vectors in the liver (Ward, Read and Seymour 2001). 
Macrophages have a number of markers on the cell surface including the complement 
component C3b and IgG receptors, both are essential for the opsonisation of 
complement or antibody bound antigens respectively. These bound particles are then 
ingested and destroyed by the release of enzymes into the immediate vicinity of the 
antigen
7.1.2 Immune responses to gene therapy
Host immune responses to gene therapy, especially using viral vectors for 
administration has been widely reported (Zhou, Liu and Liang 2004). Replication- 
incompetent retroviral vectors have been employed in experimental settings and 
clinical trials but a potential problem with the use of such vectors may be the host 
immune responses directed against the vector particles themselves (McCormack, 
Martineau, DePolo et al. 1997). Studies into the immunogenicity of recombinant 
adeno-associated virus vector (rAAV) demonstrated that a primary target of the 
immune response is the capsid of the vector particle, even though these vectors do not 
encode any viral proteins due to the absence of viral DNA sequences in their genomes 
(Moskalenko, Chen, van Roey et al. 2000).
The detection of persistent neutralising antibodies for adenovirus mediated therapy 
(Chirmule, Propert, Magosin et al. 1999) and the CTL responses to retroviral vectors 
has been studied (Fields, Kowalczyk, Arruda et al. 2000). There is now a growing 
body of literature available describing the adverse reactions towards synthetic vectors 
by activation of the immune system. These include activation of the complement 
system (Plank, Mechtler, Szoka et al. 1996); the stimulation of antibody production 
(Lee, Partasarathy and al. 2001); and the increase in circulating pro-inflammatory 
cytokines (Norman, Denham, Denham et al. 2000).
Immune responses to the transgene and transgene product
It is known that unmethylated CpGs in bacterial and plasmid DNA are recognized by 
the immune systems as a “dangerous” signal and have immunostimulant effects. This 
recognition depends on the Toll-like receptors on the surface of the immune cells, such 
as B-lymphocytes, natural killer cells (NK cells), monocytes, macrophages, and 
dendritic cells (DCs) (Hemmi, Takeuchi, Kawai et al. 2000). CpG 
oligodeoxynucleotides or bacterial DNA can stimulate DCs and macrophages to
193
secrete cytokines (e.g., IL-2, IL-6 , IL-8 , IL-12, and TNF-a) as well as increase 
expression of co-stimulatory molecules, activating the immune sytem (Yasuda, 
Ogawa, Kishimoto et a l 2002).
As transgene products that have never been produced in the hosts due to the gene 
mutation preventing correct expression, such a protein could be considered as 
“ foreign” by the host immune system. Current attempts towards gene therapy for 
haemophilia B has revealed that neutralizing antibodies to the therapeutic products can 
be formed. The viral vector rAAV delivering transgenic FIX, has been shown to elicit 
immune responses against the secreted transgene product. Intramuscular administration 
of rAAV encoding hFIX into C57BL/6 mice has also been shown to induce a humoral 
response directed against the transgene products (Fields, Kowalczyk, Arruda et al. 
2000).
Immunogenic components of LPD/DNA complexes
Cationic lipids (the group of molecules to which LPD arguably belong) have been 
shown to produce immune responses when used as DNA carriers (Freimark, Blezinger, 
Florack et al. 1998; Norman, Denham, Denham et al. 2000) which would be an 
adverse reaction in the circumstances. Conversely, in utilising this immunostimulatory 
property, these molecules are also used as vaccines (Hermanson, Whitlow, Parker et 
al. 2004) by inducing the immune response to be directed towards a certain target, 
illustrating their versatility for many applications. Due to their similarity to cationic 
liposomes, the structure of LPD molecules would at first appear immunogenic and the 
two main component parts, the densely charged head-group and the three lipid chains, 
can be examined as such.
The branched poly-lysine structure is a strong immunogenic agent, with similar 
compounds being used as an adjuvant in immunisation experiments (Baier, Loleit, 
Fischer et al. 2000). When integrated as a component of a liposome in a 
liposome/DNA complex, early studies have suggested that both systemic and local 
administration were safe and well tolerated (Philip, Liggitt, Philip et al. 1993; 
Canonico, Plitman, Conary et al. 1994). As more investigations into cationic lipids 
were performed, other studies reported observing toxicity following the administration 
of cationic-lipids (Scheule, St George, Bagley et al. 1997). These conflicting reports
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would suggest that each newly developed carrier should be individually tested to 
determine its effect on the host.
7.2 Complement activation by LPD/DNA complexes
The complement system protects vertebrates from invasion by foreign organisms. As 
discussed earlier in this chapter, complement is activated by a wide range of agents. 
The components of the complement system are therefore likely to interact with 
(opsonise) intravenously administered DNA complexes.
Complement activation by charged liposomes has been previously documented, with 
anionic liposomes activating the classical pathway, whereas cationic liposomes 
activate the alternative pathway (Chonn, Cullis and Devine 1991). Expanding on this 
study is the report that multivalent lipids have also been shown to be potent in 
activating complement when compared with monovalent lipids (Plank, Mechtler, 
Szoka et al. 1996). This study also showed that the DNA, although itself activates the 
complement system, when compared to polycations it is an extremely weak activator 
and is barely detectable given the sensitivity of the assay. Following the discovery that 
serum without the heat-labile fraction of serum removed inactivated LPD/DNA 
complexes in vitro (see Chapter 5 page 135), the extent of this interaction was studied.
Aims
The aims of this experiment are twofold, firstly to determine which of the LPD 
variations activate complement and secondly to measure the level of activation.
Experimental design
The protocol for detecting the activation of complement by LPD/DNA complexes was 
adapted from Plank et al (Plank, Mechtler, Szoka et al. 1996) and Klerx et al (Klerx, 
Beukelman, Van Dijk et al. 1983). The original experimental principals on which 
theses studies were based were conceived by K. Whaley (Whaley 1985) stating that if 
serum is incubated with a substance that activates complement, the complement 
components will be depleted for that sample as they are not renewable. A subsequent, 
measurable reaction requiring complement with the same serum sample would then 
require a higher volume of the sample to achieve the same level of activity.
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The activation of complement by LPD/DNA complexes is examined in this work 
(without discrimination between classic and alternative pathways) and utilises a 96- 
well plate assay format. The amount of complement in a given serum sample is 
expressed in terms of its CH50 value and describes a particular serum dilution. 
Specifically, adding this dilution (200pL total volume) to 2 x 108 antibody sensitised 
sheep red blood cells (SRBs) in 200pL of buffer will result in 50% haemolysis of the 
cells (see Chapter 3 page 85 for protocol). The CH50 was calculated for the serum 
used in this work using the von Krogh equation (see Chapter 3 page 98), with the 
results plotted in figure 7.2.
The actual levels of complement are measured by its ability to lyse pre-sensitised red 
blood cells, a property which can be easily quantified by the amount of released 
haemoglobin by spectrophotometry. The experiments follow the principal previously 
mentioned in that if a given sera is incubated with LPD/DNA complexes which 
activate the complement, this depletes the levels of complement components available 
for the haemolysis reaction, requiring a larger volume of sera to produce the same 
levels of released haemoglobin as would be seen pre-incubation (the CH50max). The 
quantity of serum required to produce lysis in 50% of the cells, can then be compared.
The concentration effect on the CH50 value of the serum for each LPD/DNA complex 
was then compared to the CH50max. This allows the depletion of complement factors 
in the serum due to activation to be measured by linear regression and expressed as a 
CH50 value for each LPD/DNA complex tested.
196
Figure 7.2 Log-log plot to show CH50 calculation of red blood cells 
used
Using the von Krogh equation, when y/l-y  = 1, a 50% lysis o f red blood cells has 
occurred. The line (A) below illustrates that the volume o f normal serum achieving 
50% lysis o f the SRBs is 44fjL. The same test is applied following incubation o f a 
complement activator with the serum prior to this mixing is illustrated by the parallel 
broken line (B) which, as an example, required 7 OpL o f serum to lyse 50% o f the cells.
y!{\-y)
4
Volume of serum (xlOpL)
The determination of a CH50 value for each test required that erythrocyte haemolysis 
was measured at five different serum dilutions. Experiments were carried out in 
duplicate with the fraction of the CH50max shown as a percentage and plotted against 
the concentration of the total positive charge in the solution contributed by the terminal
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amine groups of the LPD tested (see figure 7.3). It is the concentration of positive 
charge that is the predominant factor that governs complement activation in these 
experiments. The complexes were formed as for gene transfer protocols with a 5:1 
charge ratio (+ve : -ve) in order to reproduce the same complexes that would be 
administered in vivo.
Results
Figure 7.3 shows that LPD/DNA complexes created using these LPD are all capable of 
significantly activating complement in increased concentrations. It is interesting to 
note that complexes formed with dendrimer lb do not follow the trend of the others, 
which show a higher level of complement activation in line with increasing 
concentration of +ve charge. In the case of lb the level of complement activation is 
constant from 100 to 101 pM positive charge, with a decrease in activation at 102 pM.
The dendrimers with a higher charge density display greater complement activation at 
concentrations up to 101 pM i.e.3a>2a>la.
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Figure 7.3 Diagram to show effect of different LPD/DNA constructs on the CH50 of serum
Following incubation with LPD/DNA complexes, the sera was then added to the red blood cells in serial dilutions and the CH50 calculated. Any 
complement activation by the LPD/DNA complexes would result in an increased CH50 value for those particular sera (compared to serum which 
hasn’t been incubated = CH50max). The data points are labeled according to which dendrimer was used.
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The composition of the dendrimer appears significant with the ornithine based 
dendrimer showing a consistently higher level of complement activation than the same 
concentration of the corresponding lysine dendrimer.
Complexes formed with dendrimer 3a completely prevented any complement activity 
following incubation indicating an exhaustive depletion of complement components.
Discussion
Interactions with the immune system in general, including the complement system and 
RES could severely diminish the effectiveness of synthetic gene transfer complexes in 
vivo. When compared to the study of several different synthetic cationic molecules 
and their complexes (Plank, Mechtler, Szoka et al. 1996), LPD shows a similar 
complement activation profile to fifth generation PAMAM dendrimer/DNA 
complexes. The results confirm that all the LPD/DNA complexes tested activate 
complement, with the glucose-modified dendrimer showing the most potent at 
activating the complement cascade. It is interesting however that the dendrimer lb 
proved an exception to the trend in its ability to activate complement by becoming less 
of an agonist at increased concentrations. This could be a property unique to this 
particular variation in the structure of the LPD molecule (16 amino terminals and no 
modifications - see Chapter 1 page 53) conferring a characteristic to the complex it 
forms with the DNA which, as its concentration is increased, reduces the interaction 
with complement.
As with all assays using biological agents, particularly cells, careful consideration was 
used to standardise reagents and ensure quality control measures are in place such as 
the constant production of the standard CH50 measurement for each assay.
A further study involving the LPD lb would confirm it as an exception to the observed 
trend. As a pooled batch of reagents (including SRBs), were used for the assays with 
controls, reagent failure can be ruled out. As was the case for previous experiments, 
dendrimers 2b and 2c were not tested due to their poor solubility. Dendrimers 3b and 
3c were not available for testing due to synthesis problems, however it can be
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postulated that if activation of complement is a function of charge, they would follow a 
similar profile to 3 a.
This study concluded that complement activation by polycation/DNA complexes 
occurs and increases according to the amount of positive charge involved. This is an 
important issue to consider for systemic delivery of the complexes in in vivo protocols. 
Reducing the optimised charge ratio (5:1) of the complexes would reduce their 
efficacy so is not a rational solution. Masking or neutralising the surface charge of the 
LPD/DNA complexes along with the addition of hydrophilic steric stabilizers such as 
PEG, may lead to significant improvements in the LPD for in vivo systemic gene 
delivery.
7.3 Inflammatory responses to LPD/DNA complexes
Recent studies involving DNA/liposomes have show unacceptable levels of 
inflammation accompanying expression of the transgene, which was attributable to the 
increased number of unmethylated CpG motifs in the transgene DNA (Krieg 2000; 
Krieg 2002). The inflammatory response to unmethylated DNA was originally 
demonstrated following exposure to heat-denatured (single-stranded) bacterial 
genomic DNA and was suggested that the immune system recognises this molecular 
pattern as ‘foreign’, activating appropriate immune responses (Krieg 1996). These 
results have serious ramifications on the development of protocols for gene therapy, as 
the vast majority use bacterial DNA to form the gene construct to be delivered. These 
inflammatory responses are very pronounced as bacterial DNA and oligonucleotides 
derived from bacterial DNA and grown in E.coli can be efficient in activating 
macrophages and dendritic cells, resulting in the release of proinflammatory cytokines 
such as tumour necrosis factor a  (TNFa) (Klinman, Yi, Beaucage et al 1996).
One way of studying the cellular reactions to an administered therapy is to investigate 
the signals that trigger them. The cells of the immune system are widely distributed 
throughout the body, but should an infection or other pro-inflammatory event occur in 
a particular area of the body, it is necessary to concentrate them and their products to 
the site. The process by which this occurs manifests itself as inflammation and 
involves the release of numerous cytokines. These soluble molecules are secreted by
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the cells of the immune system to modulate immune responses. This is a general term 
for a large group of proteins or peptides involved in signalling between cells and which 
fall into a number of categories outlined below.
The interferons are mainly involved in limiting the spread of viral infection; in 
particular IFNa and IFNp are produced by cells that have become virally infected. 
Interleukins are a large group of cytokines produced mainly by T cells, although some 
are produced by mononuclear phagocytes or tissue cells. Those produced by 
lymphocytes are usually called lymphokines and have a variety of functions, but most 
are involved in directing other cells to divide or differentiate. Each interleukin acts on 
a specific, limited group of cells that express the correct receptors for that interleukin.
Other cytokines include the colony-stimulating factors (CSFs) involved in directing the 
division and differentiation of bone marrow stem cells and the precursors of blood 
leukocytes as well as transforming growth factors (TGFs), which have a variety of 
functions involving the differentiation and activation of immune cells.
Selection of cytokines to test for inflammatory responses
Determining which inflammatory markers to investigate was derived from published 
studies. In the context of inflammatory responses to the administration of LPD/DNA 
complexes in wild-type mice, three cytokines were identified as, together, giving a 
good indication of an immune response. These were ILlp, IL-6 and TNFa as which 
have been documented in being central to inflammatory responses to non-viral gene 
transfer protocols (Norman, Denham, Denham et al. 2000).
Interleukin-1 /3 (IL-lp) is produced by activated Macrophages, endothelial cells, B- 
cells, and fibroblast cells. It induces further inflammatory responses, oedema, 
promotes the production of prostaglandins, IL-2, and the growth of leukocytes. IL-1 
also augments corticosteroid release, inducing fever and shivering which can elevate 
the core body temperature as a way of reducing bacterial growth.
Tumour Necrosis Factor (TNF) is released by activated Macrophages. It enhances 
activation of T-cells, and induces proliferation of T-Cells and B-cells. TNF also
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attracts additional Macrophages and granulocytes to the site. This prompts 
macrophages and other immune cells to release tissue-damaging, oxygen-containing 
substances and prostaglandins to promote inflammation. TNFa levels have been 
shown to increase following stimulation by bacterial DNA itself, particularly DNA 
containing unmethylated CpG motifs (Krieg, Yi, Matson et al. 1995; Stacey, Sweet 
and Hume 1996).
Interleukin 6 (IL-6) is a mediator of the inflammatory response and is involved in the 
stimulation several types of leucocytes and the production of Acute Phase Proteins in 
the liver. It is also particularly important in inducing B-cells to differentiate into 
antibody forming cells (plasma cells). An increase in IL-6 production has been 
associated with the presence of bacterial Lipopolysaccharuides (LPS), unmethylated 
CpG motifs and liposomes (Zhang, Shoda, Brayton et al. 2001; Yamamoto, Ishida, 
Inoue et al. 2002). However a study has suggested that elevated levels of IL-6 were 
primarily due to the liposome rather than the plasmid DNA (McLachlan, Stevenson, 
Davidson et al. 2000). LPS molecules are extremely potent immunogens and are often 
a contaminant of plasmid DNA derived from bacteria for use in gene transfer protocols 
(Cotten, Baker, Saltik et al. 1994). Many commercial bacterial plasmid preparation 
protocols now include a step to remove these molecules (often called endotoxins) 
which are potent activators of complement (Yokochi, Inoue, Kimura et al. 1990).
Aims
The aims of this study is to determine the effect administration of LPD/DNA 
complexes to mice have on the tissue concentration and circulating levels of the 
inflammatory markers IL-6 IL-lp and TNFa and define the hosts immune reaction to 
the complexes.
Experimental design
The experimental design was based on a previous study measuring the inflammatory 
response to systemic administration of cationic liposomes and plasmid DNA (Norman, 
Denham, Denham et al. 2000). The inflammatory markers tested are accepted as 
indicators of a response to injury and stress (Gershenwald, Fong, Fahey et al. 1990;
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Klinman, Yi, Beaucage et al 1996) and levels produced often correlate with the 
severity of the inflammatory stimulus.
LPDla/DNA complexes formed as previously described (see Chapter 3 page 85) were 
administered to immune-competent mice (n=3) by intra-venous administration. 
Approximately 24 hours post-administration the animals were sacrificed and various 
tissue samples taken for total cellular RNA extraction. Quantified samples of RNA 
were then selectively amplified by RT-PCR and compared with ‘sham’ treated animals 
(injection vehicle only) and animals administered with the Sigma™ In vivo 
Transfection Reageant™ (n=2) as negative and positive controls respectively. This 
control is a cationic lipid comprising of DOSPER and DOPE (see chapter 1 page 48). 
With each inflammatory marker a small portion of murine P-actin mRNA was co­
amplified to indicate the viability of the amplification reaction tested, in the absence of 
specific bands for the cytokines.
The measurement of inflammatory marker expression was performed by the reverse 
transcription and amplification of mRNA and is adapted from Norman et. al. (Norman, 
Denham, Denham et al. 2000). Specifically, constant amount of cDNA is used in the 
amplification reaction and the target is co-amplified with a housekeeping gene (P- 
actin). This control also indicates that the levels of template are consistent from 
sample to sample. The PCR products are visualised by staining with EthBr and the 
intensity of the bands, which correlate to the amount of DNA, measured by 
densitometry (Bio Rad™ Quantity One® software version 4.5.2). The level of 
expression of the inflammatory marker is then measured as a ratio between the 
intensity of these bands relative to the intensity of the housekeeping gene.
Results
Liver, lung, samples were tested as they showed the highest levels of dendrimer uptake 
during tissue-distribution studies as well as being practically more desirable due to the 
abundance of tissue. Pancreas and spleen samples were also tested as they would 
provide the best indication of increased inflammatory activity. The testing of blood 
samples were attempted to determine circulating levels, however insufficient material 
could be collected for test purposes.
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A summary of the results as measured by comparative densitometry can be seen on 
page 206. Figures 7.4, 7.4a, 7.5 and 7.6 show the individual bands of amplified 
inflammatory markers following electrophoresis and staining for densitometry.
Figure 7.4a shows the amplification of IL-lp from liver and lung samples following 
agarose gel electrophoresis. The level of expression is expressed as a percentage of the 
band intensity as compared to the housekeeping gene, p-actin determined by 
densitometry. Noticeably, the LPD/DNA complexes show similar levels of IL-lp 
mRNA in liver to the commercial preparation (0.24 and 0.27 respectively) when 
administered intravenously, both of which are higher than the negative control of 0. 
Lung samples show an increase in the expression of IL-lp from a background level of 
0.49 for the negative control to 0.62 for the LPD/DNA complexes.
No IL-ip expression was detected in the pancreas of the negative control, however the 
level was elevated to 0.11), which was sampled along with the spleen (shown in figure 
7.4b) to a provide an indication of any systemic inflammatory responses.
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Figure 7.4a Interleukin-1 p gene expression in the liver, lungs and 
pancreas following LPD/DNA gene transfer
The level o f expression o f inflammatory marker IL -lp  is shown in the tissues indicated. 
The relative level o f inflammatory marker expression is shown as a ratio between the 
intensity o f the IL -lp  bands relative to the internal control P-actin. 2jug o f total 
cellular RNA was used in the PCR.
B-actin
Route: -velV IV +veIV IV
Sample: Li Li Li Pa
IL-l/p-Actin 0 0.24 0.27 0.11
-velV IV -velV -ve lOObp 
Pa Lu Lu PCR 
0 0.62 0.49
Legend: Li=liver; Lu=lung; Pa=pancreas; IV= intra-venous +ve=commercial
preparation; -ve=negative control (injection vehicle only).
Figure 7.4a shows relatively high levels of IL-P expression in the spleen. Samples 
tested showed 100% intensity as compared to the housekeeping gene with the baseline 
levels of the negative control at 85%.
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Figure 7.4b Interleukin-1 p gene expression in the spleen following 
LPD/DNA gene transfer
The level of inflammatory marker IL-lp is shown in the spleen (Sp). From the total 
cellular RNA extracted, 2pg was used in the PCR which amplified the inflammatory 
marker as well as an internal p-actin internal standard, -ve results were derived from 
animals injected with the buffer used. The relative level of inflammatory marker 
expression is shown as a ratio between the intensity of the IL-ip bands relative to the 
internal control.
IL-lp
p-actin
Route:
Sample:
Figure 7.5 shows a large increase in IL-6 mRNA levels in liver tissue when treated 
with LPD/DNA complexes administered by intravenous injection as compared to the 
negative control. The lung sample however shows only a small increase in the 
intensity in the band.
Pancreatic and splenic IL-6 levels are reduced as compared to the positive control so as 
to be undetectable
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Figure 7.5 Agarose gel electrophoresis of RT-PCR products using 
primers for Interleukin-6 and P-actin.
Total cellular RNA used for RT; 2pg used in PCR Li=liver; Pa= pancreas; Lu=lung; 
Iv=intravenous; -ve=injection vehicle only
IL-6
P-actin
Route: -velV IV -ve IV IV
Sample: Lu Lu Li Li
IL-6
p-actin
Route: -velV IV +veIV IV -velV +veIV
Sample: Pa Pa Pa Sp Sp Sp
Figure 7.6 shows the amplification of TNF-a from liver, spleen and pancreas samples. 
In the lungs there appears to be undetectable levels of TNFa in animals treated with 
the LPD/DNA complexes. A small increase in the TNFa levels is seen in the liver and 
a more marked increase seen in the spleen as compared to the negative control.
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TNFa mRNA was not detected in the other tissues tested.
Figure 7.6 Agarose gel electrophoresis of RT-PCR products using 
primers for TNFa and p-actin.
Total cellular RNA used for RT; 2jug used in PCR.
TNFa
(3-actin
Route
Sample
TNFa
(3-actin
Route -velV IV IV -velV
Sample Sp Sp Pa Pa
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Table 7.1 Summary of results for tissues and inflammatory markers 
tested following administration with LPD/DNA complexes
The values are expressed as a mean percentage (n=3, s.d <6%) rise in band intensity 
(with internal control P-actin 100%) from the background levels o f expression as 
defined by the negative control.
Tissue IL-6 IL -lp TNFa
Liver 100 24 13
Lungs 1 11 0
Spleen 0 13 0
Pancreas 0 15 56
Summary o f results comparing inflammatory markers tested
For IL-ip, the tissues tested all showed a modest rise in expression as compared to the 
negative control;
For IL-6, the liver showed a rise to 100% of the housekeeping gene from the baseline 
level of 0 with no increase seen in other tissues;
For TNFa, a significant rise in TNFa expression in the pancreas and a modest rise 
(similar to rises seen with IL-1 p) can be seen in the liver.
Summary o f results comparing tissues tested
The liver showed a rise in the expression of all inflammation markers:
IL-6 » I L - ip  >TNFa;
The Lungs showed a rise in the expression of IL-1 p with the others unchanged;
The Spleen showed a rise in the expression of IL-1 p with the others unchanged;
The pancreas showed a rise in the expression of inflammation markers TNFa > IL-1 p.
Discussion
As the negative control was injected with buffer used to form the complexes, any 
change in inflammatory marker expression can be attributed to the LPD/DNA 
complexes. The most significant raise in tissue cytokine levels of those tested was 
seen by liver IL-6 following intravenous administration. IL-6 is involved in the
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stimulation of the acute phase proteins in the liver as well as B-cell differentiation 
towards antibody production and leucocyte stimulation so it would appear that an 
inflammatory response activating these processes has taken place. LPS is a classical 
stimulator of inflammation and specifically IL-6 however, its removal in the plasmid 
preparation procedure should greatly reduce its contribution to the unmunogenicity of 
the complexes. Although endotoxin levels were not assayed following plasmid 
preparation, a commercial proctocol was followed (see chapter 3 page 71) with a 
specific step to remove LPS to a negligible level. The possibility of LPS 
contamination, however small, cannot be completely ruled out. Another possibility is 
that the LPD is initiating the response. As a cationic lipid, it shares certain structural 
similarities to membrane lipids, such as long acyl chains and a polar head group, so it 
would not be unreasonable to conclude that the immune system may respond to the 
LPD complexes or uncomplexed LPD as it would to foreign (bacterial) membrane 
components. This could be determined by a purification step following complex 
formation to remove the unincorporated LPD prior to administration.
In this experiment the unmethylated CpG motifs in the plasmid DNA would be 
expected add to the complexes immunogenicity, but how significant these sequences 
are to the initiation of the immune response is unknown. Repeating the experiment 
with a plasmid treated with a specific methyl-transferase would go some way to 
determine the contribution of the immune stimulation by unmethylated CpG motifs.
The rise in all tissues of IL-lp is modest and due to the constitutive expression in the 
tissues tested may not be significant. This correlates with the results observed by 
Norman et al (Norman, Denham, Denham et al 2000) who in separate experiments 
determined that the administration of DNA or liposomes alone recapitulated the 
increase in levels as seen with DNA complexed to the liposomes.
The increase in TNFa levels seen in the pancreas indicate sterile pancreatitis and are a 
classic indication of an acute systemic immune response. The fact that the spleen did 
not show similar rises in the inflammatory markers tested indicates that the recruitment 
of macrophages and dendritic cells, both vital in T-cell mediated responses, was not 
induced at the time of testing.
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With the increasing awareness of the immune system and its role in the success or 
failure of a given gene therapy protocol, it is necessary to include some form of 
immunogenicity study to anticipate possible neutralizing effects. A study into which 
components of the lipid/DNA complex contributed to the immune response concluded 
that bacterial endotoxins were not responsible when present at levels found in the 
plasmid preparations used (Freimark, Blezinger, Florack et a l 1998). In addition the 
cell uptake of immunostimulatory oligonucleotides when complexed with Lipofectin 
has been shown to induce interferon-T 3000-fold more effectively than plasmid alone 
(Yamamoto, Yamamoto, Kataoka et al 1994). The immune responses elicited by 
LPD/DNA complexes may be due to several mechanisms and the fact that the 
complexes were not purified to remove un-complexed plasmid or LPD may be 
significant.
Virus mediated gene transfer avoids bacterial derived immunostimulatory problems by 
using eukaryotic cells to produce the mature virus containing the therapeutic gene. 
However, viruses do not entirely escape the effects of the immune system since cell- 
mediated responses are effective in the destruction of infected cells. The use of 
eukaryotic cells for the large-scale production of gene constructs is expensive and time 
consuming so ideally the use of a bacterial clone that has a similar profile of 
methylated CpG motifs to eukaryotic cell DNA would be advantageous. This creates a 
problem however since methylated DNA in the region of the gene regulatory 
sequences could silence any transcription.
The sample size included in this study was insufficient to calculate P values and give 
and indication of the statistical significance of the results. This study would benefit 
from a comprehensive sampling of tissues from a large pool of animals to provide 
sufficient data for statistical analysis. It does however provide an indication that the 
systemic administration of LPD/DNA complexes stimulates an innate immune 
response which must be considered in if this approach is being employed. Modifying 
the composition of DNA to reduce its inherent inflammatory properties or co­
administering an immunosuppressant to reduce the innate immune response are two 
potential approaches to improve tolerance.
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7.4 Summary of results
This chapter has studied the interaction of LPD/DNA complexes with components of 
the immune system, specifically complement activation and the induction of 
inflammatory responses.
All complexes activated complement, with the level of activation increasing as the 
amount of positive charge increased in the LPD component of the complexes. The 
ability of the different LPD variations to activate complement can be expressed as 
3a>lc>2a>la with lb showing reversing the trend and showing a decreased ability to 
activate complement at the higher positive charge levels.
When intravenously administered to mice in vivo, the liver showed a significant 
increase in IL-6 levels, with a modest detected increase in IL-lp or TNFa. The lung 
showed a small increase in IL-6 expression in comparison to the negative control. . 
The localised raised IL-6 levels indicate a possible inflammatory reaction to the DNA 
component of the complexes in the liver, with systemic raised IL-lp levels indicating a 
response to the circulating complexes by the innate immune system.
The LPD/DNA compared favourably to a commercial in vivo gene transfer preparation 
and this effect should be studied further to determine the extent of the immune 
response, it’s significance to the administration of gene complexes and the effect this 
may have on the host.
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Chapter 8 
Summary of Results
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Introduction
This chapter brings together the results reported in the previous chapters in a concise 
format.
Chapter 4
The purpose of these initial experiments was to look at the properties of LPD and 
complexes they form with DNA prior to introduction to cells and ultimately animal 
systems.
• The complexes are retarded with increasing LPD if DNA amount is constant is 
likely to be due to increase in positive charge rather than size.
• The addition of 10%FBS alters the morphology of the LPD/DNA complexes 
creating small homogeneous particles
• The appearance of electron dense material on the interface of the LPD and the 
endosome wall is similar to that seen in clathrin mediated endocytosis and is 
possibly a mechanism to facilitate the transfer of material across the endosomal 
membrane.
• Chloroquine does not enhance transfection efficiency of LPD/DNA complexes 
and endosome escape would not appear to be a limiting factor for LPD/DNA 
complexes.
Chapter 5
Chapter 5 reports the administration of LPD/DNA complexes to living cells to 
determine their efficacy as vectors for gene transfer. This is developed with the 
modification of the DNA by replacing the CMV promoter/enhancer with a tissue 
specific promoter. Additionally, co lipids are investigated as a means of improving 
uptake of the LPD/DNA complexes as well as targeting specific tissues using receptor 
mediated interactions.
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• The addition of 10%FBS to the transfection media reduces expression of hFIX 
Ag.
• The commercially available Optimem™ buffer appear to be most effective 
giving highest levels of expression when compared with other media and using 
FBS.
• Similar levels of expression were seen between different variations of the LPD 
at the same charge ratio (to DNA) and when incubated with mouse plasma.
• The use of the targeting lipid galactocerebroside enhanced expression.
• The tissue specific promoter/enhancer (liver) showed lower activity compared 
to the CMV regulatory sequences.
Chapter 6
Chapter 6 looks at the behaviour of the LPD/ DNA complexes when administered to 
mice using different methods, namely per-oral, sub-cutaneous and intra-venous.
• The fate of the complexes is undetermined, however a higher incidence was 
seen in the liver compared to other tissues. This could be due to 
inconsistencies in the tissue processing or physiological factors causing 
aggregation of the complexes within tissues not sampled.
• hFIX mRNA was detected in mice treated with PCR primers. On sequencing 
the forward primer positively identified human hFIX DNA, however the 
reverse primer had misprimed despite repeated attempts to resolve this.
• The LPD containing the glucose molecule modification was able to deliver a 
detectable reporter gene in GI tissue following per-oral administration.
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Chapter 7
Chapter 7 looked at the inflammatory response both in vitro and in vivo to LPD/DNA 
complexes. This was done by an assay to measure the extent that the complexes 
activate complement and an assay of significant inflammation markers present in 
tissues, namely IL-6, IL-lp and TNFa.
• All complexes activated complement in a manner which increased in 
proportion to the amount of positive charge. The ability to activate 
complement can be expressed as 3a>lc>2a>la with lb showing a decreased 
ability to activate complement at the higher positive charge levels.
• When intravenously administered to mice in vivo, the liver showed a significant 
increase in IL-6 levels, with no detected increase in IL-ip or TNFa. The lung 
showed a small increase in IL-6 expression in comparison to the negative 
control.
• Following subcutaneous administration, a small increase in IL-lp in the lung 
was seen.
• The LPD/DNA complex used compared favourably to a commercial in vivo 
gene transfer preparation which gave rise to elevated TNF a expression in liver 
following intravenous administration.
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Chapter 9 
Discussion
218
Evolution of haemophilia therapy
The treatment of haemophilia from the first plasma infusion has evolved to encompass 
more than just the correction of a bleeding disorder. Today a holistic approach to the 
disease utilises a multi-discipline team of specialists including surgeons, councillors, 
pathologists and community health workers as well as the physician to provide not 
only provide treatment of the effects of haemophilia but also to improve the quality of 
life of suffers using regimes such as home treatment and prophylaxis. From 
historically being a disease with a high mortality, it is now a disease where now it can 
be expected that most patients can live relatively normal lives with timely intervention 
from healthcare professionals. The recognition that the chronic and debilitating 
disease-related complications could be prevented and ameliorated by the infusion of 
clotting factor concentrates and maintaining a clotting factor above 1% is a major 
factor for the current quality of life experienced by sufferers.
The drive towards more effective treatment using blood products has not been without 
incidence, with emerging pathogens such as HIV, Hepatitis C and possibly 
Creutzfeldt-Jacobs disease proving devastating to the treated community before 
reactive measures were implemented to avoid contamination of therapeutic products. 
These measures included chemical or heat treatment of blood products and required 
expensive equipment to be utilised, increasing the cost of blood fractions. The cost of 
treatment spiralled with the eventual development of synthetically produced 
recombinant clotting factors, giving the guarantee of purity for clotting factors and the 
protection from future emerging pathogens. One of the effects of the inescapable 
commercialisation of the production of these high purity concentrated clotting factors, 
is the prohibitively expensive tariff imposed precluding developing countries from 
implementation of the treatment to sufferers.
The development of a gene based approach, although removing some of the inherent 
risks experienced in the development of haemophilia treatment could possibly 
introduce new issues that would need to be addressed. The use of viral vectors brings 
with them the possibility of an inhibitory immune response to the therapy similar to the 
inhibitors currently seen. The immune response to a dose escalation study of a viral 
vector resulted in the death of the patient which caused a moratorium on clinical trials
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to revise the governance of such studies. The potential of reversion to pathogenicity of 
the viral vector by recombination or by contamination of the stocks used is a real, if 
unlikely possibility.
The prospects for gene therapy
Gene therapy is regarded as a potential revolution in the treatment of inherited disease 
as it is aimed at ultimately eliminating the cause of the disease at its fundamental, 
level. The nature of disease whether viral, bacterial, spontaneous or inherited arises 
from the expression of genes. Whether the gene expressed produces a toxin or results 
in the aberrant and damaging production of an otherwise benign protein, to harness this 
activity and control it would have wide ranging implications in the treatment of 
disease.
The death of a patient receiving adenovirus in 1999 (Raper, Chirmule, Lee et al. 2003), 
a more stringent oversight of the design of gene therapy studies and a more robust 
culture of reporting adverse events has evolved. The first successful gene therapy at 
the turn of the century utilised a retrovirus based vector to treat infants with life- 
threatening X-linked severe combined immune deficiency (X-SCID) resulted in 
reconstitution of the immune system (Hacein-Bey-Abina, Von Kalle, Schmidt et al. 
2003). This success was dealt a severe blow when two of the recipients developed 
leukaemia 3 years after gene transfer due to an insertion-mutagenesis. Further research 
is being carried out on safer vectors to clearly define the interactions with host genes.
Clinical trials involving AAV for haemophilia B gene therapy are not without adverse 
events with a dose escalation study in 2002/3 resulting in 2 patients developing 
elevated liver enzymes. Also the feasibility study involving direct intramuscular 
injection of AAV serotype-2 (AAV-2) containing the hFIX gene resulted in the 
conclusion that the number of injections required was unrealistic. From this, two 
approaches have evolved utilising the muscle tissue: the continuing use of AAV-2 but 
using an intravascular administration method to transducer a wider region of muscle 
cells (Arruda, Stedman, Nichols et al. 2005) and the use of AAV serotype-1 (AAV-1) 
with a tissue specific regulator (Liu, Mingozzi, Rodriguez-Colon et al. 2004). The 
development of a systemic administration to target the liver with the same vector was
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suspended due to a transient elevation in liver enzymes observed in a patient, believed 
to be an immunological response to the transduced cells (Kaiser 2004).
Adverse events such as the transformation of the target cells to a malignant state and 
the induction of an inflam m atory response have always been identified as possible 
side-effect of the viral treatments. Viruses, although by far superior to their non-viral 
counterparts in gene transfer activity, have still not fulfilled the promise of a safe and 
effective means of gene therapy since their initial use in clinical trials over ten years 
ago. However, these vectors will undoubtedly be revised, modified and possibly used 
in conjunction with other therapies as a combined regime to achieve the desired effect. 
It may be some time before synthetic carrier gene transfer achieves the same level of 
success observed in these clinical trials.
Lipidic pedtide dendrimers as potential agents for gene 
therapy
LPD were originally developed as a potential drug carrier to encapsulated a variety of 
compounds for delivery to the target tissue (Toth 1994). The modification of these 
compounds to condense DNA for delivery to the cell nucleus followed along with a 
possible application for gene therapy. This thesis looked at the properties likely to 
determine whether LPD are a viable prospect for the delivery of a FIX gene to correct 
a deficiency in the coagulation factor IX, essential to normal blood clotting.
Chapter 4 describes the investigations into the properties of LPD/DNA complexes 
prior to their addition to cells or other living tissue. The complexes gradually exclude 
EthBr from intercalating with the DNA as the concentration of LPD increases relative 
to the DNA. The LPD protects the DNA in this respect and the complexes may benefit 
from a high positive to negative charge ratio when being formed. EM visualisation of 
the complexes formed in different media showed that FBS alters the morphology of 
LPD/DNA complexes formed in a saline/hydrogencarbonate and EMEM. These 
changes do not appear to occur when the complexes were formed in Optimem®. This 
may adversely affect the ability of the complexes to transfer genes to cultured cells in 
the presence of serum or tissues in vivo. The visualisation of the complexes in situ 
following transfection of showed the complexes interact with the endosome membrane
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and possible facilitate their own transition to the cytoplasm, enabling DNA delivery to 
the nucleus.
Essentially these studies elucidated the complexes interactions with EthBr, serum and 
intracellular transport mechanisms. Although the complexes appear to protect DNA 
and enable it’s delivery to the nucleus, the reduction in activity by serum components 
may be revealed be a substantial obstacle.
Chapter 5 reported on the transfection of different cell lines using a reporter gene and a 
hFIX construct. The LPD la variation (8 amino terminals with no modification) 
performed better in some instances than a commercial transfection reagent 
Lipofectamine™. The question of serum inactivation raised in Chapter 4 was 
confirmed to some extent, as the amount of gene product detected was lower when 
cells were transfected in the presence of serum. LPD/DNA complexes can transfect 
cell types that are actively dividing but cannot transfect terminally differentiated 
myotubes, which would exclude direct injection of complexes to tissues such as 
muscle. To further investigate the observation of LPD/DNA complexes interacting 
with the endosome membrane in Chapter 3, it was shown using a lysomotropic agent, 
that endosome escape is not a limiting factor in the mechanism by which LPD/DNA 
complexes deliver the transgene to the cell nucleus.
The addition of a cell-specific targeting co-lipid selectively improved the levels of 
transgene expression in the target cell type. However it was not determined whether 
this was due to increased uptake by a constant number of cells or the fact that more 
cells were taking up the complexes and expressing the gene.
These experiments provided a proof of principle that LPD/DNA complexes can deliver 
a hFIX gene to cells which produce a functional hFIX protein. The experiments 
revealed the deficiencies in the complexes characteristics as potential agents for gene 
therapy, namely the inability to transfect quiescent cells and the reduction in activity in 
the presence of serum.
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Chapter 6 described experiments where the complexes were administered to mice by 
tail vein injection or per-orally. A tissue distribution study showed only low amounts 
of labelled LDP/DNA complexes being detected in the major tissues for both methods 
of administration. Also disappointing was the absence of any detectable hFIX Ag in 
the tissues tested, although the limitations of the detection method used may have been 
factor. The detection of reporter gene activity in gastro-intestinal epithelia following 
oral delivery of glucose-modified LPD/DNA complexes is an exciting prospect. This 
development provides justification for further study in this particular area of gene 
delivery.
Chapter 7 investigated immune responses to LPD/DNA complexes in the form of 
complement activation and inflammation in various tissues following systemic 
administration. All complexes tested activated complement at levels which increased 
in line with the net positive charge of the complexes with one exception. This 
supported the hypothesis that serum components were interacting with the complexes 
and identified the complement system as being responsible.
In testing for markers indicating inflammation, raised IL-6 levels in the liver of mice 
indicated a possible inflammatory reaction to the DNA component of the complexes. 
Elevated systemic IL-ip levels indicated a response to the circulating complexes by 
the innate immune system and clearing them from the circulation.
Appraisal
LPD have shown to be effective in delivering a functional hFIX gene in vitro for it to 
be expressed to produce a functional protein and they exhibit low toxicity to cells at 
working concentrations. They can be combined with targeting lipids to deliver to 
increase uptake by a specific cell type and when administered per-orally can deliver a 
reporter gene that is expressed in the gut epithelia. This last observation can be 
feasibly developed and may produce some exciting prospects for LPD.
These results are comparable to previously described non-viral gene transfer 
technologies, but overall LPD show lower activity than published studies of similar 
agents such as PEG-ylated liposomes (Allen, Hansen, Martin et al. 1991); cholesterol
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containing lipids (Crook, Stevenson, Dubouchet et al. 1998); targeted liposomes 
(Bandyopadhyay, Kren, Ma et al 1998) and polymers (Haensler and Szoka 1993). 
The lack of a significant development in this area of gene therapy indicates non viral 
vectors have a restricted application in the search for an effective treatment of genetic 
disorders.
Specific deficiencies in the performance of LPD include the inability to transfect non­
dividing cells. This restricts their activity to cells that are actively dividing and raises 
difficulties in the delivery of the complexes to these tissues. They are adversely 
affected by serum components and are rapidly cleared from the circulation when 
administered systemically with no evidence of successful gene transfer. LPD/DAN 
complexes activate the complement system and produce a systemic inflammatory 
response following intra-venous administration. It could be argued that in their present 
form, LPD/DNA complexes are ineffective for systemic gene delivery.
For all studies except the in vivo administrations, LPD la  performed consistently better 
than the others tested both in terms of activity in vitro and immune response 
evaluation. Dendrimer 3a (which is the structural equivalent to la  with a glucose 
molecule added (see Chapter 1 page 53) so it can be concluded that the smaller lysine 
head-group (8 terminal amino groups) is favourable in these studies. It is possible that 
further modifications of the LPD la  could be advantageous however, it is unlikely the 
other variations will posses all of the favourable characteristics to be worthwhile 
pursuing. However, as with all new developments, only after the comprehensive 
testing of all variables can decisive conclusions be drawn.
LPD/DNA complexes have substantial deficiencies in many areas surrounding a 
successful agent for gene therapy. Although moderately successful for in vitro 
applications, they are not suitable for systemic in vivo protocols in their present form. 
There is possibly only one application that warrants further investigation which is the 
glucose modified LPD/DNA complex for oral delivery. This method of administration 
by-passes the inhibitive interactions observed when LPD/DNA complexes were 
introduced to the circulation and as a result may prove productive.
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A number of areas of possible study have not been covered in this thesis and many 
questions still exist concerning the efficiency of LPD. The properties of the complexes 
following structural modification or the combining with co-factors have only been 
briefly examined and require a more comprehensive investigation. A lack of 
availability and the scale of synthesis of LPD resulted in sporadic experiments giving 
rise to discrepancies in the reproducibility in the results. A number of experiments 
were performed prematurely due to patent application requirements and in hindsight 
appear to be disparate. The study would have also benefited from an experienced 
project leader to coordinate efforts with the collaborators to ensure that they are 
towards a common goal.
The use of more appropriate labels and detection methods is a particular area needing 
revision if embarking on a similar exercise again. The inclusion of controls are also 
lacking in some experiments, reducing the information that can be obtained from the 
study.
Implications of this study for gene therapy
Although preliminary in respect to proposing an alternative treatment for haemophilia 
B, the fundamental questions have been answered. LPD are easily synthesised, can 
deliver a gene intact to tissues when delivered per-orally, where it can be expressed 
and produce a functional product. Although not apparently toxic, they initiate an 
immune response resulting in the production of inflammatory cytokines which would 
be unacceptable in a clinical environment. The investigation of oral delivery as a 
method of administration could offer an alternative approach which could circumvent 
this potentially disastrous issue. The only possible application that can be foreseen, 
where LPD and indeed most non viral vectors may be clinically effective is in the ex 
vivo transduction of stem cells. As the cells will expand to produce clones containing 
the transgene on administration, the need for highly efficient, tissue-wide gene transfer 
of a large number of cells is removed. This method also allows for the careful control 
of conditions surrounding the gene transfer process, which appear to be prohibitive in 
systemic delivery of the LDP/DNA complexes.
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Future work
The results seen in this study provide the basis on which a focused investigation into 
the use of LPD/DNA complexes for the gene therapy of haemophilia B. The 
modification of the LPD molecule and selection of the most suitable for a particular 
application is central to developing this approach to gene therapy. The versatility of 
the compounds and their ability to incorporate modifiers such as targeting co-lipids or 
stabilisers, offers numerous directions with which to improve their efficacy. Particular 
areas identified in this thesis for the use of LPD include the oral delivery of glucose 
modified variations and the successful targeting to a specific tissue. It will require a 
substantial amount of resources to perform the comprehensive study of all variables 
needed to ultimately determine the potential of LPD as agents for the gene therapy of 
haemophilia B.
Conclusion
LPD/DNA complexes are one of many preparations of non-viral preparations that are 
being tested for gene therapy applications. In comparison to the current non-viral and 
viral vectors, they are inferior in a comparison of efficacy. There are many methods 
currently being developed for gene transfer that are more effective and have greater 
potential. Although LPD may have a possible application in the oral delivery of genes, 
much more work is needed to ascertain if this is a feasible prospect. The leading 
clinical trials for the treatment of Haemophilia B have all used viral vectors (which are 
also constantly being improved) and this is likely to remain the case for the foreseeable 
future.
The work described in this thesis contributed to the following publications (See 
Appendix A. N.B. S.T.P Pharma Sciences publication not included).
Bayele, H. K., T. Sakthivel, M. O’Donell, K. J. Pasi, A. F. Wilderspin, C. A. Lee, I. 
Toth and A. T. Florence (2005). "Versatile peptide dendrimers for nucleic acid 
delivery." J Pharm Sci 94(2): 446-57.
Toth, I., T. Sakthivel, A. F. Wilderspin, H. Bayele, M. O'Donnell, D. J. Perry, K. J.
Pasi, C. A. Lee and A. T. Florence (1999). "Novel cationic lipidic peptide 
dendrimer vectors in vitro gene d e liv e ry S.T.P Pharma Sciences 9(1): 93-9.
226
Appendix A
227
Bibliography
Abshire, T. C., H. H. Brackmann, I. Scharrer, K. Hoots, C. Gazengel, J. S. Powell, E. 
Gorina, E. Kellermann and E. Vosburgh (2000). "Sucrose formulated 
recombinant human antihemophilic factor VIII is safe and efficacious for 
treatment of hemophilia A in home therapy—International Kogenate-FS Study 
Group." Thrombosis Haemostasis 83(6): 811-6.
Adam, S. A. and L. Gerace (1991). "Cytosolic proteins that specifically bind nuclear 
location signals are receptors for nuclear import." Cell 66(5): 837-47.
Addis, T. (1911). "The pathogenesis of hereditary haemophilia." Journal of Pathology 
15: 427-452.
Agarwala, K. L., S. Kawabata, T. Takao, H. Murata, Y. Shimonishi, H. Nishimura and 
S. Iwanaga (1994). "Activation peptide of human factor IX has oligosaccharides 
O-glycosidically linked to threonine residues at 159 and 169." Biochemistry 
33(17): 5167-71.
Aggeler, P. M , et al (1952). "Plasma Thromboplastin Component (PTC) Deficiency: 
A New Disease Resembling Haemophilia." Proc. Soc. Expr. Biol. Med. 79: 692.
Allen, T. M., C. Hansen, F. Martin, C. Redemann and A. Yau-Young (1991).
"Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show 
prolonged circulation half-lives in vivo." Biochim Biophys Acta 1066(1): 29-36.
Alton, E. W., P. G. Middleton, N. J. Caplen, S. N. Smith, D. M. Steel, F. M.
Munkonge, P. K. Jeffery, D. M. Geddes, S. L. Hart, R. Williamson and et al. 
(1993). "Non-invasive liposome-mediated gene delivery can correct the ion 
transport defect in cystic fibrosis mutant mice." Nature Genetics 5(2): 135-42.
Alton, E. W., M. Stem, R. Farley, A. Jaffe, S. L. Chadwick, J. Phillips, J. Davies, S. N. 
Smith, J. Browning, M. G. Davies, M. E. Hodson, S. R. Durham, D. Li, P. K. 
Jeffery, M. Scallan, R. Balfour, S. J. Eastman, S. H. Cheng, A. E. Smith, D. 
Meeker and D. M. Geddes (1999). "Cationic lipid-mediated CFTR gene transfer
228
to the lungs and nose of patients with cystic fibrosis: a double-blind placebo- 
controlled trial." Lancet 353(9157): 947-54.
Anson, D. S., K. H. Choo, D. J. Rees, F. Giannelli, K. Gould, J. A. Huddleston and G.
G. Brownlee (1984). "The gene structure of human anti-haemophilic factor IX." 
Embo J 3(5): 1053-60.
Anson, J. P., Austen, D. E. G. and Brownlee, G. G. (1985). "Expression of active 
human clotting factor IX from recombinant DNA clones in mammalian cells." 
Nature 315: 683-685.
Arruda, V. R., H. H. Stedman, T. C. Nichols, M. E. Haskins, M. Nicholson, R. W.
Herzog, L. B. Couto and K. A. High (2005). "Regional intravascular delivery of 
AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in 
a large animal model." Blood 105(9): 3458-64.
Axelrod, J. H. e. a. (1990). "Phenotypic correction of factor IX deficiency in skin 
fibroblasts of haemophilic dogs." Proceedings of the National Academy of 
Sciences 87: 5173-5177.
Baier, W., M. Loleit, B. Fischer, G. Jung, U. Neumann, M. Weiss, J. Weckesser, P. 
Hoffmann, W. G. Bessler and K. Mittenbuhler (2000). "Generation of antibodies 
directed against the low-immunogenic peptide-toxins microcystin-LR/RR and 
nodularin." Int J Immunopharmacol 22(5): 339-53.
Bandyopadhyay, P., B. T. Kren, X. Ma and C. J. Steer (1998). "Enhanced gene transfer 
into HuH-7 cells and primary rat hepatocytes using targeted liposomes and 
polyethylenimine." Biotechniques 25(2): 282-4, 286-92.
Baumgartner, I., A. Pieczek, O. Manor, R. Blair, M. Kearney, K. Walsh and J. M.
Isner (1998). "Constitutive expression of phVEGF165 after intramuscular gene 
transfer promotes collateral vessel development in patients with critical limb 
ischemia." Circulation 97(12): 1114-23.
Bayele, H. K., T. Sakthivel, M. O’Donell, K. J. Pasi, A. F. Wilderspin, C. A. Lee, I. 
Toth and A. T. Florence (2005). "Versatile peptide dendrimers for nucleic acid 
delivery." J Pharm Sci 94(2): 446-57.
229
Behr, J. P., B. Demeneix, J. P. Loeffler and J. Perez-Mutul (1989). "Efficient gene 
transfer into mammalian primary endocrine cells with lipopolyamine-coated 
DNA." Proceedings of the National Academy of Sciences USA 86(18): 6982-6.
Bendien, W. M. a. v. C., S. (1935). "Investigations of Haemophilia." Acta brevia 
Neerlandica de physiologia, pharmacologia, microbiologia e.a.. 5: 135-138.
Bennett, A. E., G. I. Ingram and P. J. Inglish (1973). "Antifibrinolytic treatment in 
haemophilia: a controlled trial of prophylaxis with tranexamic acid." Br J 
Haematol 24(1): 83-8.
Biggs, R. e. a. (1952). "Christmas disease: a condition previously mistaken for 
haemophilia." British Medical Journal 2: 1378.
Bilbao, G., J. Gomez-Navarro and D. T. Curiel (1998). "Targeted adenoviral vectors 
for cancer gene therapy." Advances in Experimental Medicine and Biology 451: 
365-74.
Blaese, M., T. Blankenstein, M. Brenner, O. Cohen-Haguenauer, B. Gansbacher, S. 
Russell, B. Sorrentino and T. Velu (1995). "Vectors in cancer therapy: how will 
they deliver?" Cancer Gene Ther 2(4): 291-7.
Blagden, R. (1817). "Case of a fatal heamorrhage from the extraction of a tooth." 
Medico-Chirurgical Transactions 8 : 224-227.
Blatrix, C. a. S., J. P. (1959). "Preparation d'une fraction riche en
prothrombine,proconvertine, facteur Stuart et facteur antihaemophilique B 
(fraction P.P.B.)." Pathologie et Biologie (Paris) 7: 2477-2468.
Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein and W. Schaffher 
(1985). "A very strong enhancer is located upstream of an immediate early gene 
of human cytomegalovirus." Cell 41(2): 521-30.
Boukhnikachvili, T., O. Aguerre-Chariol, M. Airiau, S. Lesieur, M. Ollivon and J. 
Vacus (1997). "Structure of in-serum transfecting DNA-cationic lipid 
complexes." FEBS Letters 409(2): 188-94.
230
Boussif, O., F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix 
and J. P. Behr (1995). "A versatile vector for gene and oligonucleotide transfer 
into cells in culture and in vivo: polyethylenimine." Proceedings of the National 
Academy of Sciences USA 92(16): 7297-301.
Bray, G. L., E. D. Gomperts, S. Courter, E. M. Gordon, M. Manco-Johnson and A. e. 
a. Shapiro (1994). "A multicenter study of recombinant factor VIII 
(Recombinate): safety, efficacy, and inhibitor risk in previously untreated 
patients with haemophilia.” Blood 83: 2428-2435.
Brinkhous, K. M. (1954). "Plasma antihaemophilic factor; biological and clinical 
aspects." Sang. 25: 738.
Brinkhous, K. M. (1975). A Short History of Haemophilia. New York, American 
Elsevier.
Brunner, S., T. Sauer, S. Carotta, M. Cotten, M. Saltik and E. Wagner (2000). "Cell 
cycle dependence of gene transfer by lipoplex, polyplex and recombinant 
adenovirus." Gene Therapy 7: 401-407.
Budker, V., G. Zhang, S. Knechtle and J. A. Wolff (1996). "Naked DNA delivered 
intraportally expresses efficiently in hepatocytes." Gene Therapy 3(7): 593-8.
Canonico, A. E., J. D. Plitman, J. T. Conary, B. O. Meyrick and K. L. Brigham (1994). 
"No lung toxicity after repeated aerosol or intravenous delivery of plasmid- 
cationic liposome complexes." J Appl Physiol 77(1): 415-9.
Chance, P. F., K. A. Dyer, K. Kurachi, S. Yoshitake, H. H. Ropers, P. Wieacker and S. 
M. Gartler (1983). "Regional localization of the human factor IX gene by 
molecular hybridization." Human Genetics 65(2): 207-8.
Chillon, M., J. H. Lee, A. Fasbender and M. J. Welsh (1998). "Adenovirus complexed 
with polyethylene glycol and cationic lipid is shielded from neutralizing 
antibodies in vitro." Gene Therapy 5(7): 995-1002.
231
Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian and J. Wilson (1999).
"Immune responses to adenovirus and adeno-associated virus in humans." Gene 
Therapy 6(9): 1574-83.
Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian and J. Wilson (1999).
"Immune responses to adenovirus and adeno-associated virus in humans." Gene 
Ther 6(9): 1574-83.
Chonn, A., P. R. Cullis and D. V. Devine (1991). "The role of surface charge in the
acivation of the classical and alternative pathways of complement by liposomes." 
Journal of Immunology 146: 4234-4241.
Choo, K. H., K. G. Gould, D. J. Rees and G. G. Brownlee (1982). "Molecular cloning 
of the gene for human anti-haemophilic factor IX." Nature 299(5879): 178-80.
Colin, M., R. P. Harbottle, A. Knight, M. Komprobst, R. G. Cooper, A. D. Miller, G. 
Trugnan, J. Capeau, C. Coutelle and M. C. Brahimi-Hom (1998). "Liposomes 
enhance delivery and expression of an RGD-oligolysine gene transfer vector in 
human tracheal cells." Gene Ther 5(11): 1488-98.
Cotten, M., A. Baker, M. Saltik, E. Wagner and M. Buschle (1994).
"Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and 
can be toxic to primary human cells in the presence od adenovirus." Gene 
Therapy 1: 239-246.
Crook, K., B. J. Stevenson, M. Dubouchet and D. J. Porteous (1998). "Inclusion of 
cholesterol in DOTAP transfection complexes increases the delivery of DNA to 
cells in vitro in the presence of serum." Gene Therapy 5: 137-143.
Crossley, M., M. Ludwig, K. M. Stowell, P. De Vos, K. Olek and G. G. Brownlee 
(1992). "Recovery from hemophilia B Leyden: an androgen-responsive element 
in the factor IX promoter." Science 257(5068): 377-9.
Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetnick and I. M. Verma (1995). 
"Cellular and humoral immune responses to adenoviral vectors containing factor 
IX gene: tolerization of factor IX and vector antigens allows for long-term
232
expression." Proceedings of the National Academy of Sciences USA 92(5): 
1401-5.
Das, S. and R. P. Rand (1986). "Modification by diacylglycerol of the structure and 
interaction of various phospholipid bilayer membranes." Biochemistry 25(10): 
2882-9.
de la Salle, H., Attenburger, W., Elkiam, R. et al. (1985). "Active gamma-carboxylated 
human factor IX expressed using recombinant DNA techniques." Nature 316: 
268-273.
Didisheim, P., Loeb, J. Blatrix, C. and Soulier, J. P. (1959). "Preparation of a human 
plasma fraction rich in prothrombin, proconvertin, Stuart factor and PTC and a 
study of its activity and toxicity in rabbits and man." Journal of Laboratory 
Clinical Medicine 53: 322.
Duguid, J. G., C. Li, M. Shi, M. J. Logan, H. Alila, A. Rolland, E. Tomlinson, J. T.
Sparrow and L. C. Smith (1998). "A physicochemical approach for predicting the 
effectiveness of peptide-based gene delivery systems for use in plasmid-based 
gene therapy." Biophysics Journal 74(6): 2802-14.
Duncan, R., M. K. Pratten, H. C. Cable, H. Ringsdorf and J. B. Lloyd (1981). "Effect 
of molecular size of 1251-labelled poly(vinylpyrrolidone) on its pinocytosis by 
rat visceral yolk sacs and rat peritoneal macrophages." Biochem J 196(1): 49-55.
During, M. J., R. Xu, D. Young, M. G. Kaplitt, R. S. Sherwin and P. Leone (1998). 
"Peroral gene therapy of lactose intolerance using an adeno-associated virus 
vector." Nature Medicine 4(10): 1131-5.
Duzgunes, N., J. A. Goldstein, D. S. Friend and P. L. Feigner (1989). "Fusion of
liposomes containing a novel cationic lipid, N-[2,3-(dioleyloxy)propyl]-N,N,N- 
trimethylammonium: induction by multivalent anions and asymmetric fusion 
with acidic phospholipid vesicles." Biochemistry 28(23): 9179-84.
Editorial (2000). "Gene therapy—a loss of innocence." Nat Med 6(1): 1.
(Editorial) (2000). "Gene therapy—a loss of innocence." Nat Med 6(1): 1.
233
Ekert, H., M. Moorehead and G. Williamson (1981). "Home treatment of haemophilia. 
A follow-up study.” Med J Aust 2(1): 21-3.
Escriou, V., C. Ciolina, F. Lacroix, G. Byk, D. Scherman and P. Wils (1998).
"Cationic lipid-mediated gene transfer: effect of serum on cellular uptake and 
intracellular fate of lipopolyamine/DNA complexes.” Biochim Biophys Acta 
1368(2): 276-88.
Eyster, M. E., F. M. Gill, P. M. Blatt, M. W. Hilgartner, J. O. Ballard and T. R. Kinney 
(1978). "Central nervous system bleeding in hemophiliacs." Blood 51(6): 1179- 
88 .
Fakharzadeh, S. S., Y. Zhang, R. Sarkar and H. H. Kazazian (2000). "Correction of the 
coagulation defect in Haemophilia A mice through factor VIII expression in 
skin." Blood 95(9): 2799-2804.
Farhood, H., N. Serbina and L. Huang (1995). "The role of dioleoyl
phosphatidylethanolamine in cationic liposome mediated gene transfer." Biochim 
Biophys Acta 1235(2): 289-95.
Feissly, R. (1923). "Etudes sur l'haemophilia." Bulletin et memoires de la Societe de 
Medicine de Paris 47: 1778-1783.
Feigner, P. L. (1997). "Nonviral strategies for gene therapy." Scientific America 
276(6): 102-6.
Feigner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. 
Northrop, G. M. Ringold and M. Danielsen (1987). "Lipofection: a highly 
efficient, lipid-mediated DNA-transfection procedure." Proceedings of the 
National Academy of Sciences USA 84(21): 7413-7.
Fields, P. A., D. W. Kowalczyk, V. R. Arruda, E. Armstrong, M. L. McCleland, J. N. 
Hagstrom, K. J. Pasi, H. C. Ertl, R. W. Herzog and K. A. High (2000). "Role of 
vector in activation of T cell subsets in immune responses against the secreted 
transgene product factor IX." Molecular Therapy 1(3): 225-35.
234
Florence, A. T., T. Sakthivel and I. Toth (2000). "Oral uptake and translocation of a 
polylysine dendrimer with a lipid surface." Journal of Control Release 65(1-2): 
253-9.
Fraley, R., S. Subramani, P. Berg and D. Papahadjopoulos (1980). "Introduction of 
liposome-encapsulated SV40 DNA into cells." J Biol Chem 255(21): 10431-5.
Frechet, J. M. J. and C. J. Hawker (1996). Synthesis and properties of dendrimers and 
hyperbranched polymers. Comprehensive Polymer Science (Suppl. 2). S. L. 
Aggarwal and S. Russo, Pergamon: 71-132.
Freimark, B. D., H. P. Blezinger, V. J. Florack, J. L. Nordstrom, S. D. Long, D. S. 
Deshpande, S. Nochumson and K. L. Petrak (1998). "Cationic lipids enhance 
cytokine and cell influx levels in the lung following administration of plasmid: 
cationic lipid complexes." Journal of Immunology 160(9): 4580-6.
Gershenwald, J. E., Y. M. Fong, T. J. Fahey, 3rd, S. E. Calvano, R. Chizzonite, P. L. 
Kilian, S. F. Lowry and L. L. Moldawer (1990). "Interleukin 1 receptor blockade 
attenuates the host inflammatory response." Proc Natl Acad Sci U S A  87(13): 
4966-70.
Gershon, H., R. Ghirlando, S. B. Guttman and A. Minsky (1993). "Mode of formation 
and structural features of DNA-cationic liposome complexes used for 
transfection." Biochemistry 32(28): 7143-51.
Glader, B. (1999). A Phase I Safety Study in Patients with Severe Hemophilia B 
(Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the 
Gene for Human Factor IX into the Liver. Stanford, California, Stanford 
University.
Gorlich, D. and I. W. Mattaj (1996). "Nucleocytoplasmic transport." Science 
271(5255): 1513-8.
Gottschalk, S., J. T. Sparrow, J. Hauer, M. P. Mims, F. E. Leland, S. L. Woo and L. C. 
Smith (1996). "A novel DNA-peptide complex for efficient gene transfer and 
expression in mammalian cells." Gene Therapy 3(5): 48-57.
235
Graham, F. L. and A. J. van der Eb (1973). "A new technique for the assay of 
infectivity of human adenovirus 5 DNA." Virology 52(2): 456-67.
Grandidier, L. (1855). Die Hamophilie oder die Bluterkrankheit nach eigenen und 
ffemden Biobachtungen monographisch bearbeitet. Leipzig, O. Wigand.
Gregoriadis, G. and A. C. Allison (1974). "Entrapment of proteins in liposomes
prevents allergic reactions in pre-immunised mice." FEBS Letters 45(1): 71-4.
Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. 
Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. 
Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst,
T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. 
Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, 
M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer and M. Cavazzana- 
Calvo (2003). "LM02-associated clonal T cell proliferation in two patients after 
gene therapy for SCID-X1." Science 302(5644): 415-9.
Haensler, J. and F. C. Szoka, Jr. (1993). "Polyamidoamine cascade polymers mediate 
efficient transfection of cells in culture." Bioconiugate Chemistry 4(5): 372-9.
Hagstrom, J. N., L. B. Couto, C. Scallan, M. Burton, M. L. McCleland, P. A. Fields, V. 
R. Arruda, R. W. Herzog and K. A. High (2000). "Improved muscle-derived 
expression of human coagulation factor IX from a skeletal actin/CMV hybrid 
enhancer/promoter." Blood 95(8): 2536-42.
Hart, S. L., R. P. Harbottle, R. Cooper, A. Miller, R. Williamson and C. Coutelle
(1995). "Gene delivery and expression mediated by an integrin-binding peptide." 
Gene Ther 2(8): 552-4.
Hay, C. R. (2002). "The 2000 United Kingdom Haemophilia Centre Doctors’
Organisation (UKHCDO) inhibitor guidelines." Pathophvsiol Haemost Thromb 
32 S upp ll: 19-21.
Hayashi, Y., Y. Mori, O. E. Janssen, T. Sunthomthepvarakul, R. E. Weiss, K. Takeda, 
M. Weinberg, H. Seo, G. I. Bell and S. Refetoff (1993). "Human thyroxine-
236
binding globulin gene: complete sequence and transcriptional regulation." Mol 
Endocrinol 7(8): 1049-60.
Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. 
Hoshino, H. Wagner, K. Takeda and S. Akira (2000). "A Toll-like receptor 
recognizes bacterial DNA." Nature 408(6813): 740-5.
Hermanson, G., V. Whitlow, S. Parker, K. Tonsky, D. Rusalov, M. Ferrari, P. Lalor,
M. Komai, R. Mere, M. Bell, K. Brenneman, A. Mateczun, T. Evans, D. Kaslow, 
D. Galloway and P. Hobart (2004). "A cationic lipid-formulated plasmid DNA 
vaccine confers sustained antibody-mediated protection against aerosolized 
anthrax spores." Proc Natl Acad Sci U S A  101(37): 13601-6.
Herzog, R. W., J. N. Hagstrom, S.-H. Kung, S. J. Tai, J. Wilson, K. J. Fisher and K. A. 
High (1997). "Stable gene transfer and expression of human blood coagulation 
factor IX after intramuscular injection of recombinant adeno-associated virus." 
Proceedings of the National Academy of Sciences 94: 5804-5809.
Herzog, R. W., E. Y. Yang, L. B. Couto, J. N. Hagstrom, D. Elwell, P. A. Fields, M. 
Burton, D. A. Bellinger, M. S. Read, K. M. Brinkhous, G. M. Podsakoff, T. C. 
Nichols, G. J. Kurtzman and K. A. High (1999). "Long-term correction of canine 
hemophilia B by gene transfer of blood coagulation factor IX mediated by 
adeno-associated viral vector." Nat Med 5(1): 56-63.
Hiemenz, P. C. (1986). Principles of colloidal and surface chemistry. New York, 
Marcel Dekker Inc.
Hollon, T. (2000). "Researchers and regulators reflect on first gene therapy death." Nat 
Med 6(1): 6 .
Hollon, T. and F. K. Yoshimura (1989). "Variation in enzymatic transient gene 
expression assays." Anal Biochem 182(2): 411-8.
Hortelano, G., A. Al-Hendy, F. A. Ofosu and P. L. Chang (1996). "Delivery of human 
factor IX in mice by encapsulated recombinant myoblasts: a novel approach 
towards allogeneic gene therapy of hemophilia B." Blood 87(12): 5095-103.
237
Hsueh, J. L. (1992). "Clinical protocol of human gene transfer for hemophilia B." Hum 
Gene Ther 3(5): 543-52.
Huszar, T., I. Mucsi, T. Terebessy, A. Masszi, S. Adamko, C. Jeney and L. Rosivall 
(2001). "The use of a second reporter plasmid as an internal standard to 
normalize luciferase activity in transient transfection experiments may lead to a 
systematic error." J Biotechnol 88(3): 251-8.
Ilan, Y., R. Prakash, A. Davidson, Jona, G. Droguett, M. S. Horwitz, N. R. Chowdhury 
and J. R. Chowdhury (1997). "Oral tolerization to adenoviral antigens permits 
long-term gene expression using recombinant adenoviral vectors." Journal of 
Clinical Investigation 99(5): 1098-106.
Ill, C. R., C. Q. Yang, S. M. Bidlingmaier, J. N. Gonzales, D. S. Bums, R. M.
Bartholomew and P. Scuderi (1997). "Optimization of the human factor VIII 
complementary DNA expression plasmid for gene therapy of haemophilia A." 
Blood Coagulation and Fibrinolysis 8 ((supplement 2)): S23-S30.
Ingram, G. I., P. J. Inglish and A. E. Bennett (1972). "Tranexamic acid for prophylaxis 
in haemophilia." J Clin Pathol 25(7): 629.
Israelachvili, J. N., D. J. Mitchell and B. W. Ninham (1977). "Theory of self-assembly 
of lipid bilayers and vesicles." Biochim Biophvs Acta 470(2): 185-201.
Jesty, J. and S. A. Morrison (1983). "The activation of Factor IX by tissue factor-
Factor VII in a bovine plasma system lacking Factor X." Thrombosis Resesearch 
32(2): 171-81.
Kabat, E. A. and M. M. Mayer (1961). Experimental Immunochemistry. Springfield, 
IL. USA., Charles C. Thomas.
Kaiser, J. (2004). "Side Effects Sideline Hemophilia Trial." Science 304: 1424-5.
Kaneda, Y., K. Iwai and T. Uchida (1989). "Increased expression of DNA
cointroduced with nuclear protein in adult rat liver." Science 243(4889): 375-8.
238
Kasper, C. K., Lusher J. M. and Transfusion Practices Committe (1993). "Recent 
evolution of clotting factor concentrates fot haemphilia A and B." Transfusion 
33: 422-434.
Kaufman, R. J. (1998). "Post-translational modifications required for coagulation 
factor secretion and function." Thrombosis and Haemostasis 79: 1068-1079.
Kay, M. A., et al (2000). "Evidence for gene transfer and expression of factor IX in 
haemophilia B patients treated with an AAV vector." Nature Genetics 24: 257- 
261.
Kekwick, R. A. and P. Wolf (1957). "A concentrate of human antihaemophilic factor - 
its use in six cases of haemophilia." Lancet I: 647-650.
Kim, H. C., C. W. McMillan, G. C. White, G. E. Bergman, M. W. Horton and P. Saidi 
(1992). "Purified factor IX using monoclonal immunoaffinity technique: clinical 
trials in hemophilia B and comparison to prothrombin complex concentrates." 
Blood 79(3): 568-75.
Klasse, P. J., R. Bron and M. Marsh (1998). "Mechanisms of enveloped virus entry 
into animal cells." Advances in Drug Delivery Review 34(1): 65-91.
Klein, R. M., E. D. Wolf, R. Wu and J. C. Sanford (1992). "High-velocity 
microprojectiles for delivering nucleic acids into living cells. 1987." 
Biotechnology 24: 384-6.
Klerx, J. P. A. M., C. J. Beukelman, H. Van Dijk and J. M. N. Willers (1983).
"Microassay for Colormetric Estimation of Complement Activity in Guinea Pig, 
Human and Mouse Serum." Journal of Immunological Methods 63: 215-220.
Klibanov, A. L., K. Maruyama, V. P. Torchilin and L. Huang (1990). "Amphipathic 
polyethyleneglycols effectively prolong the circulation time of liposomes."
FEBS Letters 268(1): 235-7.
Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover and A. M. Krieg (1996). "CpG 
motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin
239
6 , interleukin 12, and interferon gamma.” Proceedings of the National Academy 
of Sciences USA 93(7): 2879-83.
Kohler, M. (1999). ’’Thrombogenicity of prothrombin complex concentrates.” Thromb 
Res 95(4 Suppl 1): S I3-7.
Koller, F., Krusi, G. and Luchsinger, G. (1950). "Uber eine besondre Form
hamorrhagischer Diathese.” Schweizerische medizinische Wochenschrift 80: 
1101-1103.
Kondoh, H., K. Yasuda and T. S. Okada (1983). "Tissue-specific expression of a 
cloned chick delta-crystallin gene in mouse cells.” Nature 301(5899): 440-2.
Kozak, M. (1986). "Point mutations define a sequence flanking the AUG initiator 
codon that modulates translation by eukaryotic ribosomes.” Cell 44: 283-292.
Krieg, A. M. (1996). "An innate immune defense mechanism based on the recognition 
of CpG motifs in microbial DNA.” Journal of Laboratory Clinical Medicine 
128(2): 128-33.
Krieg, A. M. (2000). "Immune effects and mechanisms of action of CpG motifs." 
Vaccine 19(6): 618-22.
Krieg, A. M. (2002). "CpG motifs in bacterial DNA and their immune effects." Annual 
Review of Immunology 20: 709-60.
Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G.
A. Koretzky and D. M. Klinman (1995). "CpG motifs in bacterial DNA trigger 
direct B-cell activation." Nature 374(6522): 546-9.
Kurachi, S., Y. Hitomi, M. Furukawa and K. Kurachi (1995). "Role of intron I in 
expression of the human factor IX gene." Journal of Biological Chemistry 
270(10): 5276-81.
Labat-Moleur, F., A. M. Steffan, C. Brisson, H. Perron, O. Feugeas, P. Furstenberger, 
F. Oberling, E. Brambilla and J. P. Behr (1996). "An electron microscopy study 
into the mechanism of gene transfer with lipopolyamines." Gene Therapy 3(11): 
1010-7.
240
Lane, S. (1840). "Successful transfusion of blood." Lancet 1: 185-188.
Ledley, F. D. (1996). "Pharmaceutical approach to somatic gene therapy." Pharm Res 
13(11): 1595-614.
Lee, S. C., R. Partasarathy and e. al. (2001). "Recognition Properties of Antibodies to 
PAMAM Dendrimers and Their Use in Immune Detection of Dendrimers." 
Biomedical Microdevices 3(1): 53-59.
Legg, W. (1872). A Tretise on Haemphilia. London, H. K. Lewis.
Leventis, R. and J. R. Silvius (1990). "Interactions of mammalian cells with lipid 
dispersions containing novel metabolizable cationic amphiphiles." Biochim 
Biophvs Acta 1023(1): 124-32.
Li, S., M. A. Rizzo, S. Bhattacharya and L. Huang (1998). "Characterization of
cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery." 
Gene Therapy 5(7): 930-7.
Li, S., W. C. Tseng, D. B. Stolz, S. P. Wu, S. C. Watkins and L. Huang (1999).
"Dynamic changes in the characteristics of cationic lipidic vectors after exposure 
to mouse serum: implications for intravenous lipofection." Gene Ther 6(4): 585- 
94.
Li, Y. and D. Sen (1997). "Toward an efficient DNAzyme." Biochemistry 36(18): 
5589-99.
Litzinger, D. C., J. M. Brown, I. Wala, S. A. Kaufman, G. Y. Van, C. L. Farrell and D. 
Collins (1996). "Fate of cationic liposomes and their complex with 
oligonucleotide in vivo." Biochim Biophvs Acta 1281(2): 139-49.
Liu, Y., L. C. Mounkes, H. D. Liggitt, C. S. Brown, I. Solodin, T. D. Heath and R. J. 
Debs (1997). "Factors influencing the efficiency of cationic liposome-mediated 
intravenous gene delivery." Nature Biotechnology 15(2): 167-73.
Liu, Y. L., F. Mingozzi, S. M. Rodriguez-Colon, S. Joseph, E. Dobrzynski, T. Suzuki, 
K. A. High and R. W. Herzog (2004). "Therapeutic levels of factor IX expression
241
using a muscle-specific promoter and adeno-associated virus serotype 1 vector." 
Hum Gene Ther 15(8): 783-92.
Loser, P., S. G. Jennings, M. Strauss and V. Sandig (1998). "Reactivation of the 
previously silenced cytomegalovirus major immediate-early promoter in the 
mouse liver: involvement of NFkB." Journal of Virology 72: 180-190.
Lozier, J. N., J. R. Yankaskas, W. J. Ramsey, L. Chen, H. Berschneider and R. A. 
Morgan (1997). "Gut epithelial cells as targets for gene therapy of hemophilia." 
Hum Gene Ther 8(12): 1481-90.
Lui, V. W., L. D. Falo, Jr. and L. Huang (2001). "Systemic production of IL-12 by 
naked DNA mediated gene transfer: toxicity and attenuation of transgene 
expression in vivo." J Gene Med 3(4): 384-93.
Lusher, J. M., S. Arkin, C. F. Abildgaard and R. S. Schwartz (1993). "Recombinant 
factor VIII for the treatment of previously untreated patients with haemophilia." 
New England Journal of Medicine 328: 453-459.
Makinen, K., S. Loimas, V. M. Kosma, J. Wahlfors, S. Yla-Herttuala, E. Alhava and J. 
Janne (2000). "Adenovirus-mediated gene transfer into an experimental 
pancreatic tumour." Ann Chir Gynaecol 89(2): 99-103.
Manno, Larson, Cohen and Flake (1999). A phase I study in patients with severe
haemophilia B (factor IX deficiency) using adeno associated viral (AAV) vector 
to delive rthe gene to skeletal muscle. Pennsylvania, University of Pennsylvania
School of Medicine
Philadelphia,.
Mannucci, P. M., Bauer, K. A., Gringeri, A. et al. (1991). "No activation of the
common pathway of the coagulation cascade after a highly purified factor IX 
concentrate." British Journal of Haemoatology 79: 606-611.
Matsushita, T., S. Elliger, C. Elliger, G. Podsakoff, L. Villarreal, G. J. Kurtzman, Y. 
Iwaki and P. Colosi (1998). "Adeno-associated virus vectors can be efficiently 
produced without helper virus." Gene Therapy 5(7): 938-45.
242
McCormack, J. E., D. Martineau, N. DePolo, S. Maifert, L. Akbarian, K. Townsend, 
W. Lee, M. Irwin, N. Sajjadi, D. J. Jolly and J. Warner (1997). "Anti-vector 
immunoglobulin induced by retroviral vectors." Hum Gene Ther 8(10): 1263-73.
McKenzie, D. L., K. Y. Kwok and K. G. Rice (2000). "A potent new class of 
reductively activated peptide gene delivery agents." Journal of Biological 
Chemistry 275(14): 9970-7.
McLachlan, G., B. J. Stevenson, D. J. Davidson and D. J. Porteous (2000). "Bacterial 
DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to 
mouse lungs." Gene Therapy 7: 384-392.
McLean, J. W., E. A. Fox, P. Baluk, P. B. Bolton, A. Haskell, R. Pearlman, G. 
Thurston, E. Y. Umemoto and D. M. McDonald (1997). "Organ-specific 
endothelial cell uptake of cationic liposome-DNA complexes in mice." American 
Journal of Physiology 273(1 Pt 2): H387-404.
Menache, D., Fauvert, R. and Soulier, J. P. (1959). "Utilisation en hepatologie d'une 
fraction contenant la prothrombine, le complex proconvertine-facteur Stuart et le 
facteur antihaemophilique B (RPB)." Pathologie et Biologie (Paris) 7: 2515- 
2523.
Minot, G. R. a. L., R. I. (1916). "The blood platelets in haemophilia." Archives of 
Internal Medicine 18: 474-495.
Morris, M. C., L. Chaloin, J. Mery, F. Heitz and G. Divita (1999). "A novel potent 
strategy for gene delivery using a single peptide vector as a carrier." Nucleic 
Acids Research 27( 17): 3510-7.
Moskalenko, M., L. Chen, M. van Roey, B. A. Donahue, R. O. Snyder, J. G. McArthur 
and S. D. Patel (2000). "Epitope mapping of human anti-adeno-associated virus 
type 2  neutralizing antibodies: implications for gene therapy and virus structure." 
J Virol 74(4): 1761-6.
Mukheijee, S., A. Mukhopadhyay, K. Chaudhuri and K. Ray (2003). "Analysis of 
haemophilia B database and strategies for identification of common point 
mutations in the factor IX gene." Haemophilia 9(2): 187-92.
243
Nakai, H., R. W. Herzog, J. N. Hagstrom, J. Walter, S.-H. Kung, E. Y. Yang, S. J. Tai, 
Y. Iwaki, G. J. Kurtzman, K. J. Fisher, P. Colosi, L. B. Couto and K. A. High 
(1998). "Adeno-associated viral-vector mediated gene transfer of human blood 
coagulation factor IX into mouse liver." Blood 91(12): 4600-4607.
Nakamura, M., P. Davila-Zavala, H. Tokuda, Y. Takakura and M. Hashida (1998). 
"Uptake and gene expression of naked plasmid DNA in cultured brain 
microvessel endothelial cells." Biochemistry and Biophysics Research 
Communicatons 245(1): 235-9.
Nelson, N. (1991). "Structure and pharmacology of the proton-ATPases." Trends in 
Pharmacological Science 12(2): 71-5.
Nesterova, M. and Y. S. Cho-Chung (2000). "Oligonucleotide sequence-specific
inhibition of gene expression, tumor growth inhibition, and modulation of cAMP 
signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha 
subunit." Antisense Nucleic Acid Drug Dev 10(6): 423-33.
Neumann, E., M. Schaefer-Ridder, Y. Wang and P. H. Hofschneider (1982). "Gene 
transfer into mouse lyoma cells by electroporation in high electric fields." Embo 
J 1(7): 841-5.
Newkome, G. R. e. a. (1985). Journal of Organic Chemistry 50: 2003-4.
Nigavekar, S. S., L. Y. Sung, M. Llanes, A. El-Jawahri, T. S. Lawrence, C. W. Becker, 
L. Balogh and M. K. Khan (2004). "3H dendrimer nanoparticle organ/tumor 
distribution." Pharm Res 21(3): 476-83.
Nishikawa, M., M. Yamauchi, K. Morimoto, E. Ishida, Y. Takakura and M. Hashida
(2000). "Hepatocyte-targeted in vivo gene expression by intravenous injection of 
plasmid DNA complexed with synthetic multi-functional gene delivery system." 
Gene Therapy 7(7): 548-55.
Norman, J., W. Denham, D. Denham, J. Yang, G. Carter, A. Abouhamze, C. L. 
Tannahill, S. L. MacKay and L. L. Moldawer (2000). "Liposome-mediated, 
nonviral gene transfer induces a systemic inflammatory response which can 
exacerbate pre-existing inflammation." Gene Therapy 7(16): 1425-30.
244
Oku, N. and Y. Namba (1994). "Long-circulating liposomes." Critical Review of 
Therapeutic Drug Carrier Systems 11(4): 231-70.
Otto, J. C. (1803). "An account of an haemonhagic disposition existing in certain 
families." The Medical Repository 6 : 1-4.
Oupicky, D., C. Konak, K. Ulbrich, M. A. Wolfert and L. W. Seymour (2000). "DNA 
delivery systems based on complexes of DNA with synthetic polycations and 
their copolymers." Journal Controlled Release 65(1-2): 149-71.
Pagano, J. S. and A. Vaheri (1965). "Enhancement of infectivity of poliovirus RNA 
with diethylaminoethyl-dextran (DEAE-D)." Arch Gesamte Virusforsch 17(3): 
456-64.
Pante, N. and U. Aebi (1993). "The nuclear pore complex." Journal of Cell Biology 
122(5): 977-84.
Park, F. and M. A. Kay (2001). "Modified HTV-1 Based Lentiviral Vectors Have an 
Effect on Viral Transduction Efficiency and Gene Expression in Vitro and in 
Vivo." Mol Ther 4(3): 164-73.
Patek, A. J. a. T., F. H. L. (1937). "Haemphilia; some properties of a substance
obtained from normal human plasma effective in accelerating the coagulation in 
haemophilic blood." Journal of Clinical Investigation 16: 113-124.
Payne, W. W. a. S., R.E. (1929). "Haemostatic therapy in haemphilia." British Medical 
Journal 1: 1150-1152.
Pearse, B. M. (1975). "Coated vesicles from the pig brain: purification and 
biochemical characterization." Journal of Molecular Biology 97: 93-98.
Pearse, B. M. (1976). "Coated vesicles from the pig brain: purification and
biochemical characterization." Proc Natl Acad Sci U S A 73: 1255-1259.
Perales, J. C., G. A. Grossmann, M. Molas, G. Liu, T. Ferkol, J. Harpst, H. Oda and R. 
W. Hanson (1997). "Biochemical and functional characterization of DNA 
complexes capable of targeting genes to hepatocytes via the asialoglycoprotein 
receptor." Journal of Biological Chemistry 272(11): 7398-407.
245
Perriman, R. J. and W. L. Gerlach (1990). "Manipulating gene expression by ribozyme 
technology.” Current Opinions in Biotechnology 1(1): 86-91.
Philip, R., D. Liggitt, M. Philip, P. Dazin and R. Debs (1993). "In vivo gene delivery. 
Efficient transfection of T lymphocytes in adult mice." J Biol Chem 268(22): 
16087-90.
Plank, C., K. Mechtler, F. C. Szoka, Jr. and E. Wagner (1996). "Activation of the 
complement system by synthetic DNA complexes: a potential barrier for 
intravenous gene delivery." Hum Gene Ther 7(12): 1437-46.
Plank, C., B. Oberhauser, K. Mechtler, C. Koch and E. Wagner (1994). "The influence 
of endosome-disruptive peptides on gene transfer using synthetic virus-like gene 
transfer systems." J Biol Chem 269(17): 12918-24.
Pool, J. G., Hershgold, E.J. and Pappenhagen, A.R. (1964). "High-potency
antihaemophilic factor concentrate prepared from cryoglobulin precipitate." 
Nature 203: 312.
Potter, H., L. Weir and P. Leder (1984). "Enhancer-dependent expression of human 
kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by 
electroporation." Proceedings of the National Academy of Sciences USA 81(22): 
7161-5.
Purohit, G., T. Sakthivel and A. T. Florence (2001). "Interaction of cationic partial 
dendrimers with charged and neutral liposomes." International Journal of 
Pharmaceutics 214: 71-76.
Qiu X, Lu D, Zhou J, Wang J, Yang J, Meng P and H. JL. (1996). "Implantation of 
autologous skin fibroblast genetically modified to secrete clotting factor IX 
partially corrects the hemorrhagic tendencies in two hemophilia B patients." 
Chinese Medical Journal (English edition) 109(11): 832-9.
Rabiner, S. F. and J. Lazerson (1973). "Home management and prophylaxis of 
hemophilia." Prog Hematol 8 : 223-34.
246
Ragni M. V., M. O. K., Rice E. O., Bontempo F. A., Nedjar S. (1993). "Presence of 
antibody to hepatitis C vims (HCV) in haemophilic men with HCV 
'seroconversion’." Blood 82: 1010-1015.
Ragni M. V., W. A., Kingsley L. A., Spero J. A., Lewis J. H. (1987). "1986 update of 
HIV seroprevalence, seroconversion, AIDS incidence, and immunologic 
correlates of HIV infection in patients with haemophilia A and B." Blood 70: 
786-790.
Raper, S. E., N. Chirmule, F. S. Lee, N. A. Wivel, A. Bagg, G. P. Gao, J. M. Wilson 
and M. L. Batshaw (2003). "Fatal systemic inflammatory response syndrome in a 
ornithine transcarbamylase deficient patient following adenoviral gene transfer." 
Mol Genet Metab 80(1-21: 148-58.
Remy, J. S., A. Kichler, V. Mordvinov, F. Schuber and J. P. Behr (1995). "Targeted 
gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles 
presenting galactose ligands: a stage toward artificial viruses." Proc Natl Acad 
Sci U S A 92(5): 1744-8.
Riddell, S. R., M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. 
D. Lupton, R. W. Overell, T. C. Reynolds, L. Corey and P. D. Greenberg (1996). 
"T-cell mediated rejection of gene-modified HIV-specific cytotoxic T 
lymphocytes in HIV-infected patients." Nat Med 2(2): 216-23.
Roberts, J. C., M. K. Bhalgat and R. T. Zera (1996). "Preliminary biological evaluation 
of polyamidoamine (PAMAM) Starburst dendrimers." J Biomed Mater Res 
30(1): 53-65.
Roberts, W. S., D. Cavanagh, V. C. Roberts, S. Hewitt and G. H. Lyman (1989). 
"Wound hematoma: prophylaxis with topical thrombin." South Med J 82(5): 
607-9.
Rosner, F. (1969). "Hemophilia in the Talmud and rabbinic writings." Ann Intern Med 
70(4): 833-7.
Roth, T. F. and K. R. Porter (1964). "Yolk Protein Uptake in the oocyte of the 
mosquito Aedes aegypti" Journal of Cell Biology 20: 313-332.
247
Rouet, P., G. Raguenez, F. Tranche, M. Yaniv, C. N’Guyen and J. P. Salier (1992). "A 
potent enhancer made of clustered liver-specific elements in the transcription 
control sequences of human alpha 1-microglobulin/bikunin gene." J Biol Chem 
267(29): 20765-73.
Sakthivel, T., I. Toth and A. T. Florence (1998). "Synthesis and physicochemical 
properties of lipophilic polyamide dendrimers." Pharm Res 15(5): 776-82.
Salomon, R. N., R. Underwood, M. V. Doyle, A. Wang and P. Libby (1992). 
"Increased apolipoprotein E and c-fms gene expression without elevated 
interleukin 1 or 6  mRNA levels indicates selective activation of macrophage 
functions in advanced human atheroma." Proc Natl Acad Sci U S A 89(7): 2814- 
8 .
Scheule, R. K., J. A. St George, R. G. Bagley, J. Marshall, J. M. Kaplan, G. Y. Akita, 
K. X. Wang, E. R. Lee, D. J. Harris, C. Jiang, N. S. Yew, A. E. Smith and S. H. 
Cheng (1997). "Basis of pulmonary toxicity associated with cationic lipid- 
mediated gene transfer to the mammalian lung." Hum Gene Ther 8 (6 ): 689-707.
Schiedner, G., N. Morral, R. J. Parks, Y. Wu, S. C. Koopmans, C. Langston, F. L.
Graham, A. L. Beaudet and S. Kochanek (1998). "Genomic DNA transfer with a 
high-capacity adenovirus vector results in improved in vivo gene expression and 
decreased toxicity." Nature Genetics 18(2): 180-3.
Schmid, R. M., H. Weidenbach, G. F. Draenert, M. M. Lerch, S. Liptay, J. Schorr, K.
H. Beckh and A. G. (1994). "Liposme mediated in vivo gene transfer into 
different tissues of the gastrointestinal tract." Z Gastroenterol 32: 665-670.
Schulman, I. S., C. H. (1962). "Haemorrhagic disease in an infant due to deficiency of 
a previously undescribed clotting factor." Blood 7: 794-807.
Searle, P. F. and V. Mautner (1998). "Adenoviral vectors: not to be sneezed at." Gene 
Therapy 5(6): 725-7.
Senior, J. H. (1987). "Fate and behavior of liposomes in vivo: a review of controlling 
factors." Critical Review of Therapeutic Drug Carrier Systems 3(2): 123-93.
248
Shah, D. S., T. Sakthivel, I. Toth, A. T. Florence and A. F. Wilderspin (2000). "DNA 
transfection and transfected cell viability using amphipathic asymmetric 
dendrimers." Int J Pharm 208(1-2): 41-8.
Smith, K. J. and A. R. Thompson (1981). "Labeled factor IX kinetics in patients with 
hemophilia-B." Blood 58(3): 625-9.
Snyder, R. O., C. Miao, L. Meuse, J. Tubb, B. A. Donahue, H. F. Lin, D. W. Stafford, 
S. Patel, A. R. Thompson, T. Nichols, M. S. Read, D. A. Bellinger, K. M. 
Brinkhous and M. A. Kay (1999). "Correction of hemophilia B in canine and 
murine models using recombinant adeno-associated viral vectors." Nature 
Medicine 5(1): 64-70.
Sommer, S. S., W. A. Scaringe and K. A. Hill (2001). "Human germline mutation in 
the factor IX gene." Mutat Res 487(1-2): 1-17.
Son, K. K., D. Tkach and D. H. Patel (2000). "Zeta potential of transfection complexes 
formed in serum-free medium can predict in vitro gene transfer efficiency of 
transfection reagent." Biochim Biophvs Acta 1468(1-2): 11-4.
Sparrow, J. T., V. V. Edwards, C. Tung, M. J. Logan, M. S. Wadhwa, J. Duguid and L. 
C. Smith (1998). "Synthetic peptide-based DNA complexes for nonviral gene 
delivery." Adv Drug Deliv Rev 30(1-3): 115-131.
Stacey, K. J., M. J. Sweet and D. A. Hume (1996). "Macrophages ingest and are 
activated by bacterial DNA." J Immunol 157(5): 2116-22.
Stein, C. S., Y. Kang, S. L. Sauter, K. Townsend, P. Staber, T. A. Derksen, I. Martins, 
J. Qian, B. L. Davidson and P. B. McCray, Jr. (2001). "In vivo treatment of 
hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral 
vectors." Mol Ther 3(6): 850-6.
Stopeck, A. T., E. M. Hersh, E. T. Akporiaye, D. T. Harris, T. Grogan, E. Unger, J. 
Wameke, S. F. Schluter and S. Stahl (1997). "Phase I study of direct gene 
transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with 
metastatic melanoma." J Clin Oncol 15(1): 341-9.
249
Sun, L. Q., M. J. Caims, E. G. Saravolac, A. Baker and W. L. Gerlach (2000).
"Catalytic nucleic acids: from lab to applications." Pharmacol Rev 52(3): 325-47.
Swisher, S. G., J. A oth, J. Nemunaitis, D. D. Lawrence, B. L. Kemp, C. H.
Carrasco, D. G. Connors, A. K. El-Naggar, F. Fossella, B. S. Glisson, W. K.
Nguyen, J. C. Nesbitt, R. Perez-Soler, K. M. Pisters, J. B. Putnam, Jr., W. R.
gene transfer in advanced nob-small-cell lung cancer." J Natl Cancer Inst 91(9):
Takakura, Y., T. Takagi, M. Has chi, M. Nishikawa, F. Yamashita, T. Doi, T. 
Imanisbi, H. Suzuki, T. Kodama and M. Hashida (1999). "Characterization of 
plasmid DNA binding and uptake by peritoneal macrophages from class A 
scavenger receptor knockout mice." Pharm Res 16(4): 503-8.
Takeshija, S., Y. Tsurumi, T. Couffinahl, T. Asahara, C. Bauters, J. Symes, N. Ferrara 
and J. M. Isner_(1996). "Gene transfer of naked DNA encoding for three 
isoforms of vascular endothelial growth factor stimulates collateral development 
in vivo." Lab Invest 75(4): 487-501.
Takeuchi, K., M. Ishihara, C. Kawaura, M. Noji, T. Furuno and M. Nakanishi (1996). 
"Effect of zeta potential of cationic liposomes containing cationic cholesterol 
derivatives on gene transfection." FEBS Lett 397(2-3): 207-9.
Tang, M. X., C. T. Redemann and F. C. Szoka, Jr. (1996). "In vitro gene delivery by 
degraded polyamidoamine dendrimers." Bioconiugate Chemistry 7(6): 703-14.
Tang, M. X. and F. C. Szoka, Jr. (1998). Structure of polycation-DNA complexes and 
theories of compaction. Self-Assembling Complexes for Gene Delivery. A. V. 
Kabanov, P. L. Feigner and L. W. Seymour. Chichester, UK, John Wiley and 
Sons.
Taylor, A. E. and D. N. Granger (1983). "Equivalent pore modeling: vesicles and 
channels." Fed Proc 42(8): 2440-5.
Hong, F. R. Mfiuri, J. M. Kurie, J. J. Lee, J. S. Lee, M. Mack, J. A. Merritt, D. M.
Richli, M. fcavin, M. K. Waugh and et al. (1999). "Adenovirus-mediated p53
763-71.
250
Thybusch-Bemhardt, A., A. Aigner, S. Beckmann, F. Czubayko and H. Juhl (2001). 
"Ribozyme targelng of HER-2 inhibits pancreatic cancer cell growth in vivo." 
EurJ Cancer 37(13): 1688-94.
Tilcock, C. P., P. R. Cullis and S. M. Gruner (1988). "Calcium-induced phase 
separation phenomena in multicomponent unsaturated lipid mixtures." 
Biochemistry 27(5): 1415-20.
Tomalia, D. A., H. Baker, M. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J.
Ryder and P. Smith (1985). Polymer Journal 17: 117-32.
Tomalia, D. A ., A. M. Naylor and W. A. Goddard (1990). "Starburst dendrimers:
molec 4ar -level control of size, shape, surface chemistry, topology and flexibility 
from atoms to macroscopic matter." Angew. Chem. Int. Ed. Engl. 29: 138-75.
Toth, I. (1994). "A novel chemical approach to drug delivery: lipid amino acid 
conjugates." Journal of Drug Targeting 2(3): 217-39.
Toth, I., T. Sakthivel, A. F. Wilderspin, H. Bayele, M. O'Donnell, D. J. Perry, K. J. 
Pasi, C. A^Lee and A. T. Florence (1999). "Novel cationic lipidic peptide 
dendrimer vectors in vitro gene delivery." S.T.P Pharma Sciences 9(1): 93-9.
I
Triplett, D. A. (2000). "Coagulation and bleeding disorders: review and update." Clin 
Chem 46(8 Pt 2): 1260-9.
UKHCDO (2002). UK Haemophilia Centre Doctors’ organisation: Report on the 
annual returns for 1999.
Veltkamp, J. J., J. Meilof, H. G. Remmelts, D. van der Vlerk and E. A. Loeliger 
(1970). "Another genetic variant of haemophilia B: haemophilia B Leyden." 
Scand J Haematol 7(2): 82-90.
Virchow, R. (1854). Die Bluterkrankheit. Handbuch der sneciellen Pathologie und 
Therapie. Berlin: 263-270.
Wagner, E., M. Ogris and W. Zauner (1998). "Polylysine-based transfection systems 
utilizing receptor-mediated delivery." Adv Drug Deliv Rev 30(1-3): 97-113.
251
Walsh, P. n ', H. Bradford, D. Sinha, J. R. Pipemo and G. P. Tuszynski (1984). 
"Kinetics of the Factor XIa catalyzed activation of human blood coagulation 
Factor IX." J Clin Invest 73(5): 1392-9.
Walter, J., t). You, J. N. Hagstrom, M. Sands and K. A. High (1996). "Successful
expression of human factor IX following repeat administration of an adenoviral 
vectoifin mice." Proceedings of the National Academy of Sciences USA 93: 
3056-3061.
Waly, N. G. (1995). "Local antifibrinolytic treatment with tranexamic acid in
hemophilic children undergoing dental extractions." Egypt Dent J 41(1): 961-8.
Wang, C. Y. ind L. Huang (1987). "pH-sensitive immunoliposomes mediate target­
cell-specific delivery and controlled expression of a foreign gene in mouse." Proc 
Natl Acad Sci U S A 84(22): 7851-5.
Wang, L., K. Takabe, S. M. Bidlingmaier, C. R. Ill and I. M. Verma (1999). "Sustained 
correction of bleeding disorder in hemophilia B mice by gene therapy." 
Proceedings of the National Academy of Sciences USA 96(7): 3906-10.
Wang, R., D. L. Doolaii, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. 
R. Jones, P. Hobajt, M. Margalith, J. Ng, W. R. Weiss, M. Sedegah, C. de 
Taisne, J. A. Norlian and S. L. Hoffman (1998). "Induction of antigen-specific 
cytotoxic T lymphocytes in humans by a malaria DNA vaccine." Science 
282(5388): 476-80.
Ward (1819). (Quoted by J Wardrop). On the curative effects of the abstraction of 
blood. Philadelphia,!837, A. Waldie: 9-10.
Ward, C. M., M. L. Read and L. W. Seymour (2001). "Systemic circulation of poly(L- 
lysing)/DNA vectors is influenced by polycation molecular weight and type of 
DNA: differential circulation in mice and rats and the implications for human 
gene therapy." Blood 97(8): 2221-9.
Wasse^N. M., G. R. Matyas and C. R. Alving (1991). "Complement-dependent 
phagocytosis of liposomes by macrophages: suppressive effects of "stealth" 
lipids." Biochem Biophvs Res Commun 176(2): 866-74.
252
Whaley (1985). Methods in Complement.
White, G., Shapiro, A., Ragni, M. et al (1998). "Clinical evaluation of recombinant 
1 factor IX." Seminars in Haematology 35(Suppl. 2): 33-38.
White, S. G., Aggeler, P.M. and Emery, B.E. (1953). "Plasma thromboplastin
component (PTC) potency of plasma fractions." Proceedings of the Society for 
Experimental Biology and Medicine 83: 69.
Whittaker, G. R. and A. Helenius (1998). "Nuclear import and export of viruses and 
virus genomes." Virology 246(1): 1-23.
Wilke, M., E. Fortunati, M. van der Broek, A. T. Hoogeveen and B. J. Scholte (1996). 
"Efficacy of a peptide-based gene delivery system depends on mitotic activity." 
Gene Therapy 3: 1133-1142.
Wilson, J. (1819). Lectures on the Blood and on the Anatomy. Physiology and 
Surgickl Pathology of the Vascular System of the Human Body. London, 
Burgess and Hill.
Wilson, J., M. Grossman, C. H. Wu, N. R. Chowdhury, G. Y. Wu and J. R.
Chowdhury (1992). "Hepatocyte-directed gene transfer in vivo leads to transient 
improvement of hypercholesterolemia in low density lipoprotein receptor- 
deficient rabbits." The Journal of Biological Chemistry 267(2): 963-967.
Wilson, J. M., M. Grossman, J. A. Cabrera, C. H. Wu and G. Y. Wu (1992). "A novel 
juechanism for achieving transgene persistence in vivo after somatic gene 
transfer into hepatocytes." The Journal of Biological Chemistry 267(16): 11483- 
9.
Wiwattanapatapee, R., B. Carreno-Gomez, N. Malik and R. Duncan (2000). "Anionic 
PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral 
delivery system ?" Pharmaceutical Research 17(8): 991-998.
WolfC, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani and P. L. 
Feigner (1990). "Direct gene transfer into mouse muscle in vivo." Science 
247(4949 Pt 1): 1465-8.
253
Woodley, J. F. (2000). "Lectins for gastrointestinal targeting - 15 years on." Journal of 
Drug Release 7: 325-333.
Wright, A. E. (1893). "On the method of determining the condition of blood 
coagulability for clinical and experimental purposes and on the effects of 
administration of calcium salts in haemophilia and actual or threatened 
haemorrhage." British Medical Journal 2: 109-139.
Wrobel, I. and D. Collins (1995). "Fusion of cationic liposomes with mammalian cells 
occurs after endocytosis." Biochim Biophvs Acta 1235(2): 296-304.
Wu, G. Y. and C. H. Wu (1987). "Receptor-mediated in vitro gene transformation by a 
soluble DNA carrier system." The Journal of Biological Chemistry 262(10): 
4429-32.
Wu, G. Y. and C. H. Wu (1988). "Receptor-mediated gene delivery and expression in 
vivo." The Journal of Biological Chemistry 263(29): 14621-4.
Wu, M. S., J. C. Robbins, R. L. Bugianesi, M. M. Ponpipom and T. Y. Shen (1981). 
"Modified in vivo behavior of liposomes containing synthetic glycolipids." 
Biochim Biophvs Acta 674(1): 19-29.
Xiao, W., N. Chirmule, S. C. Berta, B. McCullough, G. Gao and J. M. Wilson (1999). 
"Gene therapy vectors based on adeno-associated virus type 1." J Virol 73(5): 
3994-4003.
Xu, Y. and F. C. Szoka, Jr. (1996). "Mechanism of DNA release from cationic
liposome/DNA complexes used in cell transfection." Biochemistry 35(18): 5616- 
23.
Yamamoto, S., T. Ishida, A. Inoue, J. Mikami, M. Muraguchi, Y. Ohmoto and H.
Kiwada (2002). "HEPC-based liposomes trigger cytokine release from peripheral 
blood cells: effects of liposomal size, dose and lipid composition." International 
Journal of Pharmaceutics 236(1-2): 125-33.
Yamamoto, T., S. Yamamoto, T. Kataoka and T. Tokunaga (1994). "Lipofection of 
synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT
254
to murine splenocytes enhances interferon production and natural killer activity." 
Microbiol Immunol 38(10): 831-6.
Yang, J. P. and L. Huang (1997). "Overcoming the inhibitory effect of serum on
lipofection by increasing the charge ratio of cationic liposome to DNA." Gene 
Therapy 4(9): 950-60.
Yang, J. P. and L. Huang (1998). "Time-dependent maturation of cationic liposome- 
DNA complex for serum resistance." Gene Therapy 5(3): 380-7.
Yao, S. N. e. a. ( 1994). "Primary Myoblast-Mediated Gene Transfer:Persistant 
Expression of Human Factor IX in Mice." Gene Therapy 1: 99-107.
Yasuda, K., Y. Ogawa, M. Kishimoto, T. Takagi, M. Hashida and Y. Takakura (2002). 
"Plasmid DNA activates murine macrophages to induce inflammatory cytokines 
in a CpG motif-independent manner by complex formation with cationic 
liposomes." Biochem Biophvs Res Commun 293(1): 344-8.
Yokochi, T., Y. Inoue, Y. Kimura and N. Kato (1990). "Strong interaction of 
lipopolysaccharides possessing the mannose homopolysaccharides with 
complement and its relation to adjuvant action." Journal of Immunology 144: 
3106-3110.
Yuan, F., M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin and R. K. 
Jain (1995). "Vascular permeability in a human tumor xenograft: molecular size 
dependence and cutoff size." Cancer Research 55(17): 3752-6.
Zabner, J., A. J. Fasbender, T. Moninger, K. A. Poellinger and M. J. Welsh (1995).
"Cellular and molecular barriers to gene transfer by a cationic lipid." The Journal 
of Biological Chemistry 270(32): 18997-9007.
Zanta, M. A., P. Belguise-Valladier and J. P. Behr (1999). "Gene delivery: a single
nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus." 
Proceedings of the National Academy of Sciences USA 96(1): 91-6.
Zhang, Y., L. K. Shoda, K. A. Brayton, D. M. Estes, G. H. Palmer and W. C. Brown
(2001). "Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes,
255
monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) 
containing the GTCGTT motif." J Interferon Cytokine Res 10: 871-81.
Zhou, H. S., D. P. Liu and C. C. Liang (2004). "Challenges and strategies: the immune 
responses in gene therapy." Med Res Rev 24(6): 748-61.
Zimmermann, U. and J. Vienken (1982). "Electric field-induced cell-to-cell fusion." 
Journal of Membrane Biology 67(3): 165-82.
256
